A publication of the
American Pharmaceutical Association—
the National Professional Society
of Pharmacists

JOURNAL OF PHARMACEUTICAL SCIENCES

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 69
JANUARY TO DECEMBER, 1980

Published monthly under the supervision of the Board of Trustees

MARY H. FERGUSON
Editor

SHELLY ELLIOTT
Production Editor

NICOLETTE TRIANTAFELLU
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

BELLE R. BECK
Editorial Secretary

DAVID BOHARDT
Director of Publications

L. LUAN CORRIGAN
Assistant Director of Publications

EDITORIAL ADVISORY BOARD

John Autian
Norman R. Farnsworth
William O. Foye
William J. Jusko
Herbert A. Lieberman
David E. Mann, Jr.
Gerald J. Papariello
Edward G. Rippie

© Copyright 1980 by the American Pharmaceutical Association; all rights reserved.

AUTHOR INDEX

A

Abdel-Monem, M. M., *see* Pankaskie, M., 1000
Abdullah, M. E., *see* Said, S. A., 1238
Abou-Donia, A. H. A., *see* El-Masry, S., 597
Abu-Eittah, R., *see* Osman, A., 1164
Actor, P., *see* Pitkin, D. H., 354
Adamson, R. A., *see* Feyns, L. V., 190
Adir, J., *see* Rotenberg, K. S., 1087
Adjei, A., Newburger, J., and Martin, A., extended Hildebrand approach: solubility of caffeine in dioxane–water mixtures, 659
——*see* Martin, A., 487
Ahlquist, R. P., review of "Autonomic Pharmacology: Experimental and Clinical Aspects," 484
Ajeena, Y. H., *see* Borazan, H. N., 990
Al-Ani, N. I., *see* Borazan, H. N., 613
Alberts, D. S., *see* Chang, S. Y., 80
Alemany, M. T., *see* Salto, F., 501
Alich, A. A., and Wittmers, L. E., hydrolysis of tetrakis-μ-acetylsalicylato-dicopper(II), 725
Al-Khamis, K. I., *see* Amirjahed, A. K., 1151
Allen, L. M., analysis of 4′-demethylepipodophyllotoxin-9-(4,6-*O*-ethylidene-β-D-glucopyranoside) by high-pressure liquid chromatography, 1440
Allen, L. V., Jr., *see* Levinson, R. S., 62
Amann, A. H., *see* Yacobi, A., 1077
Amidon, G. L., Kou, J., Elliott, R. L., and Lightfoot, E. N., analysis of models for determining intestinal wall permeabilities, 1369
——Leesman, G. D., and Elliott, R. L., improving intestinal absorption of water-insoluble compounds: membrane metabolism strategy, 1363
Amirjahed, A. K., and Al-Khamis, K. I., titration of selected bases in benzene–acetonitrile binary solvent system, 1151
Amsel, L. P., comparative *in vitro* and *in vivo* antifungal activity of tolnaftate and various undecylenates: a rebuttal, 741
Andermann, G., Buhler, M. O., and Erhart, M., rapid colorimetric analysis of chlorhexidine in pharmaceutical preparations, 215
Anderson, B. D., and Conradi, R. A., prostaglandin prodrugs VI: structure–thermodynamic activity and structure–aqueous solubility relationships, 424
——Rytting, J. H., and Higuchi, T., solubility of polar organic solutes in nonaqueous systems: role of specific interactions, 676
Anderson, C., *see* Feijen, J., 871
Anderson, J., *see* Feijen, J., 871
Anderson, J. A., *see* Riffee, W. H., 980
Anderson, J. R., and Pitman, I. H., solubility and dissolution rate studies of ergotamine tartrate, 832
Anderson, W. K., Bottaro, J. C., and Halat, M. J., new compounds: synthesis of 2-chloromethylbenzo[*b*]furans, 232
Ando, H. Y., a rebuttal and some insights into cutaneous metabolism and diffusion, 127
——*see* Ventura, D. A., 891
Arakawa, M., Okumura, K., and Hori, R., tissue distribution and metabolism of drugs V: effect of secretin and pancreozymin on drug transport in rabbit pancreas, 27
——*see* Okumura, K., 157
Arena, C., and Fung, H.-L., absorption of sodium γ-hydroxybutyrate and its prodrug γ-butyrolactone: relationship between *in vitro* transport and *in vivo* absorption, 356
Arison, B. H., *see* Vandenheuvel, W. J. A., 1288
Ariyan, Z. S., *see* Heilman, W. P., 282
Arnold, J., Jacob, J. T., and Riley, B., bioavailability and pharmacokinetics of a new, slow-release potassium chloride capsule, 1416
Ateya, A. M., *see* El-Azizi, M. M., 360
Attinà, M., mass spectra of dexamethasone and betamethasone, 991
Azzaro, A. J., *see* O'Donnell, J. P., 149

B

Baaske, D. M., *see* Yacobi, A., 1077
Baba, S., Goromaru, T., Yamazaki, K., and Kasuya, Y., use of stable isotopes in the study of pharmacokinetics of drugs by mass fragmentography II: detailed examination of pharmacokinetics of a single oral dose of phenytoin in humans, 1300
Babhair, S., *see* Hirai, S., 857
Badawi, A. A., and El-Sayed, A. A., dissolution studies of povidone–sulfathiazole coacervated systems, 492
Baer, D. T., *see* Elvin, A. T., 47
Baert, F., *see* Bernier, J. L., 1343
——*see* Houssin, R., 888
Baggesen, S., *see* Bechgaard, H., 1327
Baker, J. K., and Fifer, E. K., high-pressure liquid chromatographic identification of drugs used in management of arthritis, 590
Balandrano, D., and Valle, R., induced resistance in *Staphylococcus aureus* for assay of antibiotic mixtures in pharmaceutical preparations, 458
Baltzer, M. O., *see* Edel, B., 287
Banker, G. S., *see* Franz, R. M., 621
Bannier, A., Brazier, J. L., Ribon, B., and Quincy, C., determination of ketoprofen in biological fluids by reversed-phase chromatography, 763
Barbe, J., *see* Levayer, C., 116
Barletta, M., *see* Kyriakidis, G., 447
Basu, M. K., *see* Colacicco, G., 406
Batenhorst, R., *see* Hussain, A., 1240
Baustian, C. L., *see* Mitra, A. K., 257
Bawarshi, R., *see* Hussain, A., 1411
Beaubien, L. J., and Vanderwielen, A. J., particle-size analysis of pharmaceutical powders, 651
Bechgaard, H., and Baggesen, S., propoxyphene and norpropoxyphene: influence of type of controlled-release formulation on intra- and intersubject variations, 1327
Becker, Y., *see* Bialer, M., 1334
Behl, C. R., *see* Durrheim, H., 781
Beihn, R. M., *see* Theodorakis, M. C., 568
Beisler, J. A., *see* Feyns, L. V., 190
Bell, A. F., *see* Scott, K. R., 234
Bell, R., *see* Schwan, T. J., 1203
Beltagy, Y. A., Waugh, W., and Repta, A. J., antioxidants in purification, stabilization, and formulation of the antineoplastic agent 6-selenoguanosine, 1168
Benedict, J. J., *see* Van Duzee, B. F., 599
Benet, L. Z., *see* Smith, D. E., 571
Beneyto, J. E., *see* Fabregas, J. L., 1378
Benson, W. R., *see* Millard, B. J., 1177
Benz, W., *see* Rubio, F., 1245
Beres, J. A., Varner, M. G., and Bria, C., synthesis and cyclization of dialkylmalonuric esters, 451
Berger, L., *see* Rubio, F., 1245
Bekersky, I., and Colburn, W. A., acetylation of sulfisoxazole by isolated perfused rat kidney, 1359
Bermudez, A. J., *see* Theodorakis, M. C., 581
Bernardoni, R. J., *see* Prancan, A. V., 970
Bernier, J. L., Henichart, J. P., Warin, V., and Baert, F., synthesis and structure–activity relationship of a pyrimido[4,5-*d*]pyrimidine derivative with antidepressant activity, 1343
Bhargava, K. K., Grady, R. W., and Cerami, A., new compounds: N^1,N^8 - bis(2,3-dihydroxybenzoyl)-spermidine and analogs as potential iron-chelating drugs, 986
Bhattacharjee, D., and Popp, F. D., new compounds: Reissert compound studies XXXII: facile synthesis of 3-azapapaverine, 120
Bhattacharyya, P. K., NMR spectral study of proton transfer in amitriptyline hydrochloride–chlordiazepoxide hydrochloride combinations in dipolar aprotic solvent, 180
——*see* NG, S. S. M., 270
Bhuta, S. I., Sugita, E. T., Niebergall, P. J., and Schnaare, R. L., influence of various anions on intestinal disappearance of hexamethonium chloride and pralidoxime chloride in rats, 923
Bialer, M., Yagen, B., Mechoulam, R., and Becker, Y., structure–activity relationships of pyrrole amidine antiviral antibiotics III: preparation of distamycin and congocidine derivatives based on 2,5-disubstituted pyrroles, 1334
Bigot, M.-C., *see* Debruyne, D., 835
Billman, J. H., *see* Roehrig, G. R., 1232
Bird, G., *see* Narang, P. K., 1384
Bivins, B. A., *see* Kanke, M., 755
Black, L. A., *see* Carter, J. E., 1439
Blanchard, J., effect of polyols on interaction of paraben preservatives with polysorbate 80, 169
Blanton, C. D., Jr., *see* Burghard, H., 933
Blickenstaff, R. T., Cox, B., Foster, E., Roberts, L., and Steinrauf, L. K., mercapto steroids in protection against mercury and lead poisoning, 556
——*see* Roberts, L. R., 964
Block, J. H., *see* Henry, D. R., 1030
Bloedow, D. C., Ralston, D. H., and Hargrove, J. C., lidocaine pharmacokinetics in pregnant and nonpregnant sheep, 32
Blum, M. R., *see* Burke, J. T., 909
Bobbitt, J. L., *see* Boots, M. R., 202
Boddapati, S., Butler, L. D., Im, S., and DeLuca, P. P., identification of subvisible barium sulfate crystals in parenteral solutions, 608
Bodek, I., *see* McComish, M., 727
Bodnar, J. A., *see* Muhammad, N., 928
Bodor, N., *see* Kohl, H. H., 1292
Bogan, J. A., and Marriner, S., analysis of benzimidazoles in body fluids by high-performance liquid chromatography, 422
Bogdansky, F. M., *see* Quadrel, R. F., 718
Bohannon, T., *see* Wen, L.-F., 140
Bone, R. C., *see* Hiller, F. C., 334
Boots, M. R., Wolfe, M. L., Boots, S. G., and Bobbitt, J. L., effect of carnitine analogs on carnitine acetyltransferase, 202
——Yeh, Y.-M., and Boots, S. G., hypocholesterolemic agents VII: inhibition of β-hydroxy-β-methylglutaryl-CoA reductase by monoesters of substituted glutaric acids, 506
Boots, S. G., *see* Boots, M. R., 202, 506
Borazan, H. N., and Ajeena, Y. H., indole–catechol charge transfer complexes I, 990
——and Al-Ani, N. I., charge transfer effect through hydrogen bonding in caffeine–*p*-cresol and theophylline–*p*-cresol complexes, 613
Born, Gordon S., review of "Radiopharmaceuticals II: Proceedings of the Second International Symposium on Radiopharmaceuticals," 1243
Born, J. L., and Early, S., ligand interaction of substituted pyridines with cytochrome P-450, 850
——and Hadley, W. M., inhibition of *in vitro* cytochrome P-450-catalyzed reactions by substituted pyridines, 465
Borne, R. F., Law, S.-J., Kapeghian, J. C., and Masten, L. W., evaluation of 2-azabicyclo[2.2.2]octane analogs of 4-anilidopiperidine analgesics, 1104
Bottari, F., *see* Di Colo, G., 387
Bottaro, J. C., *see* Anderson, W. K., 232
Boucherle, A., *see* Rieu, J.-P., 49
Branfman, A. R., *see* McComish, M., 727
Brater, D. C., *see* Smith, D. E., 571
Braun, G., *see* Braun, U., 192
Braun, U., Shulgin, A. T., and Braun, G., centrally active *N*-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine), 192
Brazier, J. L., *see* Bannier, A., 763
Breimer, D. D., *see* de Boer, A. G., 804
Brent, D. A., Chandrasurin, P., Ragouzeos, A., Hurbert, B. S., and Burke, J. T., rearrangement of chloramb-

phenicol-3-monosuccinate, 906
Bria, C., *see* Beres, J. A., 451
Brien, R., *see* Hossie, R. D., 348
Brill, P. H., and Moon, R. E., application of queueing theory to pharmacokinetics, 558
Brindle, S. D., *see* Lukas, G., 419
Brisson, J., *see* Garceau, Y., 561
Brooke, D., review of "Introduction to Powder Surface Area," 486
Brousseau, D., *see* Lesko, L. J., 358
Brower, J. F., Juenge, E. C., Page, D. P., and Dow, M. L., decomposition of aminophylline in suppository formulations, 942
Brown, L. W., and Carpenter, B. E., comparison of two high-pressure liquid chromatographic assays for carboprost, a synthetic prostaglandin, 1396
Brown, R. G., *see* Garcia, D. B., 995
Brown, R. R., *see* Park, G. B., 603
Browne, J. E., Feldkamp, J. R., White, J. L., and Hem, S. L., acid–base equilibria of tetracycline in sodium montmorillonite suspensions, 811
——Feldkamp, J. R., White, J. L., and Hem, S. L., characterization and adsorptive properties of pharmaceutical grade clays, 816
——Feldkamp, J. R., White, J. L., and Hem, S. L., potential of organic cation-saturated montmorillonite as treatment for poisoning by weak bases, 1393
Buck, J. R., *see* Franz, R. M., 621
Buckley, J. P., *see* Watzman, N., 225
Buhler, M. O., *see* Andermann, G., 215
Bukovec, Ž., *see* Butula, L., 930
Bunch, E. A., *see* Kolinski, R. E., 951
Bundgaard, H., and Johansen, M., prodrugs as drug delivery systems IV: *N*-Mannich bases as potential novel prodrugs for amides, ureides, amines, and other NH-acidic compounds, 44
Burch, H. A., White, R. E., Wright, G. C., and Goldenberg, M. M., phenylfurans IV: spasmolytic 3-diethylamino-2,2-(dimethyl)propyl esters of 5-substituted phenyl-2-furancarboxylic acids, 107
Burghard, H., and Blanton, C. D., Jr., 4,5-disubstituted primaquine analogs as potential antiprotozoan agents, 933
Burke, D., and Sokoloff, H., simultaneous high-performance liquid chromatographic determination of chlordiazepoxide and amitriptyline hydrochloride in two-component tablet formulations, 138
Burke, J. T., Wargin, W. A., and Blum, M. R., high-pressure liquid chromatographic assay for chloramphenicol, chloramphenicol-3-monosuccinate, and chloramphenicol-1-monosuccinate, 909
——*see* Brent, D. A., 906
Burns, R. H., *see* Ellis, K. O., 1198
Buskin, J. N., *see* Upton, R. A., 1254
Butler, L. D., *see* Boddapati, S., 608
Butterfield, A. G., Lovering, E. G., and Sears, R. W., high-performance liquid chromatographic determination of isoniazid and 1-isonicotinyl-2-lactosylhydrazine in isoniazid tablet formulations, 222
Butterfield, J. L., *see* Wright G. C., 842
Butula, L., and Bukovec, Ž., aminoalkanesulfonic acids IV: synthesis of mitodepressive *N*-nitrosoaminoalkanesulfonic acids, 930
Buyukyaylaci, S., *see* Levinson, R. S., 62
Byrnes, E. W., *see* Elvin, A. T., 47
Byron, P. R., Notari, R. E., and Tomlinson, E., calculation of partition coefficient of an unstable compound using kinetic methods, 527
——*see* Tomlinson, E., 655

C

Cabana, B., *see* Stavchansky, S., 1307
Caille, G., *see* Hill, J., 1341
Camazano, M. S., Sanchez, M. J., Vicente, M. T., and Dominguez-Gil, A., IR and X-ray diffraction study of chlorpheniramine maleate–montmorillonite interaction, 1142
Cammarata, A., review of "Computer Assisted Studies of Chemical Structure and Biological Function," 754
Camsonne, R., *see* Debruyne, D., 835
Canada, A. T., *see* Lesko, L. J., 358
Canti, G., Scozzafava, A., Ciciani, G., and Renzi, G., complexes between pilocarpine and cobalt(II), nickel(II), copper(II), and zinc(II) ions, 1220
Capomacchia, A. C., and Vallner, J. J., human plasma levels of propranolol: fluorometric measurement in a hydrosolvatic system, 1463
Carelli, V., *see* Di Colo, G., 387
Carignan, G., and Lodge, B. A., comparison of acidic and enzymatic hydrolysis procedures for identification of natural estrogens in pharmaceutical preparations, 1453
——Lodge, B. A., and Skakum, W., high-performance liquid chromatographic analysis of testosterone esters in oily solution, 1214
Carlin, J. R., Walker, R. W., Davies, R. O., Ferguson, R. T., and VandenHeuvel, W. J. A., capillary column GLC–mass spectrometric assay with selected-ion monitoring for timolol and [$^{13}C_3$]timolol in human plasma, 1111
Carlson, M., and Habeger, L. E., polarographic determination of edetate disodium in eyewash and ophthalmic decongestant solutions, 826
Carmichael, R. H., *see* Nash, J. F., 1094
Carney, D. P., *see* Carter, J. E., 1439
Carpenter, B. E., *see* Brown, L. W., 1396
——*see* Walker, G. A., 846
Carroll, A. M., *see* Kupchik, E. J., 340
Carstensen, J. T., and Kothari, R. C., decarboxylation kinetics of 5-(tetradecyloxy)-2-furoic acid, 123
——Kothari, R., Prasad, V. K., and Sheridan, J., time and temperature dependence of disintegration and correlation between dissolution and disintegration rate constants, 290
——Touré, P., Van Campen, L., and Zografi, G., hygroscopicity of poorly soluble porous substances, 742
——*see* Cruaud, O., 607
Carter, J. E., Dutcher, J. S., Carney, D. P., Klein, L. R., Black, L. A., and Erhardt, P. W., analysis of procainamide hydrochloride and acecainide hydrochloride in rat feed, 1439
——*see* Lai, C.-M., 681
——*see* Yacobi, A., 1077
Casalini, C., Mascellani, G., Tamagnone, G., Cesarano, G., and Giumanini, A., metabolites and analogs of 2-ethyl-2,3-dihydro-5-benzofuranacetic acid (furofenac): chemical and pharmacological properties, 164
Cascella, P. J., and Feldman, S., permeability of everted rat small intestine to lidocaine and derivatives, 643
——and Kindelspire, P. D., effect of edetate disodium on goldfish membrane, 972
Castronovo, F. P., Jr., Potsaid, M. S., and Kopiwoda, S. Y., biodistribution of ^{14}C-lomustine in an animal tumor model, 87
Caudal, F., *see* Sioufi, A., 1413
Cauthen, S. E., *see* Wallace, J. L., 1357
Cerami, A., *see* Bhargava, K. K., 986
Cesarano, G., *see* Casalini, C., 164
Chafetz, L., *see* Tsilifonis, D. C., 1461
Chakrin, L. W., and Krell, R. D., pathophysiology and pharmacotherapy of asthma: an overview, 236
——*see* Krell, R. D., 239
Chandrasekaran, S. K., and Hillman, R., heterogeneous model of drug release from polymeric matrix, 1311
Chandrasurin, P., *see* Brent, D. A., 906
Chang, K. S., and Jarowski, C. I., solid dispersion of morphine–tristearin with reduced presystemic inactivation in rats, 466
Chang, S. Y., Larcom, B. J., Alberts, D. S., Larsen, B., Walson, P. D., and Sipes, I. G., mass spectrometry of chlorambucil, its degradation products, and its metabolite in biological samples, 80
Chao, G. C., *see* Yacobi, A., 1077
Chapman, S. K., and Glant, S. K., antiproliferative effects of inhibitors of polyamine synthesis in tumors of neural origin, 733
Chase, G. D., *see* Mojaverian, P., 721
Chatterji, D. C., potential errors in kinetic studies of hydrolysis of nitrogen mustards based on chloride-ion determination, 859
Chatterjie, N., Stephani, R. A., and Strom, C. H., structural elucidation of adducts formed by ninhydrin with indoles and thiourea by ^{13}C-NMR spectroscopy, 1431
Chen, C.-H., Chen, T.-M., and Lee, C., thalifaurine and dehydrodiscretine, new quaternary protoberberines from *Thalictrum fauriei,* 1061
Chen, F. C., *see* Miszuk, S., 713
Chen, T.-M., *see* Chen, C.-H., 1061
Cheng, C. C., review of "The Chemistry of Antitumor Antibiotics, Vol. 1," 367
Chimichi, S., Innocenti, F., and Orzalesi, G., thermal decomposition of ibuproxam, 521
Chin, L., review of "Activated Charcoal: Antidotal and Other Medical Uses," 1361
Chiou, G. C. Y., and Martin, M. K., chemotherapy of neuroblastoma in mice with anticancer agents, 592
——*see* Trzeciakowski, J., 332
Chiou, W. L., new calculation method of mean total body clearance of drugs and its application to dosage regimens, 90
——new compartment- and model-independent method for rapid calculation of drug absorption rates, 57
——potential effect of early blood sampling schedule on calculated pharmacokinetic parameters of drugs after intravenous administration, 867
Chowhan, Z. T., role of binders in moisture-induced hardness increases in compressed tablets and its effect on *in vitro* disintegration and dissolution, 1
Chu, C. K., *see* Stella, V. J., 1274, 1279
Chu, S.-H., *see* Hillman, G. R., 516
Ciciani, G., *see* Canti, G., 1220
Clark, L., Jr., *see* Sarapu, A. C., 129
Clarke, G., *see* Fairbrother, J. E., 697
Clawans, C., *see* Miszuk, S., 713
Coben, L. J., and Lordi, N. G., physical stability of semisynthetic suppository bases, 955
Cohen, I., *see* Mason, W. D., 344
Colacicco, G., and Basu, M. K., surface properties of membrane systems: interaction of electrolyte and lipid with Ca^{2+} ionophores, 406
Colburn, W. A., *see* Berkersky, I., 1359
Cole, C.-A., *see* Pan, H.-L., 122
Colussi, D., *see* Sioufi, A., 1413
Cone, E. J., *see* Darwin, W. D., 253
Connors, K. A., and Rosanske, T. W., *trans*-cinnamic acid–α-cyclodextrin system as studied by solubility, spectral, and potentiometric techniques, 173
——*see* Rosanske, T. W., 564
Conrad, J. M., and Robinson, J. R., mechanisms of anterior segment absorption of pilocarpine following subconjunctival injection in albino rabbits, 875
Conradi, R. A., *see* Anderson, B. D., 424
Cook, C. E., Williams, D. L., Myers, M., Tallent, C. R., Leeson, G. A., Okerholm, R. A., and Wright, G. J., radioimmunoassay for terfenadine in human plasma, 1419
Cordell, G. A., *see* Farnsworth, N. R., 1107
Cornejo, J., Hermosin, M. C., White, J. L., Peck, G. E., and Hem, S. L., oxidative degradation of hydrocortisone in presence of attapulgite, 945
Corrigan, O. I., Su, C. C., Higuchi, W. I., and Hofmann, A. F., mesophase formation during cholesterol dissolution in ursodeoxycholate–lecithin solutions: new mechanism for gallstone dissolution in humans, 869
Cortright, R. N., *see* Will, P. C., 747
Coulson, C. J., and Smith, V. J., correlation of hydrophobicity with protein binding for clorobiocin analogs, 799
Counsell, R. E., *see* Korn, N., 1010, 1014
Cousse, H., *see* Rieu, J.-P., 49
Couvreur, P., Kante, B., Lenaerts, V., Scailteur, V., Rolend M., and Speiser, P., tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles, 199
Cox, B., *see* Blickenstaff, R. T., 556
Crabb, A., *see* Wen, L.-F., 140
Cradock, J. C., *see* Poochikian, G. K., 637
Crouthamel, W. G., *see* Narang, P. K., 1384
Cruaud, O., Duchêne, D., Puisieux, F., and Carstensen, J. T., correlation between porosity and dissolution rate constants for disintegrating tablets, 607
Curran, N. M., Lovering, E. G., McErlane, K. M., and Watson, J. R., impurities in drugs IV: indomethacin, 187
Cutie, A. J., *see* Ganjian, F., 352

D

Daly, K. F., *see* Janicki, C. A., 147
Darwin, W. D., and Cone, E. J., fluorescence proper-

ties of pseudomorphine and congeners: structure–activity relationships, 253
Das, M. K., *see* Hall, I. H., 1025
Davies, R. O., *see* Carlin, J. R., 1111
Davis, I., *see* Garceau, Y., 561
Davis, P. J., Seyhan, S., Soine, W., and Smith, R. V., convenient synthesis of (*S*)-(+)-apomorphine from (*R*)-(−)-apomorphine, 1056
Davison, E., *see* Fawzi, M. B., 104
DeAngelis, R. L., *see* Garceau, Y., 561
DeBarbieri, B., *see* Rubio, F., 1245
de Boer, A. G., Breimer, D. D., Pronk, J., and Gubbens-Stibbe, J. M., rectal bioavailability of lidocaine in rats: absence of significant first-pass elimination, 804
Debruyne, D., Moulin, M. A., Camsonne, R., and Bigot, M.-C., wall-coated open tubular column coupled with nitrogen-selective detector for routine GLC determination of diazepam, meprobamate, phenylbutazone, and thioridazine in serum, 835
De Fabrizio, F., simultaneous GLC analysis of salicylamide, phenylpropanolamine hydrochloride, caffeine, chlorpheniramine maleate, phenylephrine hydrochloride, and pyrilamine maleate in capsule preparations, 854
DeJullis, C. M., Graham, B. W., Mattson, R. J., and Sowell, J. W., Sr., evaluation of ^{99m}Tc-labeled iminodiacetic acid derivatives of substituted 2-aminopyrroles as hepatobiliary imaging agents I, 731
DeLand, F. H., *see* Theodorakis, M. C., 568
Delaney, M., *see* Glover, W., 601
De Leenheer, A. P., and Vandecasteele-Thienpont, L. M. R., electron-capture GLC determination of bromhexine in human plasma, 99
Delgado, Jaime N., review of "Atlas of the Three-Dimensional Structure of Drugs, Vol. 1," 993
——*see* Garcia, D. B., 995
DeLuca, P. P., *see* Boddapati, S., 608
——*see* Kanke, M., 755
De Nève, R. E., *see* Plaizier-Vercammen, J. A., 1403
Der Marderosian, A., review of "Toxic Plants," 1109
de Rome, P. J., *see* Jamieson, D. D., 462
de Souza, N. J., *see* Inamdar, P. K., 1449
Devous, M. D., Sr., *see* Theodorakis, M. C., 1107
Di Carlo, F. J., review of "Foreign Compound Metabolism in Mammals, Vol. 5," 618
Di Colo, G., Carelli, V., Giannaccini, B., Serafini, M. F., and Bottari, F., vehicle effects in percutaneous absorption: *in vitro* study of influence of solvent power and microscopic viscosity of vehicle on benzocaine release from suspension hydrogels, 387
Digenis, G. A., *see* Theodorakis, M. C., 568
Dighe, S., *see* Stavchansky, S., 1307
DiGregorio, G. J., and Ruch, E., human whole blood and parotid saliva concentrations of oral and intramuscular promethazine, 1457
Dimmock, J. R., review of "Selective Toxicity: The Physico-Chemical Basis of Therapy, 6th ed.," 993
——and Smith, L. M., syntheses and evaluation of ketals, hemithioketals, and dithioketals of conjugated styryl ketones principally for antineoplastic activity, 575
Dixon, R., *see* Glover, W., 601
Doluisio, J. T., *see* Stavchansky, S., 1307
Dominguez-Gil, A., *see* Camazano, M. S., 1142
Donigan, B. E., *see* Popp, F. D., 1235
Dornauer, H., *see* Inamdar, P. K., 1449
Dotson, M. J., *see* Hillman, G. R., 516
Dow, M. L., *see* Brower, J. F., 942
Drake, M. V., *see* O'Donnell, J. J., 1096
Dren, A. T., review of "Drug Toxicity," 753
Driscoll, J. S., *see* Feyns, L. V., 190
——*see* Hwang, D. R., 1074
Drummer, O. H., *see* Mihaly, G. W., 1155
D'Silva, J. B., and Notari, R. E., stability-indicating colorimetric assay for indicine *N*-oxide using TLC, 471
Duchêne, D., *see* Cruaud, O., 607
Dunn, W. J., III, Powers, J., Kaddu, J. B., and Njogu, A. R., 1-(*p*-tolyl)-3-acetyl-3-methyltriazene: a compound with activity against African trypanosomiasis, 1465
Durrheim, H., Flynn, G. L., Higuchi, W. I., and Behl, C. R., permeation of hairless mouse skin I: experimental methods and comparison with human epidermal permeation by alkanols, 781
Dutcher, J. S., *see* Carter, J. E., 1439
Duvall, R. N., *see* Gold, G., 384

E

Earley, J., *see* Glover, W., 601
Early, S., *see* Born, J. L., 850
Eastwood, G., *see* Lesko, L. J., 358
Eaves, T., *see* Kaur, R., 1317, 1321
Ecanow, B., *see* Prancan, A. V., 970
Edberg, S. C., and Miskin, A., turbidimetric determination of blood aminoglycoside levels by growth curve analysis, 1442
Edel, B., and Baltzer, M. O., nonisothermal kinetics with programmed temperature steps, 287
Edelson, J., *see* Park, G. B., 603
Edman, P., Ekman, B., and Sjöholm, I., immobilization of proteins in microspheres of biodegradable polyacryldextran, 838
Ehrsson, H., Eksborg, S., Wallin, I., Mårde, Y., and Joansson, B., determination of chlorambucil in plasma by GLC with selected-ion monitoring, 710
——Eksborg, S., Wallin, I., and Nilsson, S.-O., degradation of chlorambucil in aqueous solution, 1091
Ekman, B., *see* Edman, P., 838
Eksborg, S., *see* Ehrsson, H., 710, 1091
El-Azizi, M. M., Ateya, A. M., Svoboda, G. H., Schiff, P. L., Jr., Slatkin, D. J., and Knapp, J. E., chemical constituents of *Curatella americana* (Dilleniaceae), 360
Elberling, J. A., *see* Nagasawa, H. T., 1022
Elford, H. L., *see* van't Riet, B., 856
Elliott, R. L., *see* Amidon, G. L., 1363, 1369
Ellis, K. O., Schwan, T. J., Wessels, F. L., and Miles, N. J., 1-(substituted benzyl)-3,4,5,6-tetrahydro-2(1*H*)-pyrimidones: a series with stimulant and depressant activities, 1194
——Wessels, F. L., Burns, R. H., and Pong, S. F., pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1*H*)-pyrimidone, a novel antidepressant compound with antianxiety activity, 1198
——White, R. L., Jr., Wright, G. C., and Wessels, F. L., synthesis and skeletal muscle relaxant activity of quaternary ammonium salts of dantrolene and clodanolene, 327
——*see* Schwan, T. J., 1203
El-Masry, S., Korany, M. A., and Abou-Donia, A. H. A., colorimetric and spectrophotometric determinations of hydrastis alkaloids in pharmaceutical preparations, 597
El-Rabbat, N. A., *see* Omar, N. M., 24
El-Rashidy, R., and Niazi, S., comparative pharmacokinetics of butylated hydroxyanisole and butylated hydroxytoluene in rabbits, 1455
El-Sayed, A. A., *see* Badawi, A. A., 492
Elsohly, M. A., and Turner, C. E., GLC analysis of poison ivy and poison oak urushiol components in vegetable oil preparations, 587
——*see* Wirth, P. W., 1359
Elvin, A. T., Keenaghan, J. B., Byrnes, E. W., Tenthorey, P. A., McMaster, P. D., Takman, B. H., Lalka, D., Manion, C. V., Baer, D. T., Wolshin, E. M., Meyer, M. B., and Ronfeld, R. A., tocainide conjugation in humans: novel biotransformation pathway for a primary amine, 47
Elwood, C. M., *see* McNamara, P. J., 749
El-Yazigi, A., and Said, S. A., khellin determination in human serum and urine by high-performance liquid chromatography, 1434
Enever, R. P., *see* Summers, M. P., 612
Eng, S. S.-C., Robayo, J. R., Porter, W., and Smith, R. E., comparison of dye dilution method to radionuclide techniques for cardiac output determination in dogs, 509
Engel, G. L., *see* Indelicato, J. M., 1183
Erdtmansky, P. E., *see* Park, G. B., 603
Erhardt, P. W., topographical model of the renal vascular dopamine receptor, 1059
——*see* Carter, J. E., 1439
——*see* Lai, C.-M., 681
Erhardt, S., *see* Kaul, R., 531
Erhart, M., *see* Andermann, G., 215
Evans, M. A., GLC microdetermination of indomethacin in plasma, 219

F

Fabregas, J. L., and Beneyto, J. E., simultaneous determination of cephalexin and lysine in their salt using high-performance liquid chromatography of derivatives, 1378
Fairbrother, J. E., Heyes, W. F., Clarke, G., and Wood, P. R., evaluation of nystatin stability using tristimulus colorimetry, 697
Farnsworth, N. R., Cordell, G. A., and Kaas, C. J., what is odoratin?, 1107
Fawzi, M. B., Davison, E., and Tute, M. S., rationalization of drug complexation in aqueous solution by use of Hückel frontier molecular orbitals, 104
Feiccabrino, J. A., *see* Kupchik, E. J., 340
Feijen, J., Gregonis, D., Anderson, C., Petersen, R. V., and Anderson, J., coupling of steroid hormones to biodegradable poly(α-amino acids) I: norethindrone coupled to poly-N^6-(3-hydroxypropyl)-L-glutamine, 871
Feldkamp, J. R., *see* Browne, J. E., 811, 816, 1393
Feldman, S., *see* Cascella, P. J., 643
Ferguson, R. T., *see* Carlin, J. R., 1111
Fernández-Alonso, J. I., *see* Ortiz, A., 378
Feyns, L. V., Beisler, J. A., Driscoll, J. S., and Adamson, R. A., synthesis of propranolol mustard as a possible lung-specific antitumor agent, 190
Fifer, E. K., *see* Baker, J. K., 590
Fink, D. W., *see* Shim, J.-S. K., 275
Flanagan, T., *see* Levandoski, P., 1353
Fletcher, T. L., *see* Pan, H.-L., 122
Floyd, E., *see* Korn, N., 1014
Flynn, G. L., review of "Substituent Constants for Correlation Analysis in Chemistry and Biology," 1109
——*see* Durrheim, H., 781
——*see* Yu, C. D., 770
Foster, E., *see* Blickenstaff, R. T., 556
Foster, T., *see* Hussain, A., 1240
Foulon, M., *see* Houssin, R., 888
Fourtillan, J. B., *see* Lefebvre, M. A., 1216
Fox, J. L., *see* Yu, C. D., 770, 772, 775
Foye, W. O., review of "Comprehensive Organic Chemistry," 753
——and Kauffman, J. M., antileukemic activity of 2-bis(2-methylthio)vinyl -1- methylquinolinium iodides, 477
——Karkaria, M. M., and Parsons, W. H., antiradiation compounds XVII: binding ability of radiation-protective *N*-heterocyclic aminoethyl disulfides and thiosulfates to DNA, 84
Franz, R. M., Banker, G. S., Buck, J. R., and Peck, G. E., cost evaluation of alternative pharmaceutical tableting processes by simulation, 621
Frascella, D. W., *see* Rosenberg, J. M., 350
Freeman, J. J., *see* Powers, D. L., 473
Friedman, A. M., *see* Huang, C. C., 984
Fritz, P., *see* Roehrig, G. R., 1232
Frøkjaer, S., *see* Hoelgaard, A., 413
Fuhrmann, F., *see* Skinner, W. A., 196
Fujii, S., *see* Marunaka, T., 1296
Funaki, T., *see* Watari, N., 106
Fung, H.-L., *see* Arena, C., 356
Fung, R. M., and Parrott, E. L., measurement of film-coating adhesiveness, 439
Funk, M. L., *see* Harrison, L. I., 1268
Furukawa, H., *see* Imakura, Y., 1044
——*see* Lee, K.-H., 1050

G

Galy, A.-M., *see* Levayer, C., 116
Ganjian, F., Cutie, A. J., and Jochsberger, T., *in vitro* adsorption studies of cimetidine, 352
Gans, K. R., Wood, D. J., and Rossi, G. V., brain-to-blood and saliva-to-blood mepivacaine ratios in rats, 217
Garceau, Y., Brisson, J., Davis, I., DeAngelis, R. L., and Hasegawa, J., TLC determination of griseofulvin in plasma and 6-demethylgriseofulvin in urine, 561
Garcia, D. B., Brown, R. G., and Delgado, J. N., synthesis, stereochemical analysis, and neuromuscular blocking activity of selected *E,E*- and *Z,Z*-isomeric *O*-ethers of 4-androstene-3,17-dione dioximes, 995
Garrett, E. R., and Gurkan, T., pharmacokinetics of morphine and its surrogates IV: pharmacokinetics

of heroin and its derived metabolites in dogs, 1116
Gautieri, R. F., review of "Catalog of Teratogenic Agents, 3rd Ed.," 1362
——*see* Mahalik, M. P., 703
——*see* Russell, J. A., 214
Gaver, R. C., *see* Pfeffer, M., 398
Gee, W. L., *see* Smith, D. E., 571
Gelber, L., high-performance liquid chromatographic analysis of nitroglycerin ointment, 1084
Gelpi, E., *see* Traveset, J., 629
Genua, M. I., Giraldez, J., Rocha, E., and Monge, A., effects of antibiotics on platelet functions in human plasma *in vitro* and dog plasma *in vivo,* 1282
Gershon, H., and Shanks, L., antifungal properties of *n*-alkanols, α,ω-*n*-alkanediols, and ω-chloro-α-alkanols, 381
Ghani, M., *see* Shek, E., 1135
Ghosal, S., and Jaiswal, D. K., chemical constituents of Gentianaceae XXVIII: flavonoids of *Enicostemma hyssopifolium* (Willd.) Verd., 53
Giacomini, K. M., Nakeeb, S. M., and Levy, G., pharmacokinetic studies of propoxyphene I: effect of portacaval shunt on systemic availability in dogs, 786
Giannaccini, B., *see* Di Coli, G., 387
Gibson, J. K., *see* Korn, N., 1010
Giraldez, J., *see* Genua, M. I., 1282
Giraldi, T., Goddard, P. M., Nisi, C., and Sigon, F., antitumor activity of hydrazones and adducts between aromatic aldehydes and *p*-(3,3-dimethyl-1-triazeno)benzoic acid hydrazide, 97
——*see* Lassiani, L., 1098
Girault, J., *see* Lefebvre, M. A., 1216
Giumanini, A., *see* Casalini, C., 164
Glant, S. K., *see* Chapman, S. K., 733
Glover, W., Earley, J., Delaney, M., and Dixon, R., radioimmunoassay of flurazepam in human plasma, 601
Goddard, P. M., *see* Giraldi, T., 97
Goehl, T. J., Sundaresan, G. M., Hunt, J. P., Prasad, V. K., Toothaker, R. D., and Welling, P. G., suppression of endogenous hydrocortisone with dexamethasone, 1409
Gokhale, R. D., *see* Miller, S. C., 615
Gold, G., Duvall, R. N., and Palermo, B. T., new instrumentation for determining flexure-breaking strength of capsule-shaped tablets, 384
Goldenberg, M. M., *see* Burch, H. A., 107
Gonzalo, R., *see* Traveset, J., 629
Gordon, N. A., *see* Yu, C. D., 775
Goromaru, T., *see* Baba, S., 1300
Grady, L. T., and Thakker, K. D., stability of solid drugs: degradation of ergocalciferol (vitamin D_2) and cholecalciferol (vitamin D_3) at high humidities and elevated temperatures, 1099
Grady, R. W., *see* Bhargava, K. K., 986
Graham, B. W., *see* DeJuliis, C. M., 731
Grant, D. J. W., *see* Kaur, R., 1317, 1321
Grebow, P. E., *see* Johnston, M. M., 1158
Green, J. F., Jham, G. N., Neumeyer, J. L, and Vouros, P., aporphines XXVI: GLC and mass spectrometric properties of trifluoroacetyl derivatives of *N*-methyl-, *N*-propyl-, and noraporphines, 936
Green, M., Guideri, G., and Lehr, D., role of α- and β-adrenergic activation in ventricular fibrillation death of corticoid-pretreated rats, 441
Greenblatt, D. J., electron-capture GLC determination of clobazam and desmethylclobazam in plasma, 1351
Greene, D. S., *see* Schwartz, P. A., 1345
Gregoire, J., *see* Heusse, D., 273
Gregonis, D., *see* Feijen, J., 871
Grieve, R. J., *see Phillips,* T. A., 1428
Grill, H., *see* Wagner, J., 1423
Groutas, W. C., *see* Theodorakis, M. C., 581
Gubbens-Stibbe, J. M., *see* de Boer, A. G., 804
Guerret, M., Lavene, D., and Kiechel, J. R., determination of pindolol in biological fluids by electron-capture GLC, 1191
Guideri, G., *see* Green, M., 441
Gullo, J. M., *see* Heilman, W. P., 282
Gupta, A., *see* Gupta, V. D., 1145
Gupta, B. M., see Miszuk, S., 713
Gupta, V. D., high-pressure liquid chromatographic determination of salicylic acid in aspirin powder and pharmaceutical dosage forms, 113
—— simultaneous quantitation of acetaminophen, aspirin, caffeine, codeine phosphate, phenacetin, and salicylamide by high-pressure liquid chromatography, 110
——and Gupta, A., effect of pyridoxal 5-phosphate on carbidopa and decarboxylation of levodopa, 1145
——and Stewart, K. R., quantitation of carbenicillin disodium, cefazolin sodium, cephalothin sodium, nafcillin sodium, and ticarcillin disodium by high-pressure liquid chromatography, 1264
——*see* Shah, K. A., 594
Gurka, D. F., Kolinski, R. E., Myrick, J. W., and Wells, C. E., scope of differential UV and differential fluorescence assays for phenothiazines: comparison with official methods, 1069
Gürkan, T., *see* Garrett, E. R., 1116

H

Habara, T., *see* Sasahara, K., 261, 1374
Habeger, L. E., *see* Carlson, M., 826
Habib, A.-A. M., false-positive alkaloid reactions, 37
Haddadin, M., *see* Hussain, A. A., 364
Hadley, W. M., *see* Born, J. L., 465
Halat, M. J., *see* Anderson, W. K., 232
Hall, I. H., review of "The Anticancer Drugs," 484
——, Hall, J. E., Jr., Mohseni, M., and Sajadi, Z., anti-inflammatory activity of diazomethyl ketone and chloromethyl ketone analogs prepared from *N*-tosyl amino acids, 1451
——Holshouser, M. H., and Loeffler, L. J., effects of *cis*-malonato-diammino platinum(II) on P-388 lymphocytic leukemia cell metabolism, 1160
——Lee, K. H., Starnes, C. O., Muraoka, O., Sumida, Y., and Waddell, T. G., antihyperlipidemic activity of sesquiterpene lactones and related compounds, 694
——Lee, K. H., Williams, W. L., Jr., Kimura, T., and Hirayama, T., antitumor agents XLI: effects of eupaformosanin on nucleic acid, protein, and anaerobic and aerobic glycolytic metabolism of Ehrlich ascites cells, 294
——Starnes, C. O., Jr., Lee, K. H., and Waddell, T. G., mode of action of sesquiterpene lactones as anti-inflammatory agents, 537
——Starnes, C. O., McPhail, A. T., Wisian-Neilson, P., Das, M. K., Harchelroad, F., Jr., and Spielvogel, B. F., anti-inflammatory activity of amine cyanoboranes, amine carboxyboranes, and related compounds, 1025
——*see* Imakura, Y., 1044
——*see* Lee, K.-H., 1050
Hall, J. E., Jr., *see* Hall, I. H., 1451
Hamid, K. A., *see* Razzak, K. S. A., 796
Hanifin, J. W., *see* Regan, B. A., 789
Hanks, M., *see* Loebenberg, D., 739
Hanson, R. N., *see* Kam, S.-T., 1007
Harchelroad, F., Jr., *see* Hall, I. H., 1025
Hargrove, J. C., *see* Bloedow, D. C., 32
Harris, A. S., Kirstein-Pedersen, A., Stenberg, P., Ulmsten, U., and Wingerup, L., preparation, characterization, and stability of new prostaglandin E_2 gel for local administration, 1271
Harrison, L. I., Funk, M. L., and Ober, R. E., high-pressure liquid chromatographic determination of salicylsalicylic acid, aspirin, and salicylic acid in human plasma and urine, 1268
Hasegawa, J., *see* Garceau, Y., 561
Hasumi, S., *see* Sonobe, T., 410
Heilman, R. D., *see* Heilman, W. P., 282
Heilman, W. P., Heilman, R. D., Scozzie, J. A., Wayner, R. J., Gullo, J. M., and Ariyan, Z. S., synthesis and anti-inflammatory evaluation of 3-methylthio-1,2,4-triazines, 3-alkoxy-1,2,4-triazines, and 3-aryloxy-1,2,4-triazines, 282
Held, H. R., and Landi, S., binding of toxic metabolites of isoniazid by aconiazide, 1284
Hem, S. L., *see* Browne, J. E., 811, 816, 1393
——*see* Cornejo, J., 945
——*see* Wang, M. K., 668
Hempel, B., *see* Kaul, R., 531
Hénichart, J.-P., see Bernier, J. L., 1343
——*see Houssin, R., 888*
Henry, D. R., and Block, J. H., pattern recognition of steroids using fragment molecular connectivity, 1030
Henschler, D., *see* Wagner, J., 1423
Heotis, J. P., *see* Wright, G. C., 842
Herbst, D. V., applications of TLC and bioautography to detect contaminated antibiotic residues: tetracycline identification scheme, 616
Hermosin, M. C., *see* Cornejo, J., 945
Herrett, R. J., *see* Wright, G. C., 842
Heusse, D., Populaire, P., Renard, A., Pasquier, P., and Gregoire, J., determination of nofedone in human serum by electron-capture GLC, 273
Heyes, W. F., *see* Fairbrother, J. E., 697
Heyndrickx, A., *see* Van Peteghem, C., 118
Higuchi, T., *see* Anderson, B. D., 676
——*see* Mikkelson, T. J., 133
——*see* Nishihata, T., 744
Higuchi, W. I., *see* Corrigan, O. I., 869
——*see* Durrheim, H., 781
——*see* Yu, C. D., 770, 772, 775
Hill, J., Roussin, A., LeLorier, J., and Caille, G., high-pressure liquid chromatographic determination of lidocaine and its active deethylated metabolites, 1341
Hiller, F. C., Mazumder, M. K., Wilson, J. D., and Bone, R. C., effect of low and high relative humidity on metered-dose bronchodilator solution and powder aerosols, 334
Hillman, G. R., Chu, S.-H., and Dotson, M. J., effects of dansylated acetylcholine analogs on *Schistosoma mansoni,* 516
Hillman, R., *see* Chandrasekaran, S. K., 1311
Himmelstein, K. J., *see* Miller, S. C., 615
Hirai, S., Hussain, A., and Babhair, S., sensitive method for determination of ethinyl estradiol in presence of norethindrone, 857
——*see* Hussain, A., 738, 1240, 1411
Hirayama, T., *see* Hall, I. H., 294
Ho, N. F. H., *see* Yu, C. D., 770, 772, 775
Hoelgaard, A., and Frøkjaer, S., adsorption of lecithin by cholesterol, 413
Hofmann, A. F., *see* Corrigan, O. I., 869
Holak, W., and Plank, W. M., differential pulse polarographic determination of colchicine, 1436
Holford, N. H. G., *see* Upton, R. A., 1254
Hollenbeck, R. G., determination of differential heat of solution in real solutions from variation in solubility with temperature, 1241
Holshouser, M. H., *see* Hall, I. H., 1160
Honigberg, I. L., and Stewart, J. T., radioimmunoassay of hydromorphone and hydrocodone in human plasma, 1171
Hopfer, U., *see* Will, P. C., 747
Hori, R., *see* Arakawa, M., 27
——*see* Okumura, K., 157
Hosono, T., Tsuchiya, S., and Matsumaru, H., model of interaction of ajmaline with polyvinylpyrrolidone, 824
Hossie, R. D., Mousseau, N., Sved, S., and Brien, R., quantitation of acetazolamide in plasma by high-performance liquid chromatography, 348
Houssin, R., Hénichart, J.-P., Foulon, M., and Baert, F., structure–neuromuscular blocking activity relationships of ketophosphonium salts, 888
Howell, A., *see* Phillips, T. A., 1428
Hsieh, D. S. T., *see* Rhine, W. D., 265
Huang, C. C., Friedman, A. M., So, R., Simonovic, M., and Meltzer, H. Y., synthesis and biological evaluation of *p*-bromospiperone as potential neuroleptic drug, 984
Huang, H.-C., *see* Lee, K.-H., 1050
Hudgins, P. M., *see* Stubbins, J. F., 534
Hudson, J. E., *see* Soine, W. H., 1040
Hufford, C. D., Sharma, A. S., and Oguntimein, B. O., antibacterial and antifungal activity of liriodenine and related oxoaporphine alkaloids, 1180
Humphrey, D. W., *see* Wilcox, R. E., 974
Hundertmark, J. M., *see* Rosenberg, J. M., 350
Hunt, J. P., *see* Goehl, T. J., 1409
Hurlbert, B. S., *see* Brent, D. A., 906
Hussain, A., Foster, T., Hirai, S., Kashihara, T., Batenhorst, R., and Jones, M., nasal absorption of propranolol in humans, 1240
——Hirai, S., and Bawarshi, R., nasal absorption of propranolol from different dosage forms by rats and dogs, 1411
——Hirai, S., and Sieg, J., ocular absorption of propranolol in rabbits, 738

——*see* Hirai, S., 857
Hussain, A. A., Haddadin, M., and Iga, K., reaction of *cis*-platinum with sodium bisulfite, 364
——*see* Truelove, J. E., 231
Hwang, D. R., Proctor, G. R., and Driscoll, J. S., pyridones as potential antitumor agents II: 4-pyridones and bioisosteres of 3-acetoxy-2-pyridone, 1074
Hwang, S., and Kwan, K. C., further considerations on model-independent bioavailability estimation, 77

I

Ibrahim, E.-S. A., Omar, A.-M. M. E., and Khalil, M. A., novel potential anticancer agents derived from benzimidazole, 1348
Ibuka, T., *see* Lee, K.-H., 1050
Iga, K., *see* Hussain, A. A., 364
Ikeda, K., *see* Yotsuyanagi, T., 745
Im, S., *see* Boddapati, S., 608
Imakura, Y., Lee, K.-H., Sims, D., Wu, R.-Y., Hall, I. H., Furukawa, H., Itoigawa, M., and Yonaha, K., antitumor agents XXXVI: structural elucidation of sesquiterpene lactones microhelenins-A, B, and C, microlenin acetate, and plenolin from *Helenium microcephalum,* 1044
Inamdar, P. K., Dornauer, H., and de Souza, N. J., GLC method for assay of forskolin, a novel positive inotropic and blood pressure-lowering agent, 1449
Indelicato, J. M., Stewart, B. A., and Engel, G. L., formylation of glucose by cefamandole nafate at alkaline pH, 1183
Innocenti, F., *see* Chimichi, S., 521
Inotsume, N., and Nakano, M., reversible ring-opening reactions of nimetazepam and nitrazepam in acidic media at body temperature, 1331
Isaacson, E. I., review of "Foundations of Molecular Pharmacology, Vol. 1: Medicinal and Pharmaceutical Chemistry," 752
Ismail, S. I., and Tawashi, R., size distribution characteristics of mineral phase in renal stones, 829
Itoigawa, M., *see* Imakura, Y., 1044

J

Jacob, J. T., *see* Arnold, J., 1416
Jager, L. P., *see* Seegers, A. J. M., 900
Jain, R. K., *see* Weissbrod, J. M., 691
Jaiswal, D. K., *see* Ghosal, S., 53
Jamieson, D. D., de Rome, P. J., and Taylor, K. M., potent inhibition of oxidative phosphorylation by marine natural products, 462
Janicki, C. A., and Daly, K. F., stability-indicating assay for tolmetin sodium in solid dosage forms, 147
——*see* Ko, C. Y., 1081
Jarowski, C. I., *see* Chang, K. S., 466
Jham, G. N., *see* Green, J. F., 936
Jindal, S. P., Lutz, T., and Vestergaard, P., GLC–mass spectrometric determination of maprotiline and its major metabolite using stable isotope-labeled analog as internal standard, 684
Joansson, B., *see* Ehrsson, H., 710
Jochsberger, T., *see* Ganjian, F., 352
Johansen, M., *see* Bundgaard, H., 44
Johnson, N. F., *see* Rocci, M. L., Jr., 977
Johnston, M. M., Rosenberg, M. J., Yeung, A. K., and Grebow, P. E., automated analysis of indapamide in drug–rodent food mixtures, 1158
Jones, M., *see* Hussain, A., 1240
Jones, R. E., *see* Shek, E., 1135
Judis, J., effect of human serum albumin concentration on binding of [^{3}H]amphetamine, [^{3}H]atropine, [^{3}H]epinephrine, and [^{14}C]histamine, 885
——protein concentration effects on binding of [^{14}C]codeine, [^{14}C]morphine, and [^{3}H]methadone to human serum albumin, 71
Juenge, E. C., *see* Brower, J. F., 942
Juhl, W. E., and Kirchhoefer, R. D., aspirin—a national survey IV: *in vitro* dissolution of aspirin formulations, 967
——and Kirchhoefer, R. D., aspirin—a national survey I: semiautomated determination of aspirin in bulk and tablet formulations and salicylic acid in tablet formulations, 544
——see Kirchhoefer, R. D., 548, 550
Jun, H. W., and Lee, B. H., distribution of tetracycline in red blood cells, 455
——*see* Strom, J. G., Jr., 1261
Jusko, W. J., *see* Rocci, M. L., Jr., 977

K

Kaas, C. J., *see* Farnsworth, N. R., 1107
Kaddu, J. B., *see* Dunn, W. J., III, 1465
Kam, S.-T., Hanson, R. N., and Portoghese, P. S., synthesis and biological evaluation of 2,3-diazabicyclo[2.2.1]heptane derivatives as prostaglandin endoperoxide analogs, 1007
Kamath, B. L., and Yacobi, A., half-life of *N*-acetylprocainamide in rats, 864
——*see* Lai, C.-M., 681, 982
——*see* Yacobi, A., 1077
Kampa, I. S., *see* Rosenberg, J. M., 350
Kaneniwa, N., *see* Watari, N., 106
Kanke, M., Simmons, G. H., Weiss, D. L., Bivins, B. A., and DeLuca, P. P., clearance of ^{141}Ce-labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration in beagle dogs, 755
Kante, B., *see* Couvreur, P., 199
Kao, Y. J., and Loo, T. L., pharmacological disposition of negatively charged phospholipid vesicles in rats, 1338
Kapeghian, J. C., *see* Borne, R. F., 1104
Karkaria, M. M., *see* Foye, W. O., 84
Kashihara, T., *see* Hussain, A., 1240
Kashiwagi, M., Mynderse, J. S., Moore, R. E., and Norton, T. R., antineoplastic evaluation of Pacific basin marine algae, 735
Kasuya, Y., *see* Baba, S., 1300
Kauffman, J. M., *see* Foye, W. O., 477
Kaul, R., Kiefer, G., Erhardt, S., and Hempel, B., 2-^{14}C-1-(2′-deoxy-β-D-ribofuranosyl) -5- ethyluracil: synthesis and biotransformation in rats, 531
Kaur, R., Grant, D. J. W., and Eaves, T., comparison of polyethylene glycol and polyoxyethylene stearate as excipients for solid dispersion systems of griseofulvin and tolbutamide I: phase equilibria, 1317
——Grant, D. J. W., and Eaves, T., comparison of polyethylene glycol and polyoxyethylene stearate as excipients for solid dispersion systems of griseofulvin and tolbutamide II: dissolution and solubility studies, 1321
Kawashima, Y., *see* Takenaka, H., 513, 1388
Kawata, H., *see* Sonobe, T., 410
Keck, R. G., *see* Spanggord, R. J., 444
Keenaghan, J. B., *see* Elvin, A. T., 47
Khalil, M. A., *see* Ibrahim, E.-S. A., 1348
Kidd, M. R., *see* Wallace, J. L., 1357
Kiechel, J. R., *see* Guerret, M., 1191
Kiefer, G., *see* Kaul, R., 531
Kier, L. B., molecular structure influencing either a sweet or bitter taste among aldoximes, 416
——review of "Computer-Assisted Drug Designs," 994
——structural information from molecular connectivity $^4\chi_{PC}$ index, 1034
——use of molecular negentropy to encode structure governing biological activity, 807
——*see* Richard, A. J., 126
——*see* van't Riet, B., 856
Kimura, T., *see* Hall, I. H., 294
Kindelspire, P. D., *see* Cascella, P. J., 972
Kinghorn, A. D., major skin-irritant principle from *Synadenium grantii,* 1446
Kingston, David G. I., review of "The Alkaloids: The Fundamental Chemistry—A Biogenetic Approach," 367
Kirchhoefer, R. D., simultaneous determination of aspirin and salicylic acid in bulk aspirin and in plain, buffered, and enteric-coated tablets by high-pressure liquid chromatography with UV and fluorescence detectors, 1188
——and Juhl, W. E., aspirin—a national survey II: determination of salicylic acid in bulk aspirin and aspirin formulations by high-pressure liquid chromatography using a fluorescence detector, 548
——Reepmeyer, J. C., and Juhl, W. E., aspirin—a national survey III: determination of impurities in bulk aspirin and aspirin formulations by high-pressure liquid chromatography and spectrophotometry, 550
——*see* Juhl, W. E., 544, 967
Kirkman, S. K., *see* McHugh, S. L., 794
Kirkman-Bey, N., *see* VandenHeuvel, W. J. A., 1288
Kirschbaum, J., high-pressure liquid chromatography of triamcinolone acetonide: effect of different octadecylsilane columns on mobility, 481
Kirstein-Pedersen, A., *see* Harris, A. S., 1271
Klein, L. R., *see* Carter, J. E., 1439
Kluza, R. B., *see* Ng, A. S., 30
Knapp, J. E., *see* El-Azizi, M. M., 360
Knapp, J. Z., *see* Miszuk, S., 713
Kniffen, F. J., *see* Korn, N., 1010
Knowles, J. A., *see* McHugh, S. L., 794
Ko, C. Y., Marziani, F. C., and Janicki, C. A., high-performance liquid chromatographic assay of codeine in acetaminophen with codeine dosage forms, 1081
Kobayashi, Y., *see* Sonobe, T., 410
Kochak, G. M., and Mason, W. D., determination of free methyldopa in plasma by high-pressure liquid chromatography and electrochemical detection, 897
——*see* Mason, W. D., 344
Koechlin, B., *see* Rubio, F., 1245
Kohl, H. H., Wheatley, W. B., Worley, S. D., and Bodor, N., antimicrobial activity of *N*-chloramine compounds, 1292
Kolinski, R. E., Myrick, J. W., and Bunch, E. A., semiautomated method for analysis of enteric-coated and plain coated diethylstilbestrol tablets, 951
——*see* Gurka, D. F., 1069
Kopiwoda, S. Y., *see* Castronovo, F. P., Jr., 87
Korany, M. A., *see* El-Masry, S., 597
Korn, N., Gibson, J. K., Kniffen, F. J., Lucchesi, B. R., Ranade, V. V., Mimnaugh, M., Yu, T., and Counsell, R. E., potential organ- or tumor-imaging agents XIX: radioiodinated antiarrhythmic drugs as potential myocardial imaging agents, 1010
——Nordbiom, G., Floyd, E., and Counsell, R. E., potential organ- or tumor-imaging agents XX: ovarian imaging with 19-radioiodinated cholesterol, 1014
Kornet, M. J., synthesis of phenylurethans of 1,2-dialkyl-4-pyrazolidinols as anticonvulsant agents, 729
Kosh, J. W., *see* Powers, D. L., 473
Kostenbauder, H. B., *see* Truelove, J. E., 231
Kothari, R., *see* Carstensen, J. T., 124, 290
Kou, J., *see* Amidon, G. L., 1369
Kowarski, A. A., *see* Kowarski, C. R., 1222
Kowarski, C. R., and Kowarski, A. A., simplified method for estimating volume of distribution at steady state, 1222
Kozuka, M., *see* Lee, K.-H., 1050
Krell, R. D., and Chakrin, L. W., preclinical evaluation of antiallergic agents, 239
——*see* Chakrin, L. W., 236
Kubiak, E. J., and Munson, J. W., determination of dextromethorphan hydrobromide by high-performance liquid chromatography using ion-pair formation, 1380
——and Munson, J. W., high-performance liquid chromatographic analysis of codeine in syrups using ion-pair formation, 152
Kullberg, M. P., *see* Park, G. B., 603
Kupchik, E. J., Pisano, M. A., Carroll, A. M., Lumpp, J. R., and Feiccabrino, J. A., antimicrobial activity of *N*-substituted *N*-(triphenylstannyl)cyanamides and triethylammonium (organocyanoamino) chlorotriphenylstannates, 340
Kwan, K. C., *see* Hwang, S., 77
Kyriakidis, G., and Barletta, M., use of mannitol to obviate propranolol-induced myocardial depression in ischemic canine heart, 447

L

Lage, G. L., review of "CRC Handbook Series in Clinical Laboratory Science, Section B: Toxicology, Vol. 1," 485
Lai, C.-M., Kamath, B. L., Carter, J. E., Erhardt, P., Look, Z. M., and Yacobi, A., GLC determination of bretylium in biological fluids, 681
——Kamath, B. L., Look, Z. M., and Yacobi, A., determination of procainamide and *N*-acetylprocainamide in biological fluids by high-pressure liquid chromatography, 982
——*see* Yacobi, A., 14, 1077
Laika, D., *see* Elvin, A. T., 47

——*see* McNamara, P. J., *749*
Landes, M. J., *see* Regan, B. A., 789
Landi, S., *see* Held, H. R., 1284
Lane, E. A., and Levy, R. H., *prediction of steady-state behavior of metabolite from dosing of parent drug,* 610
Lang, S. A., Jr., *see* Regan, B. A., 789
Langer, R., see Rhine, W. D., 265
Larcom, B. J., *see* Chang, S. Y., *80*
Larochelle, P., *see* Varin, F., 640
Larsen, B., see Chang, S. Y., 80
Lassiani, L., *Nisi, C., Sigon, F., Sava, G., and Giraldi, T., synthesis of 1-aryl-3-formyl-3-methyltriazenes, potential metabolites of 1-aryl-3,3-dimethyltriazenes, 1098*
Lau-Cam, C. A., *see* Rosenberg, J. M., 74, 350
Lavene, D., *see* Guerret, M., 1191
Law, S.-J., *see Borne, R. F., 1104*
Lawrence, R. C., Lovering, E. G., Poirier, M. A., and Watson, J. R., impurities in drugs V: meprobamate, 1444
Lee, B. H., *see* Jun, H. W., 455
Lee, C., *see* Chen, C.-H., 1061
Lee, C. S., and Wang, L. H., improved GLC determination of ethambutol, 362
——*see* Lin, C. K., 95
Lee, H., and Vince, R., carbocyclic analogs of arabinosylpurine nucleosides, 1019
Lee, K.-H., *Ibuka, T., Furukawa, H., Kozuka, M., Wu, R.-Y., Hall, I. H., and Huang, H.-C., antitumor agents XXXVIII: isolation and structural elucidation of novel germacranolides and triterpenes from Elephantopus mollis,* 1050
——*see* Hall, I. H., 294, 537, 694
——*see Imakura, Y., 1044*
Lee, S., *see* Quadrel, R. F., 718
Lee, V. H.-L., and Robinson, J. R., preliminary examination of rabbit conjunctival mucins, 430
Leesman, G. D., *see* Amidon, G. L., 1363
Leeson, G. A., *see* Cook, C. E., 1419
Lefebvre, M. A., Girault, J., Saux, M. Cl., and Fourtillan, J. B., fluorometric high-performance liquid chromatographic determination of sotalol in biological fluids, 1216
Leffert, F. H., see Thompson, J. A., 707
Legore, A. A., *see Simmons, D. L., 220*
Lehr, D., *see* Green, M., 441
LeLorier, J., *see* Hill, J., 1341
Lenaerts, V., *see* Couvreur, P., 199
Le Sher, A. R., *see* Lukas, G., 419
Lesko, L. J., Brousseau, D., Canada, A. T., and Eastwood, G., temporal variations in trough serum theophylline concentrations at steady state, 358
Levandoski, P., and Flanagan, T., use of nitrogen-specific detector for GLC determination of caramiphen in whole blood, 1353
Levayer, C., Galy, A.-M., and Barbe, J., dipole moments and conformational structures of 2-substituted phenothiazines as solutes, 116
Levinson, R. S., Buyukyaylaci, S., and Allen, L. V., Jr., oxygen solubilization in egg lecithin dispersed in distilled water and physiological electrolyte fluids, 62
Levy, G., effect of plasma protein binding on renal clearance of drugs, 482
——quantitative change in metabolic fate of drug related to serum protein binding, 746
——*see* Giacomini, K. M., 786
——*see* Roberts, S. M., 363
——*see* Takada, K., 9
——*see* Wiegand, U. W., 481, 1228
——*see* Yacobi, A., 14, 634
Levy, R. H., *see* Lane, E. A., 610
——*see* Patel, I. H., 1218
Lichtenwalner, M. R., and Speaker, T. J., substituent constants of azulene, 337
Lien, E. J., and Wang, P. H., lipophilicity, molecular weight, and drug action: reexamination of parabolic and bilinear models, 648
——*see* Wang, P. H., 662
Lightfoot, E. N., *see* Amidon, G. L., 1369
Lin, C. K., Lee, C. S., and Perrin, J. H., determination of two fenamates in plasma by high-performance liquid chromatography, 95
Lin, E. T., *see* Smith, D. E., 571
Lin, S. Y., *see* Takenaka, H., 513, 1388
Lodge, B. A., *see* Carignan, G., 1214, 1453
Loebenberg, D., *Parmegiani, R., Hanks, M., and Waitz, J. A., comparative in vitro and in vivo antifungal activity of tolnaftate and various undecylenates, 739*
Loeffler, L. J., *see* Hall, I. H., 1160
Loo, T. L., *see* Kao, Y. J., 1338
Look, Z. M., *see* Lai, C.-M., 681, 982
Loper, A., *see* Stavchansky, S., 1307
Lordi, N. G., *see* Coben, L. J., 955
Louis, W. J., *see* Mihaly, G. W., 1155
Lovering, E. G., see Butterfield, A. G., 222
——*see Curran, N. M., 187*
——*see* Lawrence, R. C., 1444
——see Matsui, F., 469
Lucchesi, B. R., *see Korn, N., 1010*
Lukas, G., Vyas, K. H., Brindle, S. D., Le Sher, A. R., and Wagner, W. E., Jr., biological disposition of *sodium dichloroacetate in animals and humans after* intravenous administration, 419
Lumpp, J. R., *see* Kupchik, E. J., 340
Lundberg, B., *simultaneous solubilization of steroid hormones III: thermodynamic evaluation,* 20
Lutz, T., *see* Jindal, S. P., 684

M

Magnin, D., see Theodorakis, M. C., 581
Mahalik, M. P., Gautieri, R. F., and Mann, D. E., Jr., *teratogenic potential of cocaine hydrochloride in* CF-1 mice, 703
——*see* Russell, J. A., 214
Mamaril, F., *see Wen, L.-F., 140*
Manion, C. V., *see* Elvin, A. T., 47
Mann, B., *see* Weinberger, R., 475
Mann, D. E., Jr., *see Mahalik, M. P., 703*
Marcec, J., *see* Roehrig, G. R., 1232
Marchand, C., *see* Varin, F., 640
Mårde, Y., *see* Ehrsson, H., 710
Marriner, S., *see* Bogan, J. A., 422
Marshall, A., *see* Mihaly, G. W., 1155
Martin, A., Newburger, J., and Adjei, A., extended Hildebrand solubility approach: solubility of theophylline *in polar binary solents,* 487
——*see* Adjei, A., 659
——*see* Stavchansky, S., 1307
Martin, C., *see Stavchansky, S., 1307*
Martin, C. J., and Saxena, S. J., high-performance liquid chromatographic determination of metaraminol bitartrate in the presence of parabens, 1459
Martin, M. K., *see* Chiou, G. C. Y., 592
Marunaka, T., Shibata, T., Minami, Y., Umeno, Y., and Shindo, T., simultaneous high-performance liquid chromatographic determination of suxibuzone and its metabolites in plasma and urine, 1258
——Umeno, Y., Yoshida, K., Nagamachi, M., Minami, Y., and Fujii, S., high-pressure liquid chromatographic determination of ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC–mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur, 1296
Marziani, F. C., *see* Ko, C. Y., 1081
Mascellani, G., *see* Casalini, C., 164
Mason, J. T., Jr., *quantitative determination of titanium* in a commercial sunscreen formulation by atomic absorption spectrometry, 101
Mason, W. D., comparative plasma salicylate and urine salicylurate levels following administration of aspirin, magnesium salicylate, and choline magnesium trisalicylate, 1355
——Kochak, G., Winer, N., and Cohen, I., effect of exercise on renal clearance of atenolol, 344
——*see* Kochak, G. M., 897
Massias, P., *see* Sioufi, A., 1413
Masten, L. W., *see* Borne, R. F., 1104
Mata, R., and McLaughlin, J. L., cactus alkaloids XLII: 3,4-dimethoxy-β-phenethylamine and heliamine from the Mexican cereoid *Backebergia militaris,* 94
Matsui, F., Robertson, D. L., Poirier, M. A., and Lovering, E. G., identification of degradation products in phenylbutazone tablet formulation, 469
Matsumaru, H., *see* Hosono, T., 824
Mattson, R. J., *see* DeJuliis, C. M., 731
Maulding, D. L., and Young, J. F., high-pressure liquid chromatographic analysis of salicylic acid, salicyluric acid, and gentisic acid in biological matrixes, 1224
Mayol, R. F., *see* Pittman, K. A., 160
Mazumder, M. K., *see Hiller, F. C., 334*
Mazzola, E. P., Melin, J. A., and Wayland, L. G., ^{13}C-NMR spectroscopy of three tetracycline antibiotics: minocycline hydrochloride, meclocycline, and rolitetracycline, 229
McComish, M., Bodek, I., and Branfman, A. R., quantitation of the antineoplastic agent indicine-*N*-oxide in human plasma by differential pulse polarography, 727
McDevitt, J. M., *see* Russell, J. A., 214
McErlane, K. M., see Curran, N. M., 187
McGary, E. D., *quantitative semiautomated colorimetric determination of thyroid (iodine) in thyroid tablets,* 948
McGinity, J. W., *review of "Microcapsule Processing and Technology,"* 485
——*see* Riffee, W. H., 980
McHugh, S. L., Kirkman, S. K., and Knowles, J. A., macro- and micromethods for high-performance liquid chromatographic analysis of oxaprozin in plasma, 794
McLaughlin, J. L., see Mata, R., 94
McMaster, P. D., *see* Elvin, A. T., 47
McNamara, P. J., Slaughter, R. L., Visco, J. P., Elwood, C. M., Siegel, J. H., and Lalka, D., effect of smoking *on binding of lidocaine to human serum proteins,* 749
McPhail, A. T., *see* Hall, I. H., 1025
McSharry, W. O., *and Savage, I. V. E., simultaneous* high-pressure liquid chromatographic determination of acetaminophen, guaifenesin, and dextromethorphan hydrobromide *in cough syrup, 212*
Mechoulam, R., *see* Bialer, M., 1334
Melethil, S., Poklis, A., and Sagar, V. A., binding of gold to bovine serum albumin using flameless atomic absorption, 585
Melin, J. A., *see* Mazzola, E. P., 229
Meltzer, H. Y., see Huang, C. C., 984
Meyer, M. B., *see* Elvin, A. T., 47
Meyer, R. C., *determination of benzalkonium chloride* by reversed-phase high-pressure liquid chromatography, 1148
Middleton, E., Jr., antiasthmatic drug therapy and calcium ions: review of pathogenesis and role of calcium, 243
Midha, K. K., *see* Varin, F., 640
Mihaly, G. W., Drummer, O. H., Marshall, A., Smallwood, R. A., and Louis, W. J., high-pressure liquid chromatographic determination of ranitidine, a new H_2-receptor antagonist, in plasma and urine, 1155
Mikkelson, T. J., Watanabe, S., Rytting, J. H., and Higuchi, T., effect of self-association of phenol on its *transport across polyethylene film,* 133
——*see* Mitra, A. K., 257
Miles, N. J., *see* Ellis, K. O., 1194
Millard, B. J., Sheinin, E. B., and Benson, W. R., thermal decomposition of propoxyphene during GLC analysis, 1177
Miller, R., *see* Pedersen, P. V., 204, 394
Miller, R. P., *see* Rotenberg, K. S., 1087
Miller, S. C., Gokhale, R. D., and Patton, T. F., pilocarpine ocular distribution volume, 615
Mimnaugh, M., *see* Korn, N., 1010
Minami, Y., *see* Marunaka, T., 1258, 1296
Miskin, A., *see* Edberg, S. C., 1442
Misra, H. K., *see* Sen Gupta, A. K., 1313
Miszuk, S., Gupta, B. M., Chen, F. C., Clawans, C., and Knapp, J. Z., video characterization of flume patterns of inhalation aerosols, 713
Mitra, A. K., Baustian, C. L., and Mikkelson, T. J., high-performance liquid chromatographic determination of pilocarpine in aqueous humor: derivatization by quaternization of methylimidazole tertiary amine group, 257
Mizutani, T., adsorption of antibody and globulin onto glass surfaces, 1226
——decreased activity of proteins adsorbed onto glass surfaces with porous glass as a reference, 279
Mohensi, M., *see* Hall, I. H., 1451
Mojaverian, P., and Chase, G. D., production and characterization of specific antibody for radioimmunoassay of procainamide, 721

Monge, A., *see* Genua, M. I., 1282
Moon, R. E., *see* Brill, P. H., 558
Moore, R. E., see Kashiwagi, M., 735
Morgan, L., *see* Rubio, F., 1245
Morioka, T., *see* Sasahara, K., 261, 1374
Moulin, M. A., see Debruyne, D., 835
Moussa, M. A., *see* Skinner, W. A., 196
Mousseau, N., *see* Hossie, R. D., 348
Mouzin, G., *see* Rieu, J.-P., 49
Muhammad, N., and Bodnar, J. A., separation and quantitation of chlortetracycline, 4-epitetracycline, 4-epianhydrotetracycline, and anhydrotetracycline in tetracycline by high-performance liquid chromatography, 928
Munson, J. W., *see* Kubiak, E. J., 152, 1380
Muraoka, O., *see* Hall, I. H., 694
Murphy, D. C., *see* Stubbins, J. F., 534
Murphy, J. C., *see* Wirth, P. W., 1359
Murphy, M. J., and Stubbins, J. F., synthesis and anticancer activity of asparagine analogs, 553
Murray, W. J., *see* Reed, K. W., 1065
Myers, M., *see* Cook, C. E., 1419
Myers, M. J., review of "Principles of Pharmaceutical Accounting," 1361
Mynderse, J. S., *see* Kashiwagi, M., 735
Myrick, J. W., *see* Gurka, D. F., 1069
——*see* Kolinski, R. E., 951

N

Nagai, T., *see* Sonobe, T., 410
Nagamachi, M., *see* Marunaka, T., 1296
Nagasawa, H. T., Elberling, J. A., and Shirota, F. N., latentiated forms of the transport-inhibitory α-amino acid adamantanine, 1022
——*see* Zera, R. T., 1005
Nakajima, E., *see* Sasahara, K., 261, 1374
Nakano, M., *see* Inotsume, N., 1331
Nakeeb, S. M., *see* Giacomini, K. M., 786
Narang, P. K., Bird, G., and Crouthamel, W. G., high-performance liquid chromatographic assay for benzocaine and *p*-aminobenzoic acid including preliminary stability data, 1384
Nardella, P. A., *see* Pfeffer, M., 801
Nash, J. F., and Carmichael, R. H., GLC determination of aprindine in human plasma using a nitrogen–phosphorus flame-ionization detector, 1094
Neal, J. M., *see* Patel, I. H., 1218
Nelson, K. G., see Shah, A. C., 210
Neumeyer, J. L., *see* Green, J. F., 936
Newburger, J., Stavchansky, S., and Pearlman, R. S., effect of time errors on infinity values obtained using Prony's method, 1231
——*see* Adjei, A., 659
——*see* Martin, A., 487
Newton, D. W., *see* Ng, A. S., 30
Ng, A. S., Kluza, R. B., and Newton, D. W., distribution coefficients and *in vitro* human serum protein binding of spironolactone and its 7-α-carboxymethyl analog, 30
Ng, S. S. M., and Bhattacharyya, P. K., solvent effects on IR spectra of flurazepam, 270
Niazi, S., *see* El-Rashidy, R., 1455
Nickols, J. G., *see* Ueda, C. T., 1400
Niebergall, P. J., *see* Bhuta, S. I., 923
Nilsson, L., *see* Roth, G., 766
Nilsson, S.-O., *see* Ehrsson, H., 1091
Nimmerfall, F., and Rosenthaler, J., dependence of area under the curve of proquazone particle size and *in vitro* dissolution rate, 605
Nishihata, T., Rytting, J. H., and Higuchi, T., enhancement of rectal absorption of drugs by adjuvants, 744
Nishimura, E., *see* Sefton, M. V., 208
Nisi, C., *see* Giraldi, T., 97
——*see* Lassiani, L., 1098
Nitanai, T., *see* Sasahara, K., 261, 1374
Njogu, A. R., *see* Dunn, W. J., III, 1465
Noonan, P. K., and Wester, R. C., percutaneous absorption of nitroglycerin, 365
Nordblom, G., *see* Korn, N., 1014
Norton, T. R., *see* Kashiwagi, M., 735
Notari, R. E., *see* Byron, P. R., 527
——*see* D'Silva, J. B., 471
——*see* Tomlinson, E., 655

O

Ober, R. E., see Harrison, L. I., 1268
O'Donnell, J. J., Sandman, R., and Drake, M. V., measurement of pilocarpine and its degradation products by high-performance liquid chromatography, 1096
O'Donnell, J. P., Azzaro, A. J., and Urquilla, P. R., preparation and biological actions of *N*-2,2,2-trifluoroethyl -2- (3,4-dihydroxyphenyl)ethylamine, 149
Oguntimein, B. O., *see* Hufford, C. D., 1180
Okerholm, R. A., *see* Cook, C. E., 1419
Okumura, K., Arakawa, M., and Hori, R., tissue distribution and metabolism of drugs VI: effect of second drugs on pancreatic distribution and insulin-releasing activity of sulfonylureas in perfused rat pancreas, 157
——*see* Arakawa, M., 27
Olling, M., see Seegers, A. J. M., 900
Omar, A.-M. M. E., *see* Ibrahim, E.-S. A., 1348
Omar, N. M., and El-Rabbat, N. A., tetrazolium salts in pharmaceutical analysis II: direct assay of diethylstilbestrol and diethylstilbestrol dipropionate, 24
Omer, A. I. H., *see* Salama, R. B., 346
Onofrey, D., *see* VandenHeuvel, W. J. A., 1288
Ortiz, A., Pardo, A., and Fernández-Alonso, J. I., spectra of radical cations of phenothiazine derivatives in solution and solid state, 378
Orzalesi, G., *see* Chimichi, S., 521
Osman, A., and Abu-Eittah, R., complex formation between copper(II) and thiobarbiturates, 1164
Osterberg, A. C., see Regan, B. A., 789

P

Page, D. P., *see* Brower, J. F., 942
Palermo, B. T., *see* Gold, G., 384
Pan, H.-L., Cole, C.-A., and Fletcher, T. L., new compounds: derivatives of fluorene XXXVII: 9-substituted 3-nitrofluorenes, 122
Pankaskie, M., and Abdel-Monem, M. M., inhibitors of polyamine biosynthesis VII: evaluation of pyruvate derivatives as inhibitors of *S*-adenosyl-L-methionine decarboxylase, 1000
Pao, J., *see* Rubio, F., 1245
Papadimitriou, D., and Sheth, B. B., reduced dialysis of nitrofurantoin and hydrocortisone acetate from methylcellulose solutions, 1173
Pardo, A., *see* Ortiz, A., 378
Park, G. B., Erdtmansky, P. E., Brown, R. R., Kullberg, M. P., and Edelson, J., analysis of mepivacaine, bupivacaine, etidocaine, lidocaine, and tetracaine, 603
Parmegiani, R., *see* Loebenberg, D., 739
Parrott, E. L., review of "Quality Control in Pharmaceutical Industry, Vol. 3," 619
——*see* Fung, R. M., 439
——*see* Simpson, M., 227
——*see* Soci, M. M., 403
Parson, R., *see* Popp, F. D., 1235
Parsons, W. H., *see* Foye, W. O., 84
Pasquier, P., *see* Heusse, D., 273
Patel, G. J., *see* Regan, B. A., 789
Patel, I. H., Levy, R. H., Neal, J. M., and Trager, W. F., simultaneous analysis of phenobarbital and *p*-hydroxyphenobarbital in biological fluids by GLC–chemical-ionization mass spectrometry, 1218
Patil, P. N., review of "Catecholamines: Basic and Clinical Frontiers, Vols. I and II," 486
Patton, T. F., *see* Miller, S. C., 615
Pearlman, R. S., *see* Newburger, J., 1231
Peck, G. E., *see* Cornejo, J., 945
——*see* Franz, R. M., 621
Pedersen, P. V., model-independent method of analyzing input in linear pharmacokinetic systems having polyexponential impulse response II: numerical evaluation, 305
——model-independent method of analyzing input in linear pharmacokinetic systems having polyexponential impulse response I: theoretical analysis, 298
——novel approach to bioavailability testing: statistical method for comparing drug input calculated by a least-squares deconvolution technique, 318
——novel deconvolution method for linear pharmacokinetic systems with polyexponential impulse response, 312
——and Miller, R., pharmacokinetics and bioavailability of cimetidine in humans, 394
——and Miller, R., pharmacokinetics of doxycycline reabsorption, 204
Peet, N. P., *N*-demethylation of dextromethorphan, 1447
Perrin, J. H., review of "Sustained and Controlled Release Drug Delivery Systems, Vol. 6," 485
——*see* Lin, C. K., 95
Petersen, R. V., *see* Feijen, J., 871
Pfeffer, M., Gaver, R. C., and Van Harken, D. R., human pharmacokinetics of a new broad-spectrum parenteral cephalosporin antibiotic, ceforanide, 398
——Smyth, R. D., Pittman, K. A., and Nardella, P. A., pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs, 801
Philip, J., and Szulczewski, D. H., identification and analysis of persistent contaminants associated with gemcadiol, 687
Phillips, E. W., *see* Vilallonga, F. A., 65, 102
Phillips, T. A., Howell, A., Grieve, R. J., and Welling, P. G., pharmacokinetics of oral and intravenous fluorouracil in humans, 1428
Picotte, P., *see* Simmons, D. L., 220
Pile, J., *see* VandenHeuvel, W. J. A., 1288
Pilpel, N., *see* Sanniez, W. H. K., 5
Pisano, M. A., *see* Kupchik, E. J., 340
Pitkin, D. H., Actor, P., and Weisbach, J. A., serum protein binding alterations of selected cephalosporin antibiotics by fatty acids and their derivatives, 354
Pitman, I. H., *see* Anderson, J. R., 832
Pittman, K. A., Smyth, R. D., and Mayol, R. F., serum levels of butorphanol by radioimmunoassay, 160
——*see* Pfeffer, M., 801
Plaizier-Vercammen, J. A., and De Nève, R. E., interaction of povidone with aromatic compounds I: evaluation of complex formation by factorial analysis, 1403
Plank, W. M., *see* Holak, W., 1436
Pocelinko, R., *see* Rubio, F., 1245
Poirier, M. A., *see* Lawrence, R. C., 1444
——*see* Matsui, F., 469
Poklis, A., *see* Melethil, S., 585
Polesuk, J., disintegration test for hard gelatin capsules, 749
Pommier, F., *see* Sioufi, A., 167
Pong, S. F., *see* Ellis, K. O., 1198
——*see* Wessels, F. L., 1102
Poochikian, G. K., and Cradock, J. C., stability of brompton mixtures: determination of heroin (diacetylmorphine) and cocaine in presence of their hydrolysis products, 637
Popp, F. D., Parson, R., and Donigan, B. E., synthesis of potential anticonvulsants: condensation of isatins with acetone and related ketones, 1235
——*see* Bhattacharjee, D., 120
Populaire, P., *see* Heusse, D., 273
Porter, W., *see* Eng, S. S.-C., 509
Portoghese, P. S., *see* Kam, S.-T., 1007
Posluszny, J., *see* Weinberger, R., 475
Potsaid, M. S., *see* Castronovo, F. P., Jr., 87
Powers, D. L., Sowell, J. W., Sr., Freeman, J. J., and Kosh, J. W., anticonvulsant properties of selected pyrrolo[2,3-*d*]pyrimidine-2,4-diones and intermediates, 473
Powers, J., *see* Dunn, W. J., III, 1465
Prancan, A. V., Ecanow, B., Bernardoni, R. J., and Sadove, M. S., poloxamer 188 as vehicle for injectable diazepam, 970
Prasad, V. K., *see* Carstensen, J. T., 290
——*see* Goehl, T. J., 1409
Prieto, J. G., *see* Salto, F., 501
Proctor, G. R., *see* Hwang, D. R., 1074
Pronk, J., *see* de Boer, A. G., 804
Pugh, D., *see* Schwan, T. J., 1203
Puisieux, F., *see* Cruaud, O., 607

Q

Quadrel, R. F., Lee, S., and Bogdansky, F. M., microcolumn chromatographic cleanup and GLC determination of 11-methyl-16,16-dimethylprostaglandin E_2 in polyethylene glycol 400 solutions, 718

Quincy, C., *see* Bannier, A., 763

R

Ragouzeos, A., *see* Brent, D. A., 906
Ralston, D. H., *see* Bloedow, D. C., 32
Ranade, V. V., *see* Korn, N., 1010
Razzak, K. S. A., and Hamid, K. A., electronic study of receptor binding of analgesic aryl moiety II: prodine analogs, 796
Reed, K. W., Murray, W. J., and Roche, E. B., acetylcarnitine and cholinergic receptors, 1065
Reepmeyer, J. C., *see* Kirchhoefer, R. D., 550
Regan, B. A., Hanifin, J. W., Landes, M. J., Osterberg, A. C., Patel, G. J., Ridge, D. N., Sloboda, A. E., and Lang, S. A., Jr., anti-inflammatory and analgesic profile of amidines of 3-amino-1,2,4-benzotriazine and 3-amino-1,2,4-benzotriazine-1-oxide, 789
Reid, V., *see* Rosenberg, J. M., 350
Renard, A., *see* Heusse, D., 273
Renzi, G., *see* Canti, G., 1220
Repta, A. J., *see* Beltagy, Y. A., 1168
Rhine, W. D., Hsieh, D. S. T., and Langer, R., polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics, 265
Rhodes, C. T., *see* Schwartz, P. A., 1345
Ribon, B., *see* Bannier, A., 763
Richard, A. J., and Kier, L. B., structure–activity analysis of hydrazide monoamine oxidase inhibitors using molecular connectivity, 125
Ridge, D. N., *see* Regan, B. A., 789
Riegelman, S., *see* Upton, R. A., 1254
Rieu, J.-P., Mouzin, G., Cousse, H., and Boucherle, A., secondary products of itanoxone, 49
Riffee, W. H., Wilcox, R. E., Anderson, J. A., and McGinity, J. W., polydimethylsiloxane pellets for sustained delivery of morphine in mice, 980
——*see* Wilcox, R. E., 974
Riley, B., *see* Arnold, J., 1416
Riley, T. N., review of "Alicyclic Chemistry, Vol. 6," 130
Robayo, J. R., *see* Eng, S. S.-C., 509
Roberts, L. R., Steinrauf, L. K., and Blickenstaff, R. T., new evaluation of potential methylmercury scavengers, 964
——*see* Blickenstaff, R. T., 556
Roberts, S. M., and Levy, G., pharmacokinetic studies of propoxyphene IV: effect of renal failure on systemic clearance in rats, 363
Robertson, D. L., *see* Matsui, F., 469
Robinson, J. R., *see* Conrad, J. M., 875
——*see* Lee, V. H.-L., 430
Rocci, M. L., Jr., Johnson, N. F., and Jusko, W. J., serum protein binding of prednisolone in four species, 977
Rocha, E., *see* Genua, M. I., 1282
Roche, E. B., *see* Reed, K. W., 1065
Roden, P., *see* Townley, E., 523
Roehrig, G. R., Billman, J. H., Marcec, J., Fritz, P., and Shea, F., synthesis and antitumor activity of 4-[*p*-[bis(2-chloroethyl)amino]phenyl]butyrates, 1232
Roland, M., *see* Couvreur, P., 199
Ronfeld, R. A., *see* Elvin, A. T., 47
Rosanske, T. W., and Connors, K. A., stoichiometric model of α-cyclodextrin complex formation, 564
——*see* Connors, K. A., 173
Rosenberg, J. M., and Lau-Cam, C. A., small animal model for evaluating neuroleptic potency, 74
——Kampa, I. S., Reid, V., Hundertmark, J. M., Frascella, D. W., and Lau-Cam, C. A., effect of hyperthermically elevated serum prolactin on epididymal cyclic AMP (adenosine 3′,5′-cyclic monophosphate) levels in rats, 350
Rosenberg, M. J., *see* Johnston, M. M., 1158
Rosenthal, R. R., clinical evaluation of antiallergic agents, 251
Rosenthaler, J., *see* Nimmerfall, F., 605
Rossi, G. V., *see* Gans, K. R., 217
Rotenberg, K. S., Miller, R. P., and Adir, J., pharmacokinetics of nicotine in rats after single-cigarette smoke inhalation, 1087
Roth, G., Wikby, A., Nilsson, L., and Thalén, A., high-performance liquid chromatographic determination of epimers, impurities, and content of the glucocorticoid budesonide and preparation of primary standard, 766
Roussin, A., *see* Hill, J., 1341
Rubio, F., Seawall, S., Pocelinko, R., DeBarbieri, B., Benz, W., Berger, L., Morgan, L., Pao, J., Williams, T. H., and Koechlin, B., metabolism of carprofen, a nonsteroidal anti-inflammatory agent, in rats, dogs, and humans, 1245
Ruch, E., *see* DiGregorio, G. J., 1457
Rupe, B. D., *see* Seymour, D., 701
Russell, J. A., Mahalik, M. P., McDevitt, J. M., and Gautieri, R. F., nonvariance of LD_{50} values of drugs in gravid and nongravid mice, 214
Rutledge, L. C., *see* Skinner, W. A., 196
Rytting, J. H., *see* Anderson, B. D., 676
——*see* Mikkelson, T. J., 133
——*see* Nishihata, T., 744

S

Sadove, M. S., *see* Prancan, A. V., 970
Sagar, V. A., *see* Melethil, S., 585
Said, S. A., Shibl, A. M., and Abdullah, M. E., influence of various agents on adsorption capacity of kaolin for *Pseudomonas aeruginosa* toxin, 1238
——*see* El-Yazigi, A., 1434
Sajadi, Z., *see* Hall, I. H., 1451
Salama, R. B., and Omer, A. I. H., colorimetric determination of procaine hydrochloride in pharmaceutical preparations, 346
Salto, F., Prieto, J. G., and Alemany, M. T., interactions of cephalosporins and penicillins with nonpolar octadecylsilyl stationary phase, 501
Salvesen, B., *see* Testa, B., 497
Sanchez, M. J., *see* Camazano, M. S., 1142
Sancilio, F. D., *see* Singletary, R. O., Jr., 144
Sandman, R., *see* O'Donnell, J. J., 1096
Sanniez, W. H. K., and Pilpel, N., photodecomposition of sulfonamides and tetracyclines at oil–water interfaces, 5
Sarapu, A. C., and Clark, L., Jr., elimination of tablet air entrapment using USP 1 rotating-basket dissolution apparatus, 129
Sasahara, K., Nitanai, T., Harbara, T., Morioka, T., and Nakajima, E., dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients, 261
——Nitanai, T., Habara, T., Morioka, T., and Nakajima, E., dosage form design for improvement of bioavailability of levodopa III: influence of dose on pharmacokinetic behavior of levodopa in dogs and parkinsonian patients, 1374
Saux, M. Cl., *see* Lefebvre, M. A., 1216
Sava, G., *see* Lassiani, L., 1098
Savage, I. V. E., *see* McSharry, W. O., 212
Saxena, S. J., *see* Martin, C. J., 1459
Scailteur, V., *see* Couvreur, P., 199
Scher, M., kinetic ratio as a parameter for product stability calculations, 325
Schiff, P. L., Jr., review of "Pharmacognosy, 11th ed.," 619
——*see* El-Azizi, M. M., 360
Schnaare, R. L., *see* Bhuta, S. I., 923
Schoeller, J. P., *see* Sioufi, A., 1413
Schoenwald, R. D., and Stewart, P., effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits, 391
Schott, H., determination of extent of hydration of water-miscible organic liquids in aqueous solution from viscosity data, 369
——saturation adsorption at interfaces of surfactant solutions, 852
Schreck, C. E., *see* Skinner, W. A., 196
Schwan, T. J., Ellis, K. O., Wessels, F. L., Pugh, D., and Bell, R., isolation, synthesis, and pharmacology of metabolites of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1*H*)-pyrimidone, 1203
——*see* Ellis, K. O., 1194
——*see* Wessels, F. L., 1102
Schwartz, P. A., Greene, D. S., and Rhodes, C. T., effect of sodium oleate on salicylic acid binding to human serum albumin, 1345
Sciarra, J. J., review of "Handbook of Aerosol Technology, 2nd Ed.," 130
Sciarrone, B. J., review of "Modern Pharmaceutics," 1243
Scott, K. R., Bell, A. F., and Telang, V. G., drug interactions I: folic acid and calcium gluconate, 234
Scozzafava, A., *see* Canti, G., 1220
Scozzie, J. A., *see* Heilman, W. P., 282
Sears, R. W., *see* Butterfield, A. G., 222
Seawall, S., *see* Rubio, F., 1245
Seegers, A. J. M., Olling, M., Jager, L. P., and Van Noordwijk, J., interactions of aspirin with acetaminophen and caffeine in rat stomach: pharmacokinetics of absorption and accumulation in gastric mucosa, 900
Sefton, M. V., and Nishimura, E., insulin permeability of hydrophilic polyacrylate membranes, 208
Seidel, R., *see* Wirth, P. W., 1359
Selzer, G. B., review of "Antibiotics: Isolation, Separation, and Purification," 754
Sen Gupta, A. K., and Misra, H. K., synthesis and evaluation of substituted quinazolone derivatives for antibacterial, antifungal, and antiacetylcholinesterase activities, 1313
Serafini, M. F., *see* Di Colo, G., 387
Seyhan, S., *see* Davis, P. J., 1056
Seymour, D., and Rupe, B. D., high-pressure liquid chromatographic determination of sulfamethazine residues in beef tissues, 701
Shah, A. C., and Nelson, K. G., membrane transport of alkyl homologs: role of fluid flow in aqueous diffusion region, 210
Shah, K. A., Gupta, V. D., and Stewart, K. R., effect of pH, chlorobutanol, cysteine hydrochloride, ethylenediaminetetraacetic acid, propylene glycol, sodium metabisulfite, and sodium sulfite on furosemide stability in aqueous solutions, 594
Shambhu, M. B., *see* Theodorakis, M. C., 568
Shanks, L., *see* Gershon, H., 381
Sharma, A. S., *see* Hufford, C. D., 1180
Shaw, S. M., review of "Nuclear Medicine: Review Syllabus," 1362
Shea, F., *see* Roehrig, G. R., 1232
Sheinin, E. B., *see* Millard, B. J., 1177
——*see* Wainer, I. W., 459
Shek, E., Ghani, M., and Jones, R. E., simplex search in optimization of capsule formulation, 1135
Sheridan, J., *see* Carstensen, J. T., 290
Sheth, B. B., *see* Papadimitriou, D., 1173
Shibata, T., *see* Marunaka, T., 1258
Shibl, A. M., *see* Said, S. A., 1238
Shim, J.-S. K., Tolan, J. W., and Fink, D. W., fluorometric determination of thiazole-containing compounds, 275
Shindo, T., *see* Marunaka, T., 1258
Shipchandler, M. T., allyl derivatives of zearalenone, 1017
Shirota, F. N., *see* Nagasawa, H. T., 1022
Shoulders, B. A., *see* Soine, W. H., 1040
Shulgin, A. T., *see* Braun, U., 192
Sieg, J., *see* Hussain, A., 738
Sieg, J. W., and Triplett, J. W., precorneal retention of topically instilled micronized particles, 863
Siegel, J. H., *see* McNamara, P. J., 749
Sigon, F., *see* Giraldi, T., 97
——*see* Lassiani, L., 1098
Simmons, D. L., Legore, A. A., and Picotte, P., peristaltic dissolution apparatus: prediction of relative *in vivo* performance of prednisone tablets in humans, 220
Simmons, G. H., *see* Kanke, M., 755
Simonovic, M., *see* Huang, C. C., 984
Simpson, D. R., *see* Theodorakis, M. C., 1107
Simpson, M., and Parrott, E. L., oral and rectal absorption of chloral hydrate and its betaine complex, 227
Sims, D., *see* Imakura, Y., 1044
Singletary, R. O., Jr., and Sancilio, F. D., high-performance liquid chromatographic analysis of trimethoprim and sulfamethoxazole in dosage forms, 144
Sioufi, A., and Pommier, F., GLC determination of α- and β-tribenosides in human plasma, 167
——Colussi, D., Caudal, F., Schoeller, J. P., and Massias, P., pharmacokinetics of phenylbutazone in healthy subjects after oral administration of single and multiple doses, 1413
Sipes, I. G., *see* Chang, S. Y., 80
Sjöholm, I., *see* Edman, P., 838
Skakum, W., *see* Carignan, G., 1214
Skinner, W. A., Fuhrmann, F., Rutledge, L. C., Moussa, M. A., and Schreck, C. E., topical mosquito repellents XIII: cyclic analogs of lactic acid, 196

Slatkin, D. J., *see* El-Azizi, M. M., 360
Slattery, J. T., *see* Yacobi, A., 634
Slaughter, R. L., *see* McNamara, P. J., 749
Sloboda, A. E., *see* Regan, B. A., 789
Smallwood, R. A., *see* Mihaly, G. W., 1155
Smith, D. E., Gee, W. L., Brater, D. C., Lin, E. T., and Benet, L. Z., preliminary evaluation of furosemide–probenecid interaction in humans, 571
Smith, L. M., *see* Dimmock, J. R., 575
Smith, M. D., kinetic study of USP blue tetrazolium assay with methylprednisolone, hydrocortisone, and their hemisuccinate esters by high-pressure liquid chromatography, 960
Smith, R. E., *see* Eng, S. S.-C., 509
Smith, R. V., *see* Davis, P. J., 1056
——*see* Soine, W. H., 1040
——*see* Wilcox, R. E., 974
Smith, V. J., *see* Coulson, C. J., 799
Smyth, R. D., *see* Pfeffer, M., 801
——*see* Pittman, K. A., 160
Soci, M. M., and Parrott, E. L., influence of viscosity on absorption from nitrofurantoin suspensions, 403
Soda, D. M., *see* Wiegand, U. W., 1228
Soine, W. H., Hudson, J. E., Shoulders, B. A., and Smith, R. V., synthesis of [8,9-$^2H_2$] apomorphine and [1,3,8,9-$^2H_4$]apomorphine for PMR, ^{13}C-NMR, and mass spectral studies, 1040
——*see* Davis, P. J., 1056
Sokoloff, H., *see* Burke, D., 138
Sonobe, T., Hasumi, S., Yoshino, T., Kobayashi, Y., Kawata, H., and Nagai, T., digoxin degradation in acidic dissolution medium, 410
Sowell, J. W., Sr., *see* DeJuliis, C. M., 731
——*see* Powers, D. L., 473
Spanggord, R. J., and Keck, R. G., application of high-pressure liquid chromatography and thermal energy analyzer to analysis of trinitroglycerin and its metabolites in blood, 444
Speaker, T. J., *see* Lichtenwalner, M. R., 337
Speiser, P., *see* Couvreur, P., 199
Spielvogel, B. F., *see* Hall, I. H., 1025
Starnes, C. O., Jr., *see* Hall, I. H., 537, 694, 1025
Stavchansky, S., Doluisio, J. T., Martin, A., Martin, C., Cabana, B., Dighe, S., and Loper, A., correlation of *in vivo* bioavailability of erythromycin stearate tablets with *in vitro* tests, 1307
——*see* Newburger, J., 1231
Stefanakou, S.-V. S., *see* Theodorakis, M. C., 581
Steinrauf, L. K., *see* Blickenstaff, R. T., 556
——*see* Roberts, L. R., 964
Stella, V. J., and Chu, C. K., effect of short-term exposure to polychlorinated biphenyls on first-pass metabolism of pentobarbital in rats, 1279
——and Chu, C. K., effects of short-term dietary exposure to polychlorinated biphenyls on pharmacokinetics of intravenous pentobarbital in rats, 1274
Stenberg, P., *see* Harris, A. S., 1271
Stephani, R. A., *see* Chatterjie, N., 1431
Stewart, B. A., *see* Indelicato, J. M., 1183
Stewart, J. T., review of "Analytical Profiles of Drug Substances, Vol. 8," 484
——*see* Honigberg, I. L., 1171
Stewart, K. R., *see* Gupta, V. D., 1264
——*see* Shah, K. A., 594
Stewart, P., *see* Schoenwald, R. D., 391
Stewart, P. J., potential errors in kinetic studies of hydrolysis of nitrogen mustards based on chloride-ion determination: a reply, 861
Stoll, R. G., *see* Yacobi, A., 1077
Strom, C. H., *see* Chatterjie, N., 1431
Strom, J. G., Jr., and Jun, H. W., kinetics of hydrolysis of methenamine, 1261
Stubbins, J. F., review of "Drug Design, Vol. VIII," 618
——Hudgins, P. M., and Murphy, D. C., antimuscarinic agents: furan analogs of benzilate esters, 534
——*see* Murphy, M. J., 553
Su, C. C., *see* Corrigan, O. I., 869
Such, V., *see* Traveset, J., 629
Sugita, E. T., *see* Bhuta, S. I., 923
Sumida, Y., *see* Hall, I. H., 694
Summers, M. P., and Enever, R. P., glass transition temperature of citric acid, 612
Sunberg, R. J., *see* Van Duzee, B. F., 599
Sundaresan, G. M., *see* Goehl, T. J., 1409
Sved, S., *see* Hossie, R. D., 348
Svoboda, G. H., *see* El-Azizi, M. M., 360
Szulczewski, D. H., *see* Philip, J., 687

T

Takada, K., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XLIV: dose-dependent pharmacokinetics of warfarin in rats, 9
Takahashi, D. M., rapid determination of chlorpromazine hydrochloride and two oxidation products in various pharmaceutical samples using high-performance liquid chromatography and fluorescence detection, 184
Takenaka, H., Kawashima, Y., and Lin, S. Y., micromeritic properties of sulfamethoxazole microcapsules prepared by gelatin–acacia coacervation, 513
——Kawashima, Y., and Lin, S.-Y., preparation of enteric-coated microcapsules for tableting by spray-drying technique and *in vitro* simulation of drug release from the tablet in GI tract, 1388
Takman, B. H., *see* Elvin, A. T., 47
Tallent, C. R., *see* Cook, C. E., 1419
Tamagnone, G., *see* Casalini, C., 164
Tawashi, R., *see* Ismail, S. I., 829
Taylor, K. M., *see* Jamieson, D. D., 462
Telang, V. G., *see* Scott, K. R., 234
Tempio, J. S., and Zatz, J. L., flocculation effect of xanthan gum in pharmaceutical suspensions, 1209
Tenthorey, P. A., *see* Elvin, A. T., 47
Testa, B., and Salvesen, B., quantitative structure–activity relationships in drug metabolism and disposition: pharmacokinetics of *N*-substituted amphetamines in humans, 497
Thakker, K. D., *see* Grady, L. T., 1099
Thalén, A., *see* Roth, G., 766
Theodorakis, M. C., Devous, M. D., Sr., and Simpson, D. R., monitoring *in vivo* disintegration time of tablets by external scintigraphy, 1107
——Digenis, G. A., Beihn, R. M., Shambhu, M. B., and DeLand, F. H., rate and pattern of gastric emptying in humans using ^{99m}Tc-labeled triethylenetetraamine–polystyrene resin, 568
——Groutas, W. C., Bermudez, A. J., Magnin, D., and Stefanakou, S.-V. S., localization of technetium 99m-ethylenediamine-*N,N'*-bis(α-2-hydroxy-5-bromophenyl)acetic acid and technetium 99m-*N*-(2-mercapto-1-oxopropyl)glycine in hepatobiliary system, 581
Thompson, J. A., and Leffert, F. H., sensitive GLC–mass spectrometric determination of chlorpheniramine in serum, 707
Tischler, M. A., *see* Wainer, I. W., 459
Tolan, J. W., *see* Shim, J.-S. K., 275
Tomlinson, E., Notari, R. E., and Byron, P. R., simultaneous partitioning and hydrolysis kinetics of amoxicillin and ampicillin, 655
——*see* Byron, P. R., 527
Toothaker, R. D., *see* Goehl, T. J., 1409
Touré, P., *see* Carstensen, J. T., 742
Townley, E., and Roden, P., high-performance liquid chromatographic analysis of griseofulvin in drug substance and solid dosage forms: separation of impurities and metabolites, 523
Trager, W. F., *see* Patel, I. H., 1218
Travesel, J., Such, V., Gonzalo, R., and Gelpi, E., derivative and graphical procedures for correction of irrelevant UV spectrophotometric absorption in changeable matrixes, 629
Triplett, J. W., *see* Seig, J. W., 863
Truelove, J. E., Hussain, A. A., and Kostenbauder, H. B., synthesis of 1-*O*-(2′-acetoxy)benzoyl-α-D-2-deoxyglucopyranose, a novel aspirin prodrug, 231
Trzeciakowski, J., and Chiou, G. C. Y., effects of *N*-demethylated carbachol on iris and ciliary muscles, 332
Tscherne, R. J., and Umagat, H., determination of isophenindamine in phenindamine tartrate using an argentated high-performance liquid chromatographic mobile phase, 342
Tse, F. L. S., effect of changes in plasma protein binding on half-life of drugs, 751
Tsilifonis, D. C., and Chafetz, L., high-pressure liquid chromatographic assay of quinestrol tablets, 1461
Tsuchiya, S., *see* Hosono, T., 824
Tuckerman, M. M., review of "GLC and HPLC Determination of Therapeutic Agents, Parts I–III," 366
Tuescher, D. L., *see* Walker, G. A., 846
Turi, P., review of "Handbook of U.S. Colorants for Foods, Drugs, and Cosmetics," 485
Turner, C. E., *see* Elsohly, M. A., 587
——*see* Wirth, P. W., 1359
Tute, M. S., *see* Fawzi, M. B., 104

U

Ueda, C. T., and Nickols, J. G., comparative pharmacokinetics of quinidine and its *O*-desmethyl metabolite in rabbits, 1400
Ulmsten, U., *see* Harris, A. S., 1271
Umagat, H., *see* Tscherne, R. J., 342
Umeno, Y., *see* Marunaka, T., 1258, 1296
Upton, R. A., Buskin, J. N., Williams, R. L., Holford, N. H. G., and Riegelman, S., negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine, 1254
Urquilla, P. R., *see* O'Donnell, J. P., 149

V

Valle, R., *see* Balandrano, D., 458
Vallner, J. J., *see* Capomacchia, A. C., 1463
Valvani, S. C., *see* Yalkowsky, S. H., 912
Van Campen, L., *see* Carstensen, J. T., 742
Vandecasteele-Thienpont, L. M. R., *see* De Leenheer, A. P., 99
VandenHeuvel, W. J. A., Onofrey, D., Zweig, J. S., Pile, J., Kirkman-Bey, N., and Arison, B. H., identification of canine urinary metabolites of the antiprotozoal agent 3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5-nitro-1*H*-imidazol-2-yl)-1,2-benzisoxazole, 1288
——*see* Carlin, J. R., 1111
Vanderwielen, A. J., *see* Beaubien, L. J., 651
Van Duzee, B. F., Sunberg, R. J., and Benedict, J. J., effect of etidronate disodium on filterability of sickle cell erythrocytes, 599
Van Harken, D. R., *see* Pfeffer, M., 398
Van Noordwijk, J., *see* Seegers, A. J. M., 900
Van Peteghem, C., Heyndrickx, A., and Van Zele, W., GLC–mass spectral determination of mescaline in plasma of rabbits after intravenous injection, 118
van't Riet, B., Kier, L. B., and Elford, H. L., structure–activity relationships of benzohydroxamic acid inhibitors of ribonucleotide reductase, 856
Van Zele, W., *see* Van Peteghem, C., 118
Varin, F., Marchand, C., Larochelle, P., and Midha, K. K., GLC–mass spectrometric procedure with selected-ion monitoring for determination of plasma concentrations of unlabeled and labeled barbital following simultaneous oral and intravenous administration, 640
Varner, M. G., *see* Beres, J. A., 451
Ventura, D. A., and Ando, H. Y., general method for calculation of hydrogen-ion concentration in multicomponent acid–base mixtures, 891
Verpoorte, R., assignment of ^{13}C-NMR spectra of strychnine and brucine, 865
Vestergaard, P., *see* Jindal, S. P., 684
Vicente, M. T., *see* Camazano, M. S., 1142
Vilallonga, F. A., and Phillips, E. W., kinetics and mechanisms of monolayer interactions V: surface activities of alkylamides, alkylmonocarboxylic acids, and alkylketones and their interaction energies with phospholipid monolayers, 66
——and Phillips, E. W., surface activities of barbital, phenobarbital, and pentobarbital and their interaction energies with phospholipid monolayers, 102
Vince, R., *see* Lee, H., 1019
Vincent, P. G., review of "Chlorophyll Organization and Energy Transfer in Photosynthesis," 753
Visco, J. P., *see* McNamara, P. J., 749
Vouros, P., *see* Green, J. F., 936
Vyas, K. H., *see* Lukas, G., 419

W

Waddell, T. G., *see* Hall, I. H., 537, 694

Wagner, J., Grill, H., and Henschler, D., prodrugs of etilefrine: synthesis and evaluation of 3′-(*O*-acyl) derivatives, 1423
Wagner, W. E., Jr., *see* Lukas, G., 419
Wainer, I. W., Trischler, M. A., and Sheinin, E. B., determination of dextro- and levomethorphan mixtures using chiral lanthanide NMR shift reagents, 459
Waitz, J. A., *see* Loebenberg, D., 739
Walker, G. A., Carpenter, B. E., and Tuescher, D. L., determination of potential content of vitamin D_2 (ergocalciferol) and vitamin D_3 (cholecalciferol) in gelatin-coated beadlets, oil-based mixtures, and multivitamin tablet and capsule formulations 846
Walker, R. W., *see* Carlin, J. R., 1111
Wallace, J. L., Kidd, M. R., Cauthen, S. E., and Woodyard, J. D., new compounds: synthesis of *para*-substituted nortropanyl benzoates, 1357
Wallin, I., *see* Ehrsson, H., 710, 1091
Walson, P. D., *see* Chang, S. Y., 80
Walters, S. M., influence of pH on hydrolytic decomposition of diethylpropion hydrochloride: stability studies on drug substance and tablets using high-performance liquid chromatography, 1206
Wang, L. H., *see* Lee, C. S., 362
Wang, M. K., White, J. L., and Hem, S. L., effect of polybasic acids on structure of aluminum hydroxycarbonate gel, 668
Wang, P.-H., and Lien, E. J., effects of different buffer species on partition coefficients of drugs used in quantitative structure–activity relationships, 662
——*see* Lien, E. J., 648
Wang, Y.-C. J., deiodination kinetics of water-soluble radiopaques, 671
Wargin, W. A., *see* Burke, J. T., 909
Warin, V., *see* Bernier, J. L., 1343
Watanabe, S., *see* Mikkelson, T. J., 133
Watari, N., Funaki, T., and Kaneniwa, N., fluorescence assay of nitrofurantoin with *o*-aminothiophenol in plasma and urine, 106
Watson, E. S., *see* Wirth, P. W., 1359
Watson, J. R., *see* Curran, N. M., 187
——*see* Lawrence, R. C., 1444
Watzman, N., and Buckley, J. P., comparative analgesic, behavioral, and dependence properties of morphine and *O*-(4-methoxylphenylcarbamoyl)-3-diethylaminopropiophenone oxime hydrochloride, 225
Waugh, W., *see* Beltagy, Y. A., 1168
Wayland, L. G., *see* Mazzola, E. P., 229
Wayner, R. J., *see* Heilman, W. P., 282
Weinberger, R., Mann, B., and Posluszny, J., high-pressure liquid chromatographic analysis of pramoxine hydrochloride in high lipoid aerosol foam dosage form, 475
Weisbach, J. A., *see* Pitkin, D. H., 354
Weiss, D. L., *see* Kanke, M., 755
Weissbrod, J. M., and Jain, R. K., preliminary model for streptozocin metabolism in mice, 691
Welling, P. G., *see* Goehl, T. J., 1409
——*see* Phillips, T. A., 1428
Wells, C. E., *see* Gurka, D.F., 1069
Wen, L.-F., Bohannon, T., Crabb, A., Ng, S., and Mamaril, F., validation of washing procedures for maintaining a microbiologically clean gel filtration column, 140
Wessels, F. L., Schwan, T. J., and Pong, S.F., synthesis and antidepressant activity of 5-(4-dimethylaminobenzyl)imidazolidine-2,4-dione, 1102
——*see* Ellis, K. O., 327, 1194, 1198
——*see* Schwan, T. J., 1203
Wester, R. C., *see* Noonan, P. K., 365
Wheatley, W. B., *see* Kohl, H. H., 1292
White, J. L., *see* Browne, J. E., 811, 816, 1393
——*see* Cornejo, J., 945
——*see* Wang, M. K., 668
White, R. E., *see* Burch, H. A., 107
White, R. L., Jr., *see* Ellis, K. O., 327
Whitworth, C. W., review of "Prescription Drugs in Short Supply," 1361
Wiegand, U. W., and Levy, G., hepatic extraction of endogenous inhibitors of plasma protein binding, 480
——Soda, D. M., and Levy, G., effect of heparin on bilirubin clearance in rats: pharmacokinetic consequences of extensive hepatic extraction of plasma protein binding inhibitors, 1228
Wikby, A., *see* Roth, G., 766
Wilcox, R. E., Humphrey, D. W., Riffee, W. H., and Smith, R. V., stability of apomorphine in solutions containing ascorbic acid and bisulfite and effects of antioxidants on apomorphine-induced cage climbing and hypothermia in mice, 974
——*see* Riffee, W. H., 980
Will, P. C., Cortright, R. N., and Hopfer, U., polyethylene glycols as solvents in implantable osmotic pumps, 747
Williams, D. L., *see* Cook, C. E., 1419
Williams, R. L., *see* Upton, R. A., 1254
Williams, T. H., *see* Rubio, F., 1245
Williams, W. L., Jr., *see* Hall, I. H., 294
Wilson, J. D., *see* Hiller, F. C., 334
Winek, C. L., review of "Forensic Toxicology: Controlled Substances and Dangerous Drugs," 130
Winer, N., *see* Mason, W. D., 344
Wingerup, L., *see* Harris, A. S., 1271
Wirth, P. W., Watson, E. S., ElSohly, M. A., Seidel, R., Murphy, J. C., and Turner, C. E., anti-inflammatory activity of cannabichromene homologs, 1359
Wisian-Neilson, P., *see* Hall, I. H., 1025
Wittmers, L. E., *see* Alich, A. A., 725
Wolf, M. S., and Zimmerman, J. J., simultaneous GLC determination of clofibrate and clofibric acid in human plasma, 92
Wolfe, M. L., *see* Boots, M. R., 202
Wolshin, E. M., *see* Elvin, A. T., 47
Wong, D. W., effect of sodium bicarbonate on *in vitro* conversion of fibrinogen to fibrin, 978
Wood, D. J., *see* Gans, K. R., 217
Wood, P. R., *see* Fairbrother, J. E., 697
Woodyard, J. D., *see* Wallace, J. L., 1357
Worley, S. D., *see* Kohl, H. H., 1292
Wright, G. C., Herrett, R. J., Heotis, J. P., and Butterfield, J. L., isolation, identification, and synthesis of 4-amino-6,7-dimethoxy-3-quinolinol, the major metabolite of amiguinsin hydrochloride in rats and humans, 842
——*see* Burch, H. A., 107
——*see* Ellis, K. O., 327
Wright, G. J., *see* Cook, C. E., 1419
Wu, R.-Y., *see* Imakura, Y., 1044
——*see* Lee, K.-H., 1050

X

Y

Yacobi, A., Lai, C.-M., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XLV: pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin and phenylbutazone in rats, 14
——Slattery, J. T., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XLVI: effect of treatment with phenobarbital on pharmacokinetics of (*S*)-(−)-warfarin in rats, 634
——Stoll, R. G., Chao, G. C., Carter, J. E., Baaske, D. M., Kamath, B. L., Amann, A. H., and Lai, C.-M., evaluation of sustained-action chlorpheniramine–pseudoephedrine dosage form in humans, 1077
——*see* Kamath, B. L., 864
——*see* Lai, C.-M., 681, 982
Yagen, B., *see* Bialer, M., 1334
Yalkowsky, S. H., and Valvani, S. C., solubility and partitioning I: solubility of nonelectrolytes in water, 912
Yamazaki, K., *see* Baba, S., 1300
Yeh, Y.-M., *see* Boots, M. R., 506
Yeung, A. K., *see* Johnston, M. M., 1158
Yonaha, K., *see* Imakura, Y., 1044
Yoshida, K., *see* Marunaka, T., 1296
Yoshino, T., *see* Sonobe, T., 410
Yotsuyanagi, T., and Ikeda, K., kinetic characterization of liposomes, 745
Young, J. F., *see* Maulding, D. L., 1224
Yu, C.-D., calculation of cutaneous metabolic rate constant from diffusion model, 126
——Fox, J. L., Higuchi, W. I., and Ho, N. F. H., physical model evaluation of topical prodrug delivery—simultaneous transport and bioconversion of vidarabine-5′-valerate IV: distribution of esterase and deaminase enzymes in hairless mouse skin, 772
——Gordon, N. A., Fox, J. L., Higuchi, W. I., and Ho, N. F. H., physical model evaluation of topical prodrug delivery—simultaneous transport and bioconversion of vidarabine-5′-valerate V: mechanistic analysis of influence of nonhomogeneous enzyme distributions in hairless mouse skin, 775
——Higuchi, W. I., Ho, N. F. H., Fox, J. L., and Flynn, G. L., physical model evaluation of topical prodrug delivery—simultaneous transport and bioconversion of vidarabine-5′-valerate III: permeability differences of vidarabine and *n*-pentanol in components of hairless mouse skin, 770
Yu, T., *see* Korn, N., 1010

Z

Zatz, J. L., *see* Tempio, J. S., 1209
Zera, R. T., and Nagasawa, H. T., *N*-acetyl-DL-penicillamine and acetaminophen toxicity in mice, 1005
Zimmerman, J. J., *see* Wolf, M. S., 92
Zografi, G., *see* Carstensen, J. T., 742
Zweig, J. S., *see* VandenHeuvel, W. J. A., 1288

A

Absorption—compartment- and model-independent calculation for drugs with linear pharmacokinetics, 57
—hexamethonium chloride and pralidoxime chloride, influence of various anions on intestinal disappearance in rats, 923
intestinal—water-insoluble drugs, improved membrane permeability through synthesis of soluble derivative as prodrug, 1363
—lidocaine and derivatives, determination of transfer rates across everted rat intestinal mucosa, *in vitro*, 643
nasal—propranolol from different dosage forms, rats and dogs, 1411
nasal—propranolol, humans, 1240
ocular—pilocarpine, mechanisms of distribution following subconjunctival injection, rabbits, 875
ocular—propranolol in rabbits, 738
—oral and rectal, comparison of chloral hydrate and chloral betaine, 227
percutaneous—benzocaine, release from suspension hydrogels, influence of solvent power and microscopic viscosity of vehicle, *in vitro*, 387
percutaneous—nitroglycerin, rhesus monkeys, 365
rectal—enhancement by certain adjuvants, 744
Acecainide hydrochloride—GLC analysis in rat feed, 1439
Acetaminophen—administered alone and with aspirin, absorption, distribution in gastric tissue, blood plasma levels, rats, 900
—high-performance liquid chromatographic analysis of codeine and acetaminophen in capsules, tablets, and elixirs, comparison with GLC analysis, 1081
—simultaneous determination with guaifenesin and dextromethorphan hydrobromide, high-pressure liquid chromatography, 212
—simultaneous quantitation with aspirin, caffeine, codeine phosphate, phenacetin, and salicylamide, high-pressure liquid chromatography, 110
—toxicity, evaluation of protection offered by *N*-acetyl-DL-penicillamine, mice, 1005
Acetazolamide—analysis, high-performance liquid chromatography, plasma, 348
Acetone artifacts—nonnitrogenous, alkaloid-like compounds, interference with alkaloid detection, structural requirements for false-positive reaction, 37
1-*O*-(2′-Acetoxy)benzoyl -α-D-2- deoxyglucopyranose—aspirin prodrug, synthesis, 231
Acetylcarnitine—conformational analysis, comparison to cholinergic receptor patterns, 1065
***N*-Acetyl-DL-penicillamine**—evaluation for protection against acetaminophen toxicity in mice, 1005
***N*-Acetylprocainamide**—half-life in rats, 864
—simultaneous high-pressure liquid chromatographic determination with procainamide in biological fluids, 982
Acetylsalicylic anhydride—spectrophotometric determination, 550
***O*-Acetyl-*O*-salicylsalicylic acid**—high-pressure liquid chromatographic determination, 550
Acid–base mixtures—calculation of hydrogen-ion concentration in multicomponent acid–base mixtures, comparison with experimental results, 891
Acid neutralization—complex formation with polybasic acids and aluminum hydroxycarbonate gel, 668
Aconiazide—binding of toxic metabolites of isoniazid, potential as antitubercular agent, 1284
Activation parameters—cyclization of dialkylmalonuric esters to barbituric acids, 451
Activity—proteins, decrease after adsorption onto glass surfaces, 279
Adamantaine—synthesis of latentiated forms and biological evaluation, 1022
Adenosine diphosphate—stimulating and inhibitory effects on mitochondrial respiration by compounds from marine organisms, oxidative phosphorylation, 462
***S*-Adenosyl-L-methionine decarboxylase**—inhibition by pyruvate derivatives, 1000
Adenylate cyclase activity—dopamine, *N*- and *N,N*-substituted dopamine analogs, peripheral and central dopamine receptors, isolated striata and blood vessels, 149
Adhesiveness—commercial film-coated tablets, measurement of force between film coating and tablet surface, effect of solvents and humidity on bonding of film to tablet surface, 439
β-Adrenergic blocking activity—effects of propranolol on ischemic failing heart, effects of hypertonic mannitol, dogs, 447
β-Adrenergic blocking agents—atenolol, effect of exercise on renal clearance, 344
—pindolol, electron-capture GLC analysis in biological fluids, 1191
—propranolol, ocular absorption in rabbits, 738
—sotalol, high-performance liquid chromatographic analysis with fluorometric detection, human plasma and urine, 1216
—timolol, GLC–mass spectrometric analysis, human plasma and urine, 1111
α-Adrenoceptor agonists—cyclic adenosine monophosphate levels, effects on mediator release, antiallergic drugs, 239
β-Adrenoceptor agonists—antiallergic drug testing, bronchiolar smooth muscle, cyclic adenosine monophosphate levels, effects on mediator release, 251
—cyclic guanosine monophosphate levels, effects on mediator release, antiallergic drugs, 239
Adsorbents—montmorillonite saturated with organic cations, potential treatment of poisoning by weak bases, 1393
Adsorption—antibody and globulin on glass surfaces, 1226
—bonding of tetracycline to sodium montmorillonite, acid–base equilibria of tetracycline, 811
—cimetidine, various pharmaceutical adsorbents, *in vitro*, 352
—formation of adsorptive lecithin layer on cholesterol, effect of detergents, 413
—hydrocortisone onto attapulgite, oxidative degradation of hydrocortisone, 945
—mechanism of interaction of chlorpheniramine with montmorillonite, 1142
—proteins, glass surfaces, activity decrease, 279
—*Pseudomonas aeruginosa* toxin onto kaolin, effect of pH and various agents, 1238
—separation of methyldopa from plasma by alumina adsorption, high-pressure liquid chromatographic analysis, 897
—tetracycline onto pharmaceutical grade clays, 816
Aerosols—bronchodilators, metered-dose solution and powder preparations, effect of low and high humidity, 334
inhalation—characterization of flume pattern, video technique compared with chemical analysis, delivery systems analyzed, 713
Ajmaline—model of interaction with polyvinylpyrrolidone, 824
Alcohols, normal—permeability coefficients in hairless mouse skin and human skin, effect of temperature and carbon chain length, biphasic partitioning, 781
Aldoximes—influence of molecular structure on sweet or bitter taste, discriminant analysis, molecular connectivity, taste category prediction, 416
Alkaloids, cactus—heliamine, 3,4-dimethoxy-β-phenethylamine, isolation, identification, 94
—indicine *N*-oxide, stability-indicating colorimetric assay using TLC, 471
—interference by nonnitrogenous alkaloid-like compounds, structural requirements for false-positive reaction, 37
—strychnine and brucine, ^{13}C-NMR spectral analyses, chemical shifts assigned, 865
α,ω-*n*-Alkanediols—antifungal activity, *in vitro*, effect of chain length, pH, and adsorbents, 381
***n*-Alkanols**—antifungal activity, *in vitro*, effect of chain length, pH, and adsorbents, 381
Alkylating agents—propranolol mustard, synthesis, potential lung-specific anti-tumor activity, 190
Aluminum hydroxycarbonate—complexation with polybasic acids and their sodium salts, structural changes, acid neutralization, 668
Amides—*N*-Mannich base derivatives as prodrugs, hydrolysis kinetics, 44
Amine cyanoboranes and amine carboxyboranes—evaluation for anti-inflammatory activity, 1025
Amines—*N*-Mannich base derivatives as prodrugs, hydrolysis kinetics, 44
phenylalkyl, substituted—*N*-substituted analogs of psychotomimetic agents, 192
Aminoalkanesulfonic acids—synthesis of *N*-nitroso derivatives, evaluation for mitodepressive activity, 930
***p*-Aminobenzoates**—membrane permeation, fluid flow in aqueous diffusion region, 210
***p*-Aminobenzoic acid**—degradation product of benzocaine, high-performance liquid chromatographic analysis with benzocaine, 1384
3-Amino-1,2,4-benzotriazines—amidine derivatives, synthesis and testing for anti-inflammatory and analgesic activity, rats, 789
4-Amino-6,7-dimethoxy-3-quinolinol—isolation and identification as metabolite of amiquinsin hydrochloride, rats and humans, 842
Aminophylline—decomposition in suppository formulations, 942
—effect on catecholamine-induced arrhythmias, steroid-pretreated rats, 441
Aminopyrine—demethylation activity, effect of substituted pyridines on *in vitro* aminopyrine metabolism, cytochrome P-450 oxidation reactions, 465
8-Aminoquinolines, substituted—synthesis and evaluation for antiprotozoan activity, 933
Amiquinsin hydrochloride—rat and human metabolites, isolation and identification, 842
Amitriptyline hydrochloride—effect of chlordiazepoxide hydrochloride on NMR spectra, proton transfer in a dipolar aprotic solvent, 180
—simultaneous determination with chlordiazepoxide, high-performance liquid chromatography, 138
Amoxicillin—kinetics of simultaneous partitioning and hydrolysis, 655
Amphetamines—effect of human serum albumin concentration on binding, 885
N-substituted—pharmacokinetics, quantitative structure–activity relationships, humans, 497
Ampicillin—kinetics of simultaneous partitioning and hydrolysis, 655
Anabolic agents—zearalenone, synthesis of allyl derivatives, 1017
Analgesic activity—amidine derivatives of 3-amino-1,2,4-benzotriazines and their 1-oxides, synthesis and testing, rats, 789
—evaluation of 2-azabicyclo[2.2.2]octane analogs of 4-anilidopiperidines, mice, 1104
—prodine analogs, correlation between potency and energy level of highest occupied molecular orbital of aryl moiety, 796
Analgesics—aspirin, high-pressure liquid chromatographic analysis, 1188
—butorphanol, pharmacokinetics following subcutaneous and intramuscular administration, dogs, 801
—determination of aspirin and salicylic acid, 544
—determination of impurities in aspirin, 550
—determination of salicylic acid in aspirin by

high-pressure liquid chromatography, 548
—ergotamine tartrate, solubility and dissolution rate, 832
—*in vitro* dissolution of aspirin formulations, 967
—morphine, solid dispersion containing tristearin, reduced presystemic inactivation, rats, 466
—morphine sulfate, *O*-(4-methoxylphenylcarbamoyl)-3-diethylaminopropiophenone oxime hydrochloride, comparative studies in rodents, 225
narcotic—levomethorphan, NMR identification with dextromethorphan, 459
—propoxyphene, identification of thermal decomposition products formed during GLC analysis, 1177
—propoxyphene, pharmacokinetics, effect of renal failure on systemic clearance, rats, 363
4-Androstene-3,17-dione dioximes—*E,E*- and *Z,Z*-isomeric *O*-ethers, synthesis, stereochemical analysis, and evaluation for neuromuscular blocking activity, 995
Anesthetics—lidocaine, pharmacokinetics, pregnant and nonpregnant sheep, 32
local—simultaneous GLC analysis of mepivacaine, bupivacaine, etidocaine, lidocaine, and tetracaine in biological fluids, 603
—mepivacaine, brain-to-blood and saliva-to-blood ratios, rats, 217
topical—pramoxine hydrochloride, high-pressure liquid chromatographic analysis, high lipoid aerosol foam dosage form, 475
4-Anilidopiperidines—2 - azabicyclo[2.2.2]octane analogs, evaluation for analgesic activity, mice, 1104
Aniline—hydroxylase activity, effect of substituted pyridines on *in vitro* aniline metabolism, cytochrome P-450 oxidation reactions, 465
Antacids—suppression of digoxin degradation, 410
Anthelmintics—benzimidazoles, high-performance liquid chromatographic analysis, GI fluids, plasma, 422
Antiacetylcholinesterase activity—evaluation of substituted quinazolone derivatives, 1313
Antiallergic drugs—calcium antagonists, inhibition of calcium influx and intracellular calcium movements, inhibition of mediator release, 243
—cromolyn sodium, adrenergic bronchodilators, corticosteroids, anticholinergic agents, 236
—inhibition of mediator release, *in vivo* and *in vitro* models, 239
—pharmacokinetics, various clinical testing procedures in humans, inhibition of mediator release, cyclic adenosine monophosphate levels, potential asthma inhibitors, 251
Antiarrhythmic activity—procainamide, specific antibody production and characterization, 721
Antiarrhythmic agents—*N*-acetylprocainamide, half-life in rats, 864
—aprindine, GLC analysis using nitrogen–phosphorus flame-ionization detection, human plasma, 1094
—iodinated and radioiodinated analogs of propranolol and *N,N*-dimethylpropranolol, synthesis and evaluation of activity, tissue distribution of radioiodinated analogs, potential as myocardial imaging agents, 1010
—lidocaine, high-pressure liquid chromatographic analysis, human plasma, 1341
—nofedone, analysis, electron-capture GLC, human serum, 273
—procainamide, simultaneous high-pressure liquid chromatographic determination with *N*-acetylprocainamide in biological fluids, 982
—propranolol, fluorometric analysis, human plasma, 1463
—quinidine and its O-desmethyl metabolite, pharmacokinetics, rabbits, 1400
—tocainide, human metabolism, conjugation, 47
Antiarthritis agents—glucocorticoids, nonsteroidal anti-inflammatory agents, tranquilizers, high-pressure liquid chromatographic identification, 590
—gold, effect of plasma protein and gold concentration on gold binding, flameless atomic absorption determination of gold in biological fluids, 585
Antibacterial activity—evaluation of substituted quinazolone derivatives, 1313
—triethylammonium (acetylcyanoamino)chlorotriphenylstannate and triethylammonium dichlorotriphenylstannate evaluated, 340
Antibacterials—amikacin, gentamicin, kanamycin, and tobramycin, effect on bacterial growth, turbidimetric measurement of blood levels, 1442
—chloramphenicol, identification of 1-succinate ester as alternate form in equilibrium mixture with 3-succinate ester, 906
—nitrofurantoin, fluorescence assay, plasma and urine, 106
—nitrofurantoin suspensions, effect of viscosity on absorption, 403
—sulfamethoxazole, microencapsulation by gelatin–acacia coacervation, 513
—tetracycline, distribution in red blood cells, 455
—tetracycline, high-performance liquid chromatographic analysis of tetracycline epimers in tetracycline preparations, 928
—tetracyclines, ^{13}C-NMR spectra, chemical shifts assigned, 229
—trimethoprim and sulfamethoxazole, simultaneous high-performance liquid chromatographic analysis, oral suspension and solid dosage forms, 144
Antibiotics, aminoglycoside—amikacin, gentamicin, kanamycin, and tobramycin, effect on bacterial growth, turbidimetric measurement of blood levels, 1442
—carbenicillin disodium, cefazolin sodium, cephalothin sodium, nafcillin sodium, and ticarcillin disodium, high-pressure liquid chromatographic analysis, 1264
—cephalosporins and penicillins, interactions with a nonpolar octadecylsilyl stationary phase, capacity factors, 501
cephalosporins—ceforanide, pharmacokinetics, humans, 398
—cephalosporins, serum protein binding, alteration by fatty acids and their derivatives, 354
—chloramphenicol, simultaneous high-pressure liquid chromatographic assay with chloramphenicol-3-monosuccinate and chloramphenicol-1-monosuccinate, 909
—distamycin A and congocidine derivatives based on 2,5-disubstituted pyrroles, synthesis and evaluation for cytotoxicity and antiviral activity, structure–activity relationships, 1334
—effects on platelet functions, 1282
—erythromycin stearate, correlation of bioavailability of tablets with *in vitro* tests, 1307
Antibody—adsorption onto glass surfaces, 1226
Anticancer activity—asparagine analogs, 553
Anticancer agents—chemotherapy of neuroblastoma in mice, 592
Anticoagulants—warfarin, effect of phenobarbital on warfarin biotransformation, rats, 634
—warfarin, interaction with phenylbutazone, pharmacokinetics, *in vitro* and *in vivo*, rats, prothrombin complex activity, 14
Anticonvulsant activity—phenylurethans of 1,2-dialkyl-4-pyrazolidinols, synthesis and evaluation for activity, 729
—pyrrolo[2,3-*d*]pyrimidine-2,4-diones and intermediates, structure–activity relationships, 473
Anticonvulsants, potential—condensation products of isatins with acetone and related ketones, synthesis and evaluation for activity, 1235
Antidepressant activity—5-(4-dimethylaminobenzyl)imidazolidine-2,4-dione, *in vitro* and *in vivo* testing, 1102
—pyrimido[4,5-*d*]pyrimidines, synthesis and evaluation for antidepressant activity, binding at presynaptic α-receptor sites, structure–activity relationships, 1343
Antidepressants—maprotiline, GLC–mass spectrometric analysis, human and animal plasma, 684
Antiepileptic agents—phenobarbital, simultaneous analysis with *p*-hydroxyphenobarbital by GLC–chemical-ionization mass spectrometry in biological fluids, 1218
Antifungal activity—*n*-alkanols, α,ω-*n*-alkanediols, and ω-chloro-α-alkanols, *in vitro*, effect of chain length, pH, and adsorbents, 381
—evaluation of substituted quinazolone derivatives, 1313
—*N*-substituted *N*-(triphenylstannyl)cyanamides and triethylammonium (organocyanoamino)chlorotriphenylstannates evaluated, 340
—tolnaftate and various undecylenates, comparison *in vitro* and *in vivo*, 739, 741
Antifungal agents—griseofulvin, high-performance liquid chromatographic analysis of powders, tablets, capsules, and boluses, 523
—nystatin, thermal degradation colorimetry, relationship between loss of microbiological potency and color change, 697
—TLC determination of griseofulvin in plasma and 6-demethylgriseofulvin in urine, 561
Antiglaucoma agents—*N*-demethylated carbachol, effect on iris and ciliary muscles, treatment of open-angle glaucoma, 332
Antihistaminics—chlorpheniramine, GLC–mass spectrometric analysis, human serum, 707
—phenindamine tartrate, analysis of bulk powder for isophenindamine, high-performance liquid chromatography, argentated mobile phase, 342
—terfenadine, radioimmunoassay, human plasma, 1419
Antihyperlipidemic activity—sesquiterpene lactones, structure–activity relationships, serum levels of cholesterol and triglycerides, mice, 694
Antihypertensive agents—amiquinsin hydrochloride, rat and human metabolites, isolation and identification, 842
—forskolin, GLC analysis in plant extracts and pharmaceutical preparations, 1449
—indapamide, automated analysis in drug–rodent food mixtures, 1158
Anti-inflammatory activity—amidine derivatives of 3-amino-1,2,4-benzotriazines and their 1-oxides, synthesis and testing, rats, 789
—diazomethyl ketone and chloromethyl ketone analogs prepared from *N*-tosyl amino acids, biological evaluation, 1451
—evaluation of amine cyanoboranes, amine carboxyboranes, and related compounds, 1025
—evaluation of cannabichromene homologs, 1359
Anti-inflammatory agents—aspirin, comparison of hydrolysis rate with that of tetrakis-μ-acetylsalicylato-dicopper(II), pH dependency, 725
—asymmetric triazines, synthesis, evaluation of activity, 282
—budesonide, high-performance liquid chromatographic analysis of drug content, impurities, and epimer distribution, preparation of primary standard, 766
—carprofen, metabolism in rats, dogs, and humans, 1245
—2-ethyl-2,3-dihydro-5-benzofuranacetic acid, *in vivo* metabolism, rats, dogs, and humans, 164
—ibuproxam, identification of thermal degradation products, 521
—indomethacin, detection of impurities by NMR, IR, and mass spectroscopy, 187
—indomethacin, GLC analysis in human plasma, 219
—ketoprofen, high-performance liquid chromatographic analysis, human plasma and urine, 763
nonsteroidal—identification by high-pressure liquid chromatography, arthritis treatment, 590
—oxaprozin, high-performance liquid chromatographic analysis, comparison with GLC, 794
—phenylbutazone, pharmacokinetics after single and multiple oral doses, 1413
—phenylbutazone, tablets, identification of degradation products, 469
—sesquiterpene lactones, mode of action determined *in vitro* and *in vivo*, 537
—tolmetin sodium, stability-indicating assay, solid dosage forms, 147
—triamcinolone acetonide, high-pressure liquid chromatographic analysis, effects of various octadecylsilane columns on mobility, 481
—tribenoside, GLC determination of α- and β-anomers, human plasma, 167
Antileukemic activity—asparagine analogs, 553
—2-bis(2-methylthio)vinyl -1- methylquinolinium

iodides, comparative testing in cell culture and mice, 477
Antimicrobial activity—*N*-chloramine-induced inhibition of bacterial DNA, RNA, and protein synthesis, 1292
—evaluation of liriodenine and related oxoaporphine alkaloids, 1180
Antimicrobial agents—chlorhexidine, colorimetric determination in commercial dosage forms, 215
Antimuscarinic agents—furan analogs of benzilate esters, synthesis and activity, 534
Antineoplastic activity—fluorouracil, pharmacokinetics, human plasma, 1428
—ketals, hemithioketals, and dithioketals of conjugated styryl ketones, synthesis and evaluation of activity, 575
—marine algae from Pacific islands, testing against P-388 lymphocytic leukemia and Ehrlich ascites tumor, 735
Antineoplastic agents—chlorambucil, degradation in aqueous solution, influence of pH and temperature, 1091
—chlorambucil, degradation products and metabolite, mass spectrometry, human plasma and urine, 80
—chlorambucil, GLC determination with selected-ion monitoring, plasma, 710
—*cis*-malonato-diammino platinum(II), synthesis and evaluation for antineoplastic activity *in vivo* and *in vitro*, mice, 1160
—indicine *N*-oxide, quantitation by differential pulse polarography, human plasma, 727
—^{14}C-lomustine, biodistribution, rat tumor model, 87
potential—benzimidazole sulfonic esters and nitrogen mustards, synthesis and evaluation for antileukemic activity, 1348
potential—hydrazones and adducts between aromatic aldehydes and *p*-(3,3-dimethyl-1-triazeno)benzoic acid hydrazide, structure–activity relationships, 97
potential—indicine *N*-oxide, stability-indicating colorimetric assay using TLC, 471
potential—molephantin, molephantinin, and phantomolin, isolation from *Elephantopus mollis*, structural determination, 1050
—6-selenoguanosine, stabilization with antioxidants, formulation of parenteral dosage form, 1168
—uracil plus ftorafur, high-pressure liquid chromatographic and GLC–mass spectrometric analyses in biological materials, 1296
Antioxidants—ascorbic acid and sodium bisulfite, stability of apomorphine in solutions containing antioxidants, effects of antioxidants on apomorphine-induced cage climbing and hypothermia in mice, 974
—butylated hydroxyanisole and butylated hydroxytoluene, pharmacokinetics, rabbits, 1455
Antiparkinsonian agents—levodopa, bioavailability, dosage form design, dogs and humans, 261
Antiphlebotic agents—tribenoside, GLC determination of α- and β-anomers, human plasma, 167
Antiprotozoal agents—3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5-nitro-1*H*-imidazol-2-yl) -1,2- benzisoxazole, identification of urinary metabolites by NMR spectroscopy, mass spectrometry, and capillary column GLC–mass spectrometry, 1288
potential—primaquine analogs, synthesis and evaluation for activity, 933
—1-(*p*-tolyl)-3-acetyl-3-methyltriazene, activity against African trypanosomiasis, mice, 1465
Antiradiation compounds—binding ability of radioprotective *N*-heterocyclic aminoethyl disulfides and thiosulfates to DNA, 84
Antitubercular agents, potential—aconiazide, binding of toxic metabolites of isoniazid, 1284
Antitumor activity—carbocyclic analogs of arabinosylpurine nucleosides, synthesis and testing, 1019
—chlorambucil analogs, synthesis and evaluation for activity, 1232
—4-demethylepipodophyllotoxin-9-(4,6-*O*-ethylidene-β-D-glucopyranoside), high-pressure liquid chromatographic analysis, 1440
—inhibition of polyamine synthesis, *in vitro* testing of ornithine carboxylase activity, 733
—latentiated forms of adamantanine, synthesis and biological evaluation, 1022
—marine algae from Pacific islands, testing against P-388 lymphocytic leukemia and Ehrlich ascites tumor, 735
Antitumor agents—1-aryl-3,3-dimethyltriazenes, synthesis of 1-aryl-3-formyl-3-methyltriazenes as potential metabolites, 1098
—eupaformosanin, effect on nucleic acid, protein, and anaerobic and aerobic glycolytic metabolism, Ehrlich ascites cells, 294
—microhelenins, microlenin acetate, and plenolin, isolation from *Helenium microcephalum*, determination of structure and stereochemistry, 1044
potential—*cis*-platinum(II) diaminedichloride, reaction of *cis*-platinum with sodium bisulfite, 364
potential—lung specific, propranolol mustard, synthesis, 190
potential—4-pyridones and bioisosteres of 3-acetoxy-2-pyridone, synthesis and evaluation for activity, 1074
—substituted aryl hydroxamic acids, inhibition of ribonucleotide reductase, structure–activity relationships, 856
Antitussives—caramiphen, GLC analysis in whole blood with nitrogen-specific detector, 1353
—dextromethorphan, *N*-demethylation to yield 3-methoxymorphinan hydrochloride and two novel zinc salts of 3-methoxymorphinan, 1447
—dextromethorphan hydrobromide, high-performance liquid chromatographic analysis using ion-pair formation, 1360
nonnarcotic—dextromethorphan, NMR identification with levomethorphan, 459
Antiviral activity—carbocyclic analogs of arabinosylpurine nucleosides, synthesis and testing, 1019
Antiviral agents—ethyldeoxyuridine, synthesis, biotransformation in rats, metabolites, 531
—vidarabine, cutaneous metabolism, rotating-disk method, guinea pig, *in vitro* study, 126, 127
Apomorphine—stability in solutions containing ascorbic acid and sodium bisulfite, effects of antioxidants on apomorphine-induced cage climbing and hypothermia in mice, 974
—synthesis of deuterated analogs for PMR, ^{13}C-NMR, and mass spectral analyses, 1040
—synthesis of (*S*)-(+)-stereoisomer from (*R*)-(−)-stereoisomer, 1056
Aporphines—trifluoroacetyl derivatives, GLC and mass spectrometry, 936
Aprindine—GLC analysis in human plasma using nitrogen–phosphorus flame-ionization detection, 1094
Aqueous solubility—nonelectrolytes, estimation techniques, 912
Arabinosylpurine nucleosides—carbocyclic analogs, synthesis and evaluation for antitumor and antiviral activity, 1019
Arrhenius equation—calculation of product stability, kinetic ratio parameter, 325
Arrhythmias—catecholamine induced, effect of steroid pretreatment, 441
1-Aryl-3-formyl-3-methyltriazenes—synthesis as potential metabolites of 1-aryl-3,3-dimethyltriazenes, 1098
Asparagine analogs—synthesis and anticancer activity, 553
Aspirin—administered alone and with acetaminophen or caffeine, absorption, distribution in gastric tissue, blood plasma levels, rats, 900
—comparison of hydrolysis rate with that of tetrakis-μ-acetylsalicylato-dicopper(II), pH dependency, 725
—determination of impurities, 550
—determination of salicylic acid by high-pressure liquid chromatography, 548
—effect of salicylic acid on binding of gold to bovine serum albumin, flameless atomic absorption determination, 585
—high-pressure liquid chromatographic analysis with salicylsalicylic acid and salicylic acid in human plasma and urine, 1268
—high-pressure liquid chromatographic determination, 1188
—*in vitro* dissolution, comparison of basket and paddle methods, 967
—plasma salicylate levels following administration of solid dosage form, comparison with magnesium salicylate and choline magnesium trisalicylate, 1355
—powder and dosage forms, analysis of salicylic acid, high-pressure liquid chromatography, 113
prodrugs—synthesis of 1-*O*-(2′-acetoxy)benzoyl-α-D-2-deoxyglucopyranose, 231
—semiautomated UV determination in bulk and tablet formulations, 544
—simultaneous quantitation with acetaminophen, caffeine, codeine phosphate, phenacetin, and salicylamide, high-pressure liquid chromatography, 110
Asthma—review of current theories, clinical evaluation, symposium, antiallergic drugs, 236, 239, 243, 251
Asthma products—metered-dose solution and powder aerosols, effect of low and high humidity, 334
Atenolol—effect of exercise on renal clearance, 344
Atomic absorption spectrometry—analysis, titanium in sunscreens, 101
Atropine—effect of human serum albumin concentration in binding, 885
Attapulgite—effect on hydrocortisone degradation, kinetic and adsorption studies, 945
Avicularin—isolation from *Curatella americana*, identification, 360
3-Azapapaverine—synthesis from veratric acid *via* a Reissert compound, 120
Azulenes, various—substituent constants, ionization and partition coefficients, spectral characteristics, 337

B

Barbital—plasma concentrations of unlabeled and labeled drug following simultaneous oral and intravenous administration, GLC–mass spectrometric analysis, 640
Barbiturates—adsorption free energy, phospholipid monolayers, barbital, phenobarbital, pentobarbital, 102
Barbituric acids—mechanism for formation by cyclization of malonuric acids, 451
Barium sulfate—crystal formation in commercial parenteral solutions, identification by polarizing microscopy, scanning electron microscopy, micro X-ray powder diffraction, and micro Raman spectroscopy, 608
Benzalkonium chloride—high-pressure liquid chromatographic analysis, 1148
Benzilate esters, furan analogs—synthesis and antimuscarinic activity, 534
Benzimidazoles—analysis, high-performance liquid chromatography, GI fluids, plasma, 422
derivatives—sulfonic esters and nitrogen mustards, synthesis and evaluation for anticancer activity, 1348
Benzocaine—high-performance liquid chromatographic analysis with *p*-aminobenzoic acid, effects of pH, temperature, and phosphate ion on benzocaine stability, 1384
—percutaneous absorption, release from suspension hydrogels, influence of solvent power and microscopic viscosity of vehicle, *in vitro*, 387
1,4-Benzodiazepines—nimetazepam and nitrazepam, kinetics and mechanisms of reversible hydrolysis, 1331
Benzo[*b*]furans—synthesis of 2-chloromethyl compounds, 232
Benzoic acid—binding to povidone, effects of temperature, buffer composition, and ionic strength, 1403
Berberine—hydrastis alkaloid, colorimetric determination, effect of pH on alkaloid–dye complex formation, 597
Betamethasone—mass spectral analysis, comparison with mass spectrum of dexamethasone, 991
Bilirubin—effect of heparin on bilirubin clearance, pharmacokinetics, rats, 1228

Binary liquid mixtures—extent of hydration, three viscometric methods, 369
Binders—role in moisture-induced hardness increase in compressed tablets, disintegration, dissolution, in vitro, 1
Binding—effect of human serum albumin concentration on binding of amphetamine, atropine, epinephrine, and histamine, 885
protein—codeine, morphine, and methadone to human serum albumin, varying albumin concentration, 71
serum protein—prednisolone in humans, rabbits, dogs, and rats, 977
Bioavailability—chlorpheniramine and pseudoephedrine in sustained-release dosage form, 1077
—cimetidine, humans, 394
—dexamethasone, ophthalmic suspensions, effect of particle size, rabbits, 391
—levodopa, dosage form design, dogs and humans, 261
—levodopa, effect of dose, dogs and parkinsonian patients, 1374
—lidocaine following rectal, oral, and intraarterial administration, rats, 804
—model-independent estimation, 77
—nitrofurantoin suspensions, effect of viscosity on absorption, 403
—potassium chloride in slow-release capsule, 1416
—propranolol, comparison of sustained-release nasal formulation with intravenous administration, rats and dogs, 1411
—testing, drug input, least-squares deconvolution technique, 318
Biodistribution—^{14}C-lomustine, rat tumor model, 87
Biotransformation—effect of serum protein binding on drug metabolism, 746
4-[*p*-[Bis(2 - chloroethyl)amino]phenyl]butyrates—synthesis and evaluation for antitumor activity, 1232
***N*^{1},*N*^{6}-Bis(2,3 - dihydroxybenzoyl)spermidine**—synthesis and evaluation as iron-chelating drug, 986
2-Bis(2-methylthio)vinyl-1-methylquinolinium iodides—NMR analysis and synthesis of bis(methylthio)vinyl derivatives, comparative testing for antileukemic activity in cell culture and mice, 477
Blood—drug input, deconvolution method for pharmacokinetic estimation, 312
Blood cell membrane—deformability of sickled erythrocytes, effect of etidronate disodium, 599
Blood drug levels—model-independent method of input analysis, linear pharmacokinetic model, 298
Blood sampling time—effect on calculated pharmacokinetic parameters after intravenous administration, 867

BOOKS

ABC of Medical Treatment, 1244
Abrégé de Chimie Analytique, Tome III: Methodes Spectrales et Analyse Organique, 1244
Activated Charcoal: Antidotal and Other Medical Uses, 1361
Advances in Cancer Chemotherapy, Vol. 1, 131
Advances in Chromatography, Vol. 17, 620
Advances in Sex Hormone Research, Vol. 4, 1110
Advances in Steroid Biochemistry and Pharmacology, Vol. 7, 1110
Against Ourselves: Disorders from Improvements under the Organic Limitedness of Man, 368
Alicyclic Chemistry, Vol. 6, 130
Aliphatic and Related Natural Product Chemistry, Vol. 1, 1110
The Alkaloids, Vol. 8, 131
The Alkaloids, Vol. 9. A Specialist Periodical Report, 368
The Alkaloids, Chemistry and Physiology, Vol. XVII, 1312
The Alkaloids: The Fundamental Chemistry—A Biogenetic Approach, 367
Amino-acids, Peptides, and Proteins, Vol. 10, 132
Analysis of Drugs and Metabolites by Gas Chromatography–Mass Spectrometry, Vol. 6: Cardiovascular, Antihypertensive, Hypoglycemic, and Thyroid-Related Agents, 1110
Analytical Profiles of Drug Substances, Vol. 8, 484
Anatomie Physiologie Pathophysiologie des Menschen: Ein Lehrbuch für Pharmazeuten und Biologen, 874
The Anticancer Drugs, 484
Antibiotics: Isolation, Separation, and Purification, 754
Antibiotics: Origin, Nature, and Properties, Vols. I–III, 1244
Antifungal Chemotherapy, 1110
Antihypertensive Drugs Today, 1244
Applied Therapeutics for Clinical Pharmacists, 2nd Ed., 131
Arachidonic Acid Metabolism in Inflammation and Thrombosis, 368
Aromatic and Heteroaromatic Chemistry, Vol. 7, 620
Atlas of the Three-Dimensional Structure of Drugs, *Vol. 1, 993*
Autonomic Pharmacology: Experimental and Clinical Aspects, 484
Bailey's Industrial Oil and Fat Products, 4th Ed., Vol. 1, 368
Basic Biochemistry, 4th Ed., 1244
Behavior Analysis and Treatment of Substance Abuse, 620
The Behavioral Aspects of Smoking, 620
Bibliography of Doctoral Theses in Pharmaceutical Sciences, Indian Universities, 1951–1979, 1110
Biosynthetic Products for Cancer Chemotherapy, Vol. 3, 131
British Pharmacopoeia 1980, 1362
Carbohydrate Chemistry, Vol. 10. A Specialist Periodical Report, 131
Carbohydrate Chemistry, Vol. 11, 1110
Carbon-13 NMR Shift Assignments of Amines and Alkaloids, 131
Carcinogens and Related Substances: Analytical Chemistry for Toxicological Research, 620
Catalog of Teratogenic Agents, 3rd Ed., 1362
Catecholamines: Basic and Clinical Frontiers, Vols. I and II, 486
CBC Handbook Series in Clinical Laboratory Science, Section B: Toxicology, Vol. 1, 485
Cell Substrates: Their Use in the Production of Vaccines and Other Biologicals, 368
Central Nervous System Pharmacology: A Self-Instruction Text, 2nd Ed., 131
Chemicals Which Cause Birth Defects—Teratogens: A Brief Guide, 1110
The Chemistry of Antitumor Antibiotics, Vol. 1, 367
Chlorophyll Organization and Energy Transfer in Photosynthesis, 753
Cigarette Smoking as a Dependence Process, NIDA Research Monograph 23, 132
Circulating Catecholamines and Blood Pressure, 368
Clinical Pharmacological Evaluation in Drug Control, 874
A Color Atlas of The Rat Dissection Guide, 131
Common Medicines: An Introduction for Consumers, 368
Comprehensive Organic Chemistry, 753
Computer-Assisted Drug Design, 994
Computer Assisted Studies of Chemical Structure and Biological Function, 754
The Concept of a Blood–Brain Barrier, 132
Connective Tissue Change in Rheumatoid Arthritis and the Use of Penicillamine, 620
Current Chemotherapy and Infectious Disease, Vols. 1 and 2, 1110
Disposition of Toxic Drugs and Chemicals in Man. Vol. 2. Peripherally-Acting Drugs and Common Toxic Chemicals, 131
Drug Abuse Deaths in Nine Cities: A Survey Report, 1244
Drug Design, Vol. VIII, 618
Drug Disposition in Humans: The Basis of Clinical Pharmacology, 1110
Drugs and Immune Responsiveness, 620
Drugs and the Elderly: Perspectives in Geriatric Clinical Pharmacology, 1110
Drug Toxicity, 753
Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 2nd Ed., 874
Electrophoresis—A Survey of Techniques and *Applications. Part A: Techniques, 874*
Encyclopaedia of Antibiotics, 2nd Ed., 131
Essays on the Anatomy and Physiology of Lymphoid *Tissues, 620*
The Essential Guide to Prescription Drugs, Revised Edition, 874
The Family Prescription & Medication Guide, 131
Foreign Compound Metabolism in Mammals, Vol. 5, 618
Forensic Toxicology: Controlled Substances and Dangerous Drugs, 130
Foundations of Molecular Pharmacology, Vol. 2: The Chemical Basis of Drug Action, 620
Foundations of Molecular Pharmacology, Vol.1: *Medicinal and Pharmaceutical Chemistry, 752*
Fragrances and Flavors: Recent Developments, 1110
Fundamentals of Nuclear Pharmacy, 873
Fundamentals of Oncology, 132
GLC and HPLC Determination of Therapeutic *Agents, Parts I–III, 366*
Hagers Handbuch der Pharmazeutischen Praxis. 4th Ed., Vol. 6, 132
Hagers Handbuch der Pharmazeutischen Praxis, 4th Ed., Vol. 6, Part C : T–Z, 874
Handbook of Aerosol Technology, 2nd Ed., 130
Handbook of Analytical Derivatization Reactions, 619
Handbook of Biological Psychiatry, Part II: Brain Mechanisms and Abnormal Behavior—Psychophysiology, 1110
*Handbook of Biological Psychiatry, Part I: Disci*plines Relevant to Biological Psychiatry, 620
Handbook of U.S. Colorants for Foods, Drugs, and *Cosmetics, 485*
Handbook of Water-Soluble Gums and Resins, 874
Handbook on Drug Abuse, 131
The Heritage of Nuclear Medicine, 620
Human Genetics: Possibilities and Realities, 620
Human Toxicology, 368
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Supplement 1: Chemical and Industrial Processes Associated with Cancer in Humans, 1110
*IARC Monographs on the Evaluation of the Carci*nogenic Risk of Chemicals to Humans, Vol. 20: Some Halogenated Hydrocarbons, 1110
*IARC Monographs on the Evaluation of the Carci*nogenic Risk of Chemicals to Humans, Vol. 19: Some Monomers, Plastics and Synthetic Elas*tomers, and Acrolein, 131*
Immobilized Enzymes Preparation and Engineering: Recent Advances, 132
Increasing the Impact of Social Innovations Funded by Grantmaking Organizations, 1110
Index Nominum 1980, 10th Ed., 993
Index of Antibiotics from Actinomycetes, Vol. 11, 484
Inorganic Biochemistry, Vol. 1. A Specialist Periodical Report, 368
Interferon and Interferon Inducers: Clinical Applications, 1244
International Drug Use. Research Issues 23, 132
The International Pharmacopoeia, 3rd Ed., Vol. 1: General Methods of Analysis, 874
The Interpretation of Quantal Responses in Biology, 368
An Introduction to the Chemistry and Biochemistry of Pyrimidines, Purines and Pteridines, 1110
Introduction to Powder Surface Area, 486
Invertebrate Neuropharmacology, 1110
Isoenzyme Analysis, 874
Issues in Pharmaceutical Economics, 131
The Laser Doppler Techniques, 1110
Lecture Notes on Pharmaceutics, 1110
Maternal Recognition of Pregnancy, 620
Medicine Before Columbus, 132
Microbial Drug Resistance, Vol. 2, 874
Microbiology—1980, 1110
Microcapsule Processing and Technology, 485
Modern Organic Elemental Analysis, 368
Modern Pharmaceutics, 1243

Molecular Structure by Diffraction Methods. Vol. 6, 131
Monoamine Oxidase: Structure, Function, and Altered Functions, 874
The Nature of Enzymology, 620
The Neurobiology of Dopamine, 874
Newer Antiarrhythmic Agents, 1244
Noncatecholic Phenylethylamines, Part 2: Phenylethanolamine, Tyramines, and Octopamine, 1110
Nuclear Medicine: Review Syllabus, 1362
Nucleosides As Biological Probes, 368
Nutrition and Cancer, 620
Nutritional Improvement of Food and Feed Proteins, 874
Oxygen Free Radicals and Tissue Damage, 620
Perspectives on the History of Psychoactive Substance Use. Research Issues 24, 132
The Pharmaceutical Codex, 11th Ed., 368
Pharmaceutical Handbook, 19th Ed., 1109
Pharmacognosy, 11th Ed., 619
Pharmacology of Ganglionic Transmission, 874
Photochemistry, Vol. 10, 1110
Piroxicam No. 1. International Congress and Symposium Series, 131
Plant Metabolism, 368
Plant Organelles, 620
Polarography of Molecules of Biological Significance, 873
Pregnancy Metabolism, Diabetes and the Fetus, Ciba Foundation Symposium 63, 131
Prescription Drugs in Short Supply, 1361
Prevention and Detection of Cancer, Part II, Vol. 2: Cancer Detection in Specific Sites, 874
Principal Drugs: An Alphabetical Guide, 6th Ed., *1110*
Principles of Organic Stereochemistry, Vol. 6. Studies in Organic Chemistry Series, 131
Principles of Pharmaceutical Accounting, 1361
Problems of Drug Dependence. 1979, 1110
Progress in Drug Metabolism, Vol. 3, 1110
Progress in Drug Research, Vol. 23, 874
Progress in Pharmacology. Vol. 2, No. 2. Action of Cardiac Glycosides on the Excitation–Contraction Coupling in Heart Muscle, 131
Quality Control in the Pharmaceutical Industry, Vol. 3, 619
Quantitative Mass Spectrometry in Life Sciences II, 620
Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens, 131
Radiopharmaceuticals II: Proceedings of the Second International Symposium on Radiopharmaceuticals, 1243
Reagents for Organic Synthesis, Vol. 7, 132
Recent Advances in Drug Research, 620
Recent Development in Mass Spectrometry in Biochemistry and Medicine, Vol. 2, 620
Reviews of Physiology, Biochemistry and Pharmacology, Vol. 86, 368
Selected Methods in Cellular Immunology, 620
The Selection of Essential Drugs, 874
Selective Toxicity: The Physico-Chemical Basis of Therapy, 6th Ed., 993
Semisynthetic Proteins, 1110
Standard Operating Procedures in Toxicology, 368
Sterile Dosage Forms: Their Preparation and Clinical Application, 2nd Ed., 235
Studies in Drug Utilization: Methods and Applications, 620
Submolecular Biology and Cancer, 620
Substituent Constants for Correlation Analysis in Chemistry and Biology, 1109
Surface of Normal and Malignant Cells, 368
Sustained and Controlled Release Drug Delivery Systems, Vol. 6, 485
Synthetic Aspects of Biologically Active Cyclic Peptides—Gramicidin S and Tyrocidines, 620
Terpenoids and Steroids, Vol. 9, 620
Textbook of Biopharmaceutics and Clinical Pharmacokinetics, 235
Thermoregulatory Mechanisms and Their Therapeutic Implications, 1110
Topics in Antibiotic Chemistry, Vol. 4: The Chemistry and Antimicrobial Activity of New Synthetic β-Lactam Antibiotics, 1110
Toxic Plants, 1109
United States Pharmacopeia Dispensing Information, 873
1980 United States Pharmacopeia–National Formulary, 873
USAN and the USP Dictionary of Drug Names 1981, 1244
Vaccine Preparation Techniques, 1110
Vitamin E: A Comprehensive Treatise, 1110
Vitamin K Metabolism and Vitamin K-Dependent Proteins, 620
Workshop on Ursodeoxycholic Acid, 368
75 Years of Chromatography—A Historical Dialogue, 132

Bretylium*—*determination in biological fluids by GLC and direct radioactivity measurement, humans, 681
Bromhexine*—*electron-capture GLC analysis, human plasma, 99
Brompton mixtures—stability, high-performance liquid *chromatographic analysis of cocaine and heroin* with hydrolysis products, 637
Bronchodilators—metered-dose solution and powder aerosols, effect of low and high humidity, 334
—theophylline, trough serum concentrations at steady state, temporal variations, 358
Brucine—^{13}C-NMR spectral analysis, chemical shifts assigned, 865
Budesonide—*high-performance liquid chromatographic analysis of drug content, impurities, and epimer distribution, preparation of primary standard, 766*
Buffers—various octanol–buffer systems, effects on partitioning of acidic, basic, and neutral drugs, 662
Bupivacaine—simultaneous GLC analysis with mepivacaine, etidocaine, lidocaine, and tetracaine *in biological fluids, 603*
Butorphanol—pharmacokinetics following subcutaneous and intramuscular administration, dogs, 801
—radioimmunoassay in human serum, pharmacokinetics in human serum, 160
Butylated hydroxyanisole—pharmacokinetics, rabbits, 1455
Butylated hydroxytoluene—*pharmacokinetics, rabbits,* 1455
γ-Butyrolactone—prodrug for sodium γ-hydroxy-*butyrate, relationship between in vitro transport and in vivo* absorption, 356

C

Cactus alkaloids—heliamine, 3,4-dimethoxy-β-*phenethylamine, isolation, identification, 94*
Caffeine—administered alone and with aspirin, absorption, distribution in gastric tissue, blood plasma levels, rats, 900
—GLC analysis, capsule preparations, 854
—hydrogen bonding in complex with *p*-cresol, 613
—simultaneous quantitation with acetaminophen, aspirin, codeine phosphate, phenacetin, and salicylamide, high-pressure liquid chromatography, 110
—solubility in water–dioxane mixtures, extended Hildebrand approach, mathematical prediction of solute–solvent solubilities, 659
Calcium gluconate—interaction with folic acid, low concentrations, 234
Calcium-ion dependency—asthma pathophysiology, *cyclic adenosine and guanosine monophosphate* levels, mediator release, smooth muscle contraction–excitation, mast cell and mucous cell secretion, vagus nerve activation, 243
Canadine—hydrastis alkaloid, spectrophotometric determination, effect of pH on alkaloid–dye complex formation, 597
Cannabichromene homologs—evaluation for anti-inflammatory activity, 1359
Capacity factors—cephalosporins and penicillins, interactions with a nonpolar octadecylsilyl stationary phase, 501
Caramiphen—analysis in whole blood by GLC with nitrogen-specific detector, 1353
Carbachol, *N*-demethylated derivative—effect on iris and ciliary muscles, treatment of open-angle *glaucoma, 332*
—effect on schistosomes, effect of anticholinergic agents, scanning fluorescence method, motility studies, 516
Carbamazepine—prediction of steady-state metabolite concentration, monkeys, 610
Carbenicillin disodium—high-pressure liquid chromatographic analysis, 1264
Carbidopa—interaction with pyridoxal 5-phosphate, 1145
Carbonic anhydrase inhibitors—acetazolamide, *high-performance liquid chromatography, plasma,* 348
—indapamide, automated analysis in drug-rodent *food mixtures, 1158*
Carboprost—comparison of high-pressure liquid chromatographic assays with and without derivatization, 1396
Carcinogens—synthesis of 9-substituted 3-nitrofluorene intermediates for study of 3-*N*,*O*-diacetylhydroxylaminofluorene mutagenicity, 122
Cardiac output—determination, comparison of dye dilution method and radionuclide techniques, dogs, 509
Carnitine analogs—effect on carnitine acetyltransferase, spectrophotometric and radiometric measurements, kinetic parameters, *in vitro,* 202
Carprofen—metabolism in rats, dogs, and humans, 1245
Catechol—charge transfer complex with indoles, 990
Cedrela odorata—recommended assignment of odoratin as name for isolate from *Cedrela odorata* only, 1107
Cefamandole nafate—hydrolysis in presence of glucose, 1183
Cefazolin sodium—high-pressure liquid chromatographic analysis, 1264
Ceforanide—pharmacokinetics, humans, 398
Cephalexin—simultaneous high-performance liquid chromatographic determination with lysine in their salt using derivatization, 1378
Cephalosporins—interactions with a nonpolar octadecylsilyl stationary phase, 501
—serum protein binding alteration by fatty acids and *their derivatives, 354*
—TLC–bioautographic analysis as contaminants in various tetracyclines, 616
Cephalothin sodium—*high-pressure liquid chromatographic analysis,* 1264
Charge transfer complexes—hydrogen bonding in *caffeine–p-cresol and theophylline–p-cresol* complexes, 613
—interaction of catechol and indoles, 990
—*prodine analogs, correlation between analgesic* activity and energy level of highest occupied molecular orbital of aryl moiety, complex formation between aryl moiety and receptor, 796
Chelating agents—N^1,N^8-bis(2,3-dihydroxybenzoyl)spermidine and analogs, synthesis and evaluation as iron-sequestering agents, 986
Chemotherapeutic agents—sulfamethazine, high-pressure liquid chromatographic determination, beef tissues, 701
Chloral betaine—oral and rectal absorption, compared to chloral hydrate, 227
Chloral hydrate—oral and rectal absorption, compared to chloral betaine, 227
Chlorambucil analogs—synthesis and evaluation for antitumor activity, 1232
—analysis, mass spectrometry, degradation products and metabolite, human plasma and urine, 80
—degradation in aqueous solution, influence of pH and temperature, 1091
—GLC determination with selected-ion monitoring, plasma, 710
—hydrolysis kinetics, 861
—hydrolysis kinetics, potential errors based on chloride-ion determination, 859
***N*-Chloramines**—antimicrobial activity, inhibition of bacterial DNA, RNA, and protein synthesis, 1292
Chloramphenicol—simultaneous high-pressure liquid chromatographic assay with chloramphenicol-3-monosuccinate and chloramphenicol-1-monosuccinate, 909

Chloramphenicol -3- monosuccinate—identification of alternate form in equilibrium mixture as chloramphenicol-1-monosuccinate, 906
Chlordiazepoxide—simultaneous determination with amitriptyline hydrochloride, high-performance liquid chromatography, 138
Chlordiazepoxide hydrochloride—effect of amitriptyline hydrochloride on NMR spectra, proton transfer in a dipolar aprotic solvent, 180
Chlorhexidine—analysis, colorimetric determination in commercial dosage forms, 215
ω-Chloro-α-alkanols—antifungal activity, *in vitro*, effect of chain length, pH, and adsorbents, 381
2-Chloromethylbenzo[*b*]furans—synthesis, 232
Chlorpheniramine—bioavailability in sustained-release dosage form with pseudoephedrine, 1077
—GLC–mass spectrometric analysis, pharmacokinetics, human serum, 707
Chlorpheniramine maleate—GLC analysis, capsule preparations, 854
—mechanism of interaction with montmorillonite, 1142
Chlorpromazine hydrochloride—and oxidation products, high-performance liquid chromatography and fluorescence detection, dosage forms, 184
Cholecalciferol (vitamin D_3)—high-performance liquid chromatographic determination of potential content in gelatin-coated beadlets, oil-based mixtures, and multivitamin tablet and capsule formulations, 846
—stability, effects of temperature and humidity, 1099
Cholesterol—effect of lecithin adsorption on cholesterol dissolution, interfacial barrier formation, 413
—mesophase formation during dissolution in ursodeoxycholate–lecithin solutions, mechanism for gallstone dissolution in humans, 869
—19-radioiodinated analog, evaluation as ovarian imaging agent, 1014
Cholesterol-lowering agents, potential—gemcadiol, identification and analysis of persistent contaminants, 687
Choline magnesium trisalicylate—plasma salicylate levels following administration of solid dosage form, comparison with aspirin and magnesium salicylate, 1355
Cholinergic activity—acetylcarnitine, conformational analysis, comparison to cholinergic receptor patterns, 1065
Cholinergics—antagonists, dansylated acetylcholine analogs, *in vitro* scanning fluorescence method, neuroactive drugs in schistosomes, 516
Chromatography—gel filtration, washing procedures for columns contaminated with microorganisms, 140
Cimetidine—adsorption onto various pharmaceutical adsorbents, *in vitro*, 352
—pharmacokinetics, bioavailability, humans, 394
***trans*-Cinnamic acid**—analysis of complexation with α-cyclodextrin, thermodynamics, 173
Cinromide—prediction of steady-state metabolite concentration, monkeys, 610
Citric acid—glass formation, glass transition temperature, comparison of anhydrous and monohydrate forms of citric acid, 612
Clays—montmorillonite, mechanism of interaction with chlorpheniramine maleate, 1142
—pharmaceutical grade, adsorption of tetracycline, isomorphous substitution, 816
Clearance—^{141}Ce-labeled microspheres, clearance from blood following intravenous and intraarterial administration, dogs, 755
intrinsic—plasma sodium dichloroacetate concentration, pharmacokinetics, rats, dogs, humans, 419
Clobazam—electron-capture GLC analysis with desmethylclobazam, human plasma, 1351
Clodanolene—quaternary ammonium salts, synthesis, skeletal muscle relaxant activity, 327
Clofibrate—simultaneous GLC assay with clofibric acid, human plasma, 92
Clofibric acid—simultaneous GLC assay with clofibrate, human plasma, 92
Clorobiocin analogs—correlation of hydrophobicity with protein binding, 799
CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1*H*)-pyrimidone, evaluation of antidepressant and antianxiety activity, *in vitro* and *in vivo*, 1198
—1-(substituted benzyl)-3,4,5,6-tetrahydro-2(1*H*)-pyrimidones, synthesis and testing for stimulant and depressant activities, mice, 1194
CNS agents—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1*H*)-pyrimidone, isolation, synthesis, and biological activity of metabolites, 1203
Coacervation—povidone and sulfathiazole, dissolution of coacervated system, 492
Cobalt chloride—LD_{50} testing, gravid and nongravid mice, 214
Cocaine—high-performance liquid chromatographic analysis with heroin and hydrolysis products, Brompton mixtures, 637
hydrochloride—evaluation as potential teratogen, effect on catecholamine levels in placenta, skeletal and soft tissue malformations in fetal mice, 703
Codeine—analysis, high-performance liquid chromatography, ion-pair formation, effect of carbon chain length of pairing ions, syrups, 152
—binding to human serum albumin, varying albumin concentration, 71
—high-performance liquid chromatographic analysis of capsules, tablets, and elixirs with acetaminophen and codeine, comparison with GLC analysis, 1081
phosphate—simultaneous quantitation with acetaminophen, aspirin, caffeine, phenacetin, and salicylamide, high-pressure liquid chromatography, 110
Colchicine—analysis by differential pulse polarography, 1436
Colorimetry—analysis, berberine in pharmaceutical preparations and synthetic mixtures of hydrastis alkaloids, effect of pH on alkaloid–dye complex formation, 597
—analysis of chlorhexidine in commercial dosage forms, 215
—analysis of diethylstilbestrol and diethylstilbestrol dipropionate with triphenyltetrazolium chloride, 24
—analysis of nystatin, thermal degradation, relationship between loss of microbiological potency and color change, 697
—analysis, procaine hydrochloride reaction with 1,2-naphthoquinone-4-sulfonic acid sodium salt, 346
—analysis, thyroid in individual thyroid tablets, 948
Complexation—*trans*-cinnamic acid with α-cyclodextrin, thermodynamic analysis, stoichiometry, stability equilibria, determined by spectral, solubility, and pH measurements, 173
—α-cyclodextrin, stoichiometric model, 564
—of niacinamide with drug molecules, aqueous solution, frontier molecular orbital calculations, 104
—polybasic acids and their sodium salts with aluminum hydroxycarbonate gel, acid neutralization, structural changes in aluminum hydroxycarbonate gel, 668
—povidone with salicylic acid and benzoic acid, effects of temperature, buffer composition, and ionic strength, 1403
Complexes—pilocarpine with cobalt(II), nickel(II), copper(II), and zinc(II) halides, 1220
—thiobarbiturates with copper(II), 1164
Conformation—of 2-substituted phenothiazines as solutes, 116
Congocidine—derivatives based on 2,5-disubstituted pyrroles, synthesis and evaluation for cytotoxicity and antiviral activity, structure–activity relationships, 1334
Conjunctival mucins—isolation from rabbits, fractionation by gel filtration and anion-exchange chromatography, determination of molecular weight, role in tear film stability, 430
Contamination—microorganisms in gel filtration columns, washing procedures for column disinfection, 140
Contraceptives—norethindrone, coupling to poly(α-amino acids), controlled release coupled compounds, 871
Controlled-delivery system—preparation methods, polymer–drug matrix, drug release kinetics, 265
Correlation coefficients—disintegrating tablets, relationship between porosity and dissolution rate, 607
Cost evaluation—tableting processes, simulation model, 621
Cotinine—major metabolite of nicotine, comparison of pharmacokinetic parameters following single-cigarette smoke inhalation and intravenous administration, rats, 1087
Coumarin anticoagulants—warfarin, dose-dependent pharmacokinetics, rats, 9
Cromolyn sodium—prophylactic antiallergic drug, 239
Crystals—barium sulfate formation in commercial parenteral solutions, characterization by polarizing microscopy, scanning electron microscopy, micro X-ray powder diffraction, and micro Raman spectroscopy, 608
Curatella americana—chemical constituents, isolation and identification, 360
Cyclic adenosine monophosphate (cyclic AMP)—effect of sesquiterpene lactones on *in vitro* levels, role in inflammation process, 537
—epididymal levels, effect of hyperthermically elevated serum prolactin, rats, 350
α-Cyclodextrin—analysis of complexation with *trans*-cinnamic acid, thermodynamics, 173
—complexation with 3,5-dimethoxycinnamic acid, benzalacetone, and methyl cinnamate, stoichiometric model, 564
Cyclohept-2-enone—partition coefficient, calculation by kinetic methods, 527
Cyclophosphamide—chemotherapy of neuroblastoma in mice, 592

D

Dactinomycin—on polymethylcyanoacrylate and polyethylcyanoacrylate nanoparticles, distribution patterns in rats, 199
Dantrolene—quaternary ammonium salts, synthesis, skeletal muscle relaxant activity, 327
Decomposition—aminophylline in suppository formulations, 942
—diethylpropion hydrochloride drug substance and tablets, effect of pH on hydrolysis, 1206
—solid-state reactions, decarboxylation kinetics, hypolipidemic agent, 5-(tetradecyloxy)-2-furoic acid, 123
Deconvolution—least-squares technique, bioavailability testing, drug input, 318
—pharmacokinetic estimation of drug input into blood, 312
Degradation—benzocaine, effect of pH, temperature, and phosphate ion, 1384
—chlorambucil and metabolites, in aqueous solution, effect of pH and temperature, 1091
—pharmaceutical preparations, effect on UV absorbance spectra, comparison of three background correction methods, changeable matrixes, 629
products—phenylbutazone, tablets, identification, 469
products—salicylic acid metabolites, high-pressure liquid chromatographic analysis, biological matrixes, 1224
thermal—nystatin, colorimetry, relationship between loss of microbiological potency and color change, 697
Dehydrodiscretine—new quaternary protoberberine isolated from *Thalictrum fauriei*, structural determination, 1061
Delivery systems—inhalation aerosols, flume pattern characterized by video technique, 713
***N*-Demethylated carbachol**—effect on iris and ciliary muscles, treatment of open-angle glaucoma, 332
4-Demethylepipodophyllotoxin -9- (4,6 -*O*- ethylidine-β-D-glucopyranoside)—high-pressure liquid chromatographic analysis, 1440
6-Demethylgriseofulvin—TLC determination in urine, 561
Deoxyribonucleic acid synthesis, inhibitors—eupaformosanin, effect on nucleic acid, protein, and

anaerobic and aerobic glycolytic metabolism, Ehrlich ascites cells, 294
Depressants, smooth muscle—novel marine compounds, 462
Desmethylclobazam—electron-capture GLC analysis with clobazam, human plasma, 1351
Desmethylmaprotiline—GLC–mass spectrometric analysis, human and animal plasma, 684
Dexamethasone—mass spectral analysis, comparison with mass spectrum of betamethasone, 991
—ophthalmic suspensions, bioavailability, effect of particle size, rabbits, 391
—suppression of endogenous hydrocortisone, 1409
Dextromethorphan—*N*-demethylation to yield 3-methoxymorphinan hydrochloride and two novel zinc salts of 3-methoxymorphinan, 1447
hydrobromide—high-performance liquid chromatographic analysis using ion-pair formation, 1380
hydrobromide—simultaneous determination with acetaminophen and guaifenesin, high-pressure liquid chromatography, 212
—NMR determination with levomethorphan, 459
Diabetes—streptozocin induced, pharmacokinetic model, mice, 691
3 -*N,O*- Diacetylhydroxylaminofluorene—synthesis of 9-substituted 3-nitrofluorene intermediates, effect on carcinogenicity, 122
Diacetylmorphine—high-performance liquid chromatographic analysis with cocaine and hydrolysis products, Brompton mixtures, 637
Dialkylmalonuric esters—synthesis, cyclization to barbituric acids, 451
1,2-Dialkyl-4-pyrazolidinols—phenylurethan derivatives, synthesis and testing for anticonvulsant activity, 729
Diaminopropane—chemotherapy of neuroblastoma in mice, 592
Diatrizoic acid—radiopaque, deiodination kinetics, 671
Diazepam—GLC determination in serum, wall-coated open tubular column coupled with nitrogen-selective detector, 835
—reduction of thrombosis and inflammation using poloxamer 188 as vehicle, rabbits, 970
1-(3,4-Dichlorobenzyl) -3,4,5,6- tetrahydro -2(1*H*)-pyrimidone—evaluation of antidepressant and antianxiety activity, *in vitro* and *in vivo,* 1198
—isolation, synthesis, and biological activity of metabolites, 1203
Diethylpropion hydrochloride—effect of pH on hydrolytic decomposition of drug substance and tablets, 1206
Diethylstilbestrol and diethylstilbestrol dipropionate—analysis, triphenyltetrazolium chloride colorimetry, 24
—semiautomated fluorometric analysis of enteric-coated and plain coated tablets, 951
Differential heat of solution—determination in real solutions from variation in solubility with temperature, 1241
Differential UV and fluorescence spectrophotometry—analysis, phenothiazines, comparison with official methods, 1069
Diffusion—effect of molecular weight, parabolic model, 648
—heterogeneous model of drug release from polymeric matrix, 1311
—mass transport models of intestinal wall permeability, 1369
—phenol self-association, effect on membrane transport, 133
Diffusivity—vidarabine and *n*-pentanol, effect of skin strata and thickness on diffusivity, 770
Digoxin—dissolution and degradation in acidic solution, high-pressure liquid chromatography, kinetic study, 410
3,4-Dimethoxy-β-phenethylamine—isolation from cacti, identification, heliamine, 94
5-(4-Dimethylaminobenzyl)imidazolidine -2,4- dione—synthesis and testing for antidepressant activity, 1102
***p*-(3,3-Dimethyl-1-triazeno)benzoic acid hydrazide**—antineoplastic activity, hydrazones and adducts with aromatic aldehydes, structure–activity relationships, 97
Dipole moments—of 2-substituted phenothiazones as solutes, 116
Disintegration—commercial prednisone tablets, time and temperature dependence, correlation between dissolution and disintegration rate constants, 290
—compressed tablets following moisture-induced hardness increase, role of binders, *in vitro,* 1
—hard gelatin capsules, modification of USP and NF tests for tablet disintegration, 749
—monitoring of *in vivo* tablet disintegration time by external scintigraphy, 1107
—tablets, correlation between porosity and dissolution rate, 607
Dissolution apparatus, peristaltic—prednisone tablets, prediction of relative *in vivo* performance in humans, 220
—aspirin formulations, *in vitro,* basket and paddle methods compared, 967
—commercial prednisone tablets, time and temperature dependence of disintegration, correlation between dissolution and disintegration rate constants, 290
—compressed tablets following moisture-induced hardness increase, role of binders, *in vitro,* 1
—digoxin tablets, biphasic dissolution, 410
—morphine–tristearin solid dispersion, *in vitro,* 466
rate—correlation with porosity for disintegrating tablets, 607
rates—ergotamine tartrate, various dissolution media, 832
rates—ethinyl estradiol in tablets, spectrophotofluorometric analysis in the presence of norethindrone and common tablet excipients, 857
rates, *in vitro*—proquazone, dependence on particle size, 605
—tableted enteric-coated microcapsules, 1388
Distamycin—derivatives based on 2,5-disubstituted pyrroles, synthesis and evaluation for cytotoxicity and antiviral activity, structure–activity relationships, 1334
Distribution coefficients—spironolactone, 7α-(carboxymethyl analog, phosphate buffer with *n*-octanol or chloroform, 30
—^{141}Ce-labeled microspheres, distribution in specific organs following intravenous and intra-arterial administration, dogs, 755
ocular—pilocarpine, mechanisms of absorption following subconjunctival injection, rabbits, 875
—of drug in lung alveoli, analysis of delivery systems, inhalation aerosols, flume patterns characterized by video technique, 713
particle size—milled and micronized pharmaceutical powders, geometric volume mean diameter, electrolytic sensing zone method with and without a pulse-width discriminator, 651
—sulfonylureas in the perfused pancreas, correlation with pharmacological response, 157
Diterpene esters—isolation as skin irritant from *Synadenium grantii,* 1446
Diuretics—furosemide, stability in aqueous solutions, effect of formulation factors, 594
DNA—binding by radioprotective *N*-heterocyclic aminoethyl disulfides and thiosulfates, 84
Dopamine—antiparkinson drug, adenylate cyclase activity, dopamine analogs, 149
—topographical model of renal vascular receptor, 1059
Dopaminergic agonists—apomorphine, synthesis of (*S*)-(+)-stereoisomer from (*R*)-(−)-stereoisomer, 1056
Dosage forms—capsule formulations, optimization by simplex method, 1135
controlled release—propoxyphene, influence of type of formulation on drug release, pH dependency, 1327
—hard gelatin capsules, disintegration test, modification of USP and NF tests for tablet disintegration, 749
sustained release—bioavailability of chlorpheniramine and pseudoephedrine in combination product, 1077
Dosage regimens—mean total body clearance, calculation, harmonic mean method, 90
Doxycycline—pharmacokinetics of reabsorption, two cyclic linear compartment models proposed, 204
Dragendorff's reagent—false-positive alkaloid reaction with nonnitrogenous oxygenated compounds, 37
Drug absorption—compartment- and model-independent calculation for drugs with linear pharmacokinetics, 57
availability—model-independent estimation, 77
availability—testing, least-squares deconvolution technique, 318
binding—plasma protein, hepatic extraction of endogenous inhibitors, 480
bioavailability—blood, deconvolution method for pharmacokinetic estimation, 312
carriers—polymethylcyanoacrylate and polyethylcyanoacrylate nanoparticles, distribution patterns of adsorbed dactinomycin and vinblastine in rats, 199
clearance, renal—effect of plasma protein binding, 482
degradation kinetics—nonisothermal method, programmed temperature steps, comparison with isothermal kinetic method, 287
delivery systems—implantable osmotic pumps, use of polyethylene glycols as solvents, 747
delivery systems—negatively charged phospholipid vesicles, tissue distribution in rats, 1338
delivery systems—prostaglandin E_2 gel, preparation, characterization, and stability, 1271
delivery systems—sustained release of morphine from polydimethylsiloxane pellets, mice, 980
dissolution—USP 1 rotating-basket dissolution testing apparatus, modification to eliminate tablet air entrapment, 129
distribution—tetracycline, uptake by red blood cells, 455
impurities—gemcadiol, identification and analysis of persistent contaminants, 687
impurities—meprobamate, identification in tablets, 1444
input—linear pharmacokinetic systems, polyexponential impulse response, analysis by model-independent method, 305
interactions—folic acid and calcium gluconate, low concentrations, 234
metabolism—effect of serum protein binding, 746
metabolism—2-ethyl-2,3-dihydro-5-benzofuranacetic acid, *in vivo,* rats, dogs, humans, 164
partitioning—unstable compounds, cyclohept-2-enone, calculation of partition coefficient by kinetic methods, 527
potency—product stability, calculation, kinetic ratio parameter, 325
transport—alkyl *p*-aminobenzoates, membrane permeation, fluid flow in aqueous diffusion region, 210
transport—pancreas, effect of secretin, pancreozymin, pancreatic juice flow, various drugs, 27
Drug–drug interactions—pharmacokinetics and pharmacodynamics of furosemide with and without probenecid pretreatment, humans, 571
Drug–receptor interaction—structure–activity relationships, negentropy of molecules, mathematical analysis of molecular structure and biological potency, 807
—topographical model of renal vascular dopamine receptor, 1059
Dye dilution method—determination of cardiac output, comparison to radionuclide techniques, dogs, 509

E

Edetate disodium—effect on absorption of secobarbital sodium in goldfish, 972
—polarographic determination in eyewash and ophthalmic decongestant solutions, 826
EDITORIALS
Carcinogenicity Testing—A National Catastrophe (February)
An Effort to Create New Understandings (July)
Ethical Considerations in Research Publication (December)
Every Five Years (March)
FDA: Policeman or Teacher? (January)

Identifying "The Bad Characters" (April)
Maintaining NAS–NRC Credibility (August)
Playing Politics at the FDA's Expense (October)
PR in the Pharmaceutical Sciences (May)
Scientific Information in Formulating Public Policy (November)
Taking Animals Out of the Lab (September)
Where Have All The Researchers Gone? (June)
Elephantopus mollis—isolation and structural determination of molephantin, molephantinin, and phantomolin, 1050
Enantiomers—NMR determination of dextromethorphan and levomethorphan mixtures, chiral lanthanide shift reagents, 459
Enicostemma hyssopifolium—isolation and identification of flavonoids, 53
Enzymatic hydrolysis—procedure for sample preparation for identification of conjugated and esterified estrogens in pharmaceutical preparations, comparison with acidic hydrolysis procedure, 1453
Enzyme distribution studies—location and nature of adenosine deaminase and esterase in mouse skin, pharmacokinetic parameters of deaminase and esterase, 772
inhibition—*N*-chloramine-induced inhibition of sulfhydryl-containing enzymes in bacteria, 1292
inhibition—effect of monoesters of glutaric acids on cholesterol biosynthesis, rat liver microsomes, 506
inhibition—effects of pyruvate derivatives on *S*-adenosyl-L-methionine decarboxylase, 1000
Epinephrine—effect of human serum albumin concentration, 885
Equilibrium moisture content—poorly soluble substances, effect of overall porosity on hygroscopicity, 742
Ergocalciferol (vitamin D_2)—high-performance liquid chromatographic determination of potential content in gelatin-coated beadlets, oil-based mixtures, and multivitamin tablet and capsule formulations, 846
—stability, effects of temperature and humidity, 1099
Ergotamine tartrate—solubility and dissolution rate, 832
Erythrocytes—sickle cell, effect of etidronate disodium on filterability, 599
Erythromycin stearate—correlation of bioavailability of tablets with *in vitro* tests, 1307
—TLC–bioautographic analysis of penicillin and ampicillin as contaminants, 616
Estrogens—diethylstilbestrol, semiautomated fluorometric analysis of enteric-coated and plain coated tablets, 951
—identification of conjugated and esterified estrogens in pharmaceutical preparations, comparison of acidic and enzymatic hydrolysis procedures for sample preparation, 1453
Ethambutol—GLC analysis in biological fluids, 362
Ethinyl estradiol—spectrophotofluorometric analysis in the presence of norethindrone and common tablet excipients, 857
Ethyldeoxyuridine—synthesis, biotransformation in rats, metabolites, 531
2-Ethyl-2,3-dihydro-5-benzofuranacetic acid—*in vivo* metabolism, rats, dogs, humans, 164
***N*-Ethyl-2-(3,4-dihydroxyphenyl)ethylamine**—dopamine analog, adenylate cyclase activity, 149
Ethylmorphine—analysis, high-performance liquid chromatography, ion-pair formation, effect of carbon chain length of pairing ions, 152
Etidocaine—simultaneous GLC analysis with mepivacaine, bupivacaine, lidocaine, and tetracaine in biological fluids, 603
Etidronate disodium—effect on filterability of sickle cell erythrocytes, 599
Etilefrine—synthesis and evaluation of 3′-(*O*-acyl) derivatives as prodrugs, 1423
Eupaformosanin—antitumor activity, effect on nucleic acid, protein, and anaerobic and aerobic glycolytic metabolism, Ehrlich ascites cells, 294
Euphorbiaceae—isolation of phorbol ester derivative as skin irritant from *Synadenium grantii*, 1446
Excipients—polyethylene glycol and polyoxyethylene stearate, comparison as excipients for solid dispersion systems of griseofulvin and tolbutamide, dissolution and solubility studies, 1321
—polyethylene glycol and polyoxyethylene stearate, comparison as excipients for solid dispersion systems of griseofulvin and tolbutamide, phase equilibria, 1317
—solutions, suspensions, and suppositories, changeable matrixes and their effect on UV absorbance spectra, comparison of three background correction methods, 629
Expiration dating—product stability, calculation, kinetic ratio parameter, 325

F

Fibrin—effect of sodium bicarbonate and sodium citrate on *in vitro* conversion of fibrinogen, 978
Film-coated tablets—measurement of adhesion of film coating to tablet surface, effect of solvents and humidity on bonding of film to tablet surface, 439
First-pass metabolism—lidocaine following rectal and oral administration, rats, 804
—pentobarbital, effect of short-term exposure to polychlorinated biphenyls, rats, 1279
Flavonoids—isolation from *Enicostemma hyssopifolium*, identification, 53
Flexure breaking strength—determination for capsule-shaped tablets, new instrumentation, 384
Flocculation—effect of xanthan gum in pharmaceutical suspensions, 1209
Flufenamic acid—analysis, high-performance liquid chromatography, plasma, rats, humans, 95
Fluorenes—synthesis of 3-nitro-9-substituted derivatives, potential enhancement of 3-*N*,*O*-diacetylhydroxylaminofluorene carcinogenicity, 122
Fluorometry—analysis, thiazole-containing compounds, 275
—semiautomated analysis of enteric-coated and plain coated diethylstilbestrol tablets, 951
—structural effects, intensity, Stokes' shift, structural analysis, 253
Fluorouracil—comparison of oral and intravenous doses, pharmacokinetics, human plasma, 1428
—GLC–mass spectrometric analysis in biological materials, 1296
Flurazepam—IR spectral analysis, effects of various extraction solvents, transformation from dihydrochloride to monohydrochloride and free base, comparison of spectra of extracted, untreated, and solution samples, 270
—radioimmunoassay, plasma levels in humans, 601
Flux, steady state—effect of phenol self-association on transport across polyethylene film, 133
Folic acid—interaction with calcium gluconate, low concentrations, 234
Forskolin—GLC analysis in plant extracts and pharmaceutical preparations, 1449
Fragment molecular connectivity—pattern recognition of steroids, 1030
Free energy—adsorption, barbital, phenobarbital, pentobarbital, phospholipid monolayers, 102
Florafur—high-pressure liquid chromatographic analysis in biological materials, 1296
Furan analogs—of benzilate esters, synthesis and antimuscarinic activity, 534
2-Furoic acid, 5-tetradecyloxy—hypolipidemic agent, solid-state decomposition, kinetics, 123
Furosemide—pharmacokinetics and pharmacodynamics with and without probenecid pretreatment, humans, 571
—stability in aqueous solutions, effect of formulation factors, 594

G

Gallic acid—isolation from *Curatella americana*, identification, 360
Gallstones—mechanism for dissolution in humans, mesophase formation during cholesterol dissolution in ursodeoxycholate–lecithin solutions, 869
Gemcadiol—identification and analysis of persistent contaminants, 687
Gentianaceae—isolation of flavonoids from *Enicostemma hyssopifolium*, identification, 53
GI motility—determination of gastric emptying rate and pattern, radionuclide imaging, humans, 568
Glass formation—citric acid, glass transition temperature, 612
transition temperature—citric acid, glass formation, temperature variations due to water loss variations, 612
GLC—analysis, aprindine, nitrogen–phosphorus flame-ionization detection, human plasma, 1094
—analysis, bretylium in biological fluids, humans, 681
—analysis, bromhexine, electron-capture detection, human plasma, 99
—analysis, caramiphen, nitrogen-specific detector, 1353
—analysis, chlorambucil, selected-ion monitoring, plasma, 710
—analysis, diazepam, meprobamate, phenylbutazone, and thioridazine in serum, wall-coated open tubular column coupled with nitrogen-selective detector, 835
—analysis, ethambutol in biological fluids, 362
—analysis, forskolin in plant extracts and pharmaceutical preparations, 1449
—analysis, indomethacin in human plasma, 219
—analysis, mepivacaine, bupivacaine, etidocaine, lidocaine, and tetracaine in biological fluids, 603
—analysis, procainamide hydrochloride and acecainide hydrochloride in rat feed, 1439
—analysis, urushiols in pharmaceutical preparations containing poison ivy and poison oak extracts in vegetable oils, 587
electron capture—analyses, clobazam and desmethylclobazam, human plasma, 1351
electron capture—analysis, nofedone, human serum, 273
electron capture—analysis, pindolol, biological fluids, 1191
flame ionization—simultaneous analysis of salicylamide, phenylpropanolamine, caffeine, chlorpheniramine, phenylephrine and pyrilamine, capsule preparations, 854
—identification of conjugated and esterified estrogens in pharmaceutical preparations, comparison of acidic and enzymatic hydrolyses for sample preparation, 1453
—propoxyphene, identification of thermal decomposition products formed during GLC analysis, 1177
—prostaglandin analog determination, sample cleanup prior to GLC, polyethylene glycol carrier matrix, 718
—trifluoroacetyl derivatives of aporphines and noraporphines, 936
GLC–mass spectrometry—analysis, chlorpheniramine, pharmacokinetics, human serum, 707
—analysis, 5-fluorouracil and uracil in biological materials, 1296
—analysis, mescaline in rabbit plasma, 118
—analysis of plasma concentrations of unlabeled and labeled barbital following simultaneous oral and intravenous administration, specific-ion monitoring, 640
—analysis of timolol and metabolites, human plasma and urine, 1111
—stable isotope-labeled maprotiline, selected-ion monitoring, pharmacokinetics, 684
Globulin—adsorption onto glass surfaces, 1226
Glucocorticoids—identification by high-pressure liquid chromatography, arthritis treatment, 590
Glucose—effect on hydrolysis of cefamandole nafate, 1183
Glycerol—effect on interaction of parabens with polysorbate 80, 169
Griseofulvin—high-performance liquid chromatographic analysis, purity and stability of drug substance, powders, tablets, capsules, and boluses, metabolites, 523
—TLC determination in plasma, 561
Guaifenesin—simultaneous determination with acetaminophen and dextromethorphan hydrobromide, high-pressure liquid chromatography, 212

H

Half-life—effect of changes in plasma protein binding on biological half-life of drugs, 751

Half-neutralization potentials—selected bases in benzene–acetonitrile binary solvent system, 1151
Hallucinogenics—mescaline, GLC–mass spectral determination, rabbit plasma, intravenous injection, 118
Hardness, tablets—flexure breaking strength, determination for capsule-shaped tablets, new instrumentation, 384
Heavy metal poisoning—protection by mercapto steroids, 556
Heliamine—isolation from cacti, identification, 3,4-dimethoxy-β-phenethylamine, 94
Heparin—effect on plasma concentrations of bilirubin, pharmacokinetics, rats, 1228
Heroin—high-performance liquid chromatographic analysis with cocaine and hydrolysis products, Brompton mixtures, 637
—pharmacokinetics, dogs, 1116
Heterocycles—synthesis of 2-chloromethylbenzo[*b*]furans, 232
Heterocyclic adducts—cyclic ureides, condensation products of ninhydrin with indoles and thiourea, structural elucidation by NMR spectroscopy, 1431
***N*-Heterocyclic aminoethyl disulfides and thiosulfates**—DNA binding ability, radiation protection evaluated, 84
3a,4,5,6,7,7a-Hexahydro-3-(1-methyl -5- nitro-1*H*-imidazol-2-yl) -1,2- benzisoxazole—identification of urinary metabolites, dogs, 1288
Hexamethonium chloride—influence of various anions on intestinal disappearance in rats, 923
High-performance liquid chromatography—analysis, acetazolamide, plasma, 348
—analysis, benzimidazoles, GI fluids, plasma, 422
—analysis, benzocaine and *p*-aminobenzoic acid, stability studies of benzocaine, 1384
—analysis, budesonide, determination of drug content, impurities, and epimer distribution, 766
—analysis, cephalexin and lysine in their salt, derivatization, 1378
—analysis, cocaine and heroin with hydrolysis products, Brompton mixtures, 637
—analysis, codeine and acetaminophen in capsules, tablets, and elixirs, comparison with GLC analysis, 1081
—analysis, decomposition of diethylpropion hydrochloride, 1206
—analysis, dextromethorphan hydrobromide, ion-pair formation, 1380
—analysis, flufenamic acid, mefenamic acid, plasma, rats, humans, 95
—analysis, griseofulvin, purity and stability of griseofulvin dosage forms, metabolites, 523
—analysis, ketoprofen, human plasma and urine, 763
—analysis, khellin in human serum and urine, 1434
—analysis, metaraminol bitartrate in the presence of methylparaben and propylparaben, 1459
—analysis, nitroglycerin ointment, 1084
—analysis, oxaprozin, macro- and microextraction methods, comparison with GLC, human and rat plasma, 794
—analysis, pilocarpine, isopilocarpine, pilocarpic acid, and isopilocarpic acid, 1096
—analysis, potential content of vitamins D_2 and D_3 in gelatin-coated beadlets, oil-based mixtures, and multivitamin tablet and capsule formulations, 846
—analysis, promethazine, whole blood and parotid saliva concentrations following oral and intramuscular administration, 1457
—analysis, sotalol, human plasma and urine, 1216
—analysis, suxibuzone and metabolites in plasma and urine, 1258
—analysis, testosterone esters in oily solution, 1214
—analysis, tetracycline epimers in tetracycline preparations, 928
—determination of pilocarpine in aqueous humor, quaternization of the methylimidazole tertiary amine group, 257
ion-pair formation—analysis of codeine, ethylmorphine, and morphine, effect of carbon chain length of pairing ion, 152
—isophenindamine, analysis in phenindamine tartrate bulk powder, 342
—rapid determination of chlorpromazine hydrochloride and two oxidation products, dosage forms, 184
—simultaneous determination of chlordiazepoxide and amitriptyline hydrochloride, 138
—simultaneous determination of isoniazid and 1-isonicotinyl-2-lactosylhydrazine, isoniazid tablet formulation analysis, 222
High-pressure liquid chromatography—analysis, aspirin and salicylic acid, 1188
—analysis, carboprost, comparison of procedures with and without derivatization, 1396
—analysis, chloramphenicol, chloramphenicol-3-monosuccinate, and chloramphenicol-1-monosuccinate, 909
—analysis, 4-demethylepipodophyllotoxin-9-(4,6-*O*-ethylidene-β-D-glucopyranoside), 1440
—analysis, ftorafur in biological materials, 1296
—analysis, lidocaine and active dealkylated metabolites, human plasma, 1341
—analysis, methyldopa, plasma, 897
—analysis, pramoxine hydrochloride, high lipoid aerosol foam dosage form, 475
—analysis, procainamide and *N*-acetylprocainamide in biological fluids, 982
—analysis, quinestrol tablets, 1461
—analysis, ranitidine, human plasma and urine, 1155
—analysis, salicylic acid in aspirin powder and dosage forms, 113
—analysis, salicylic acid, salicyluric acid, and gentisic acid, biological matrixes, 1224
—analysis, salicylsalicylic acid, aspirin, and salicylic acid in human plasma and urine, 1268
—analysis, sulfamethazine, beef tissues, 701
—analysis, triamcinolone acetonide, effects of various octadecylsilane columns on mobility, 481
—analysis, trinitroglycerin and metabolites in whole blood, 444
—determination of salicylic acid in aspirin, 548
—identification of glucocorticoids, nonsteroidal anti-inflammatory agents, and tranquilizers used in arthritis treatment, 590
—kinetic study of USP blue tetrazolium assay with methylprednisolone and hydrocortisone and their hemisuccinate esters, 960
—monitoring of degradation of hydrocortisone in attapulgite suspensions, 945
reversed phase—analysis, benzalkonium chloride, 1148
—simultaneous determination of acetaminophen, guaifenesin, and dextromethorphan hydrobromide, analysis of cough syrup active ingredients, 212
—simultaneous quantitation of acetaminophen, aspirin, caffeine, codeine phosphate, phenacetin, and salicylamide, 110
Hildebrand solubility equation, modified—caffeine in water–dioxane mixtures, solubility predictions, 659
Histamine—effect of human serum albumin concentration on binding, 885
Hydrastine—hydrastis alkaloid, spectrophotometric determination of alkaloid–dye complex, effect of pH on complex formation, 597
Hydrastis alkaloids—spectrophotometric and colorimetric determinations of alkaloid–dye complexes, effect of pH on complex formation, 597
Hydration—water-miscible organic liquids in aqueous solution, determination using three viscometric methods, 369
Hydrocodone—radioimmunoassay in human plasma, 1171
Hydrocortisone acetate—reduced dialysis from methylcellulose solutions, 1173
—and hemisuccinate ester, high-pressure liquid chromatographic and spectrophotometric monitoring of USP assay with blue tetrazolium, 960
—oxidative degradation in attapulgite suspensions, 945
—suppression of endogenous hydrocortisone with dexamethasone, 1409
Hydrogels, suspension—percutaneous absorption of benzocaine, influence of solvent power and microscopic viscosity of vehicle, *in vitro,* 387
Hydrogen-ion concentration—general calculation method for multicomponent acid–base mixtures, calculated results compared with experimental results, 891
Hydrolysis—base-catalyzed degradation of *p*-nitrophenyl acetate in liposomal suspensions, 745
—cefamandole nafate, effect of glucose, 1183
—chlorambucil, kinetics, 861
—chlorambucil, potential errors in kinetic studies based on chloride-ion determination, 859
kinetics—amoxicillin and ampicillin, simultaneous partitioning, 655
kinetics—*N*-Mannich base prodrugs of amides, ureides, amines, and imides, 44
kinetics—methenamine in citrate–phosphate buffers, 1261
—nimetazepam and nitrazepam, kinetics and mechanisms, reversible reaction, 1331
rates—aspirin and tetrakis-μ-acetylsalicylato-dicopper(II), pH dependency, 725
Hydromorphone—radioimmunoassay in human plasma, 1171
Hydrophobicity—clorobiocin analogs, correlation with protein binding, 799
***p*-Hydroxyphenobarbital**—simultaneous analysis with phenobarbital by GLC–chemical-ionization mass spectrometry in biological fluids, 1218
Hydroxyurea analogs—substituted aryl hydroxamic acids, inhibition of ribonucleotide reductase, structure–activity relationships, molecular connectivity indexes, 856
Hygroscopicity—poorly soluble and insoluble substances, correlation between pore structure and equilibrium moisture content, 742
Hyperthermia—elevation of serum prolactin, effect on epididymal cyclic AMP levels, rats, 350
Hypnotic agents—flurazepam, radioimmunoassay, human plasma, 601
—sodium γ-hydroxybutyrate and γ-butyrolactone, relationship between *in vitro* transport and *in vivo* absorption, 356
Hypocholesterolemic agents—inhibition of β-hydroxy-β-methylglutaryl-CoA reductase, monoesters of substituted glutaric acids, rat liver microsomes, 506
Hypolipidemic agents—clofibrate, simultaneous GLC assay with clofibric acid, human plasma, 92
—itanoxone synthesis, synthesis and detection of impurities, 49
Hypouricemic agents—itanoxone, synthesis, synthesis and detection of impurities, 49

I

Ibuproxam—decomposition, identification of thermal degradation products, 521
Imides—*N*-Mannich base derivatives as prodrugs, hydrolysis kinetics, 44
Iminodiacetic acid—^{99m}Tc-labeled, derivatives of 2-aminopyrroles, evaluation as hepatobiliary imaging agents, rats, 731
Indapamide—automated analysis in drug–rodent food mixtures, carbonic anhydrase inhibitor, 1158
Indicine-*N*-oxide—quantitation by differential pulse polarography, human plasma, 727
—stability-indicating colorimetric assay using TLC, 471
Indoles—charge transfer complex with catechol, 990
Indomethacin—GLC analysis, human plasma, 219
—impurities, detection by NMR, IR, and mass spectroscopy, 187
Inhibition, competitive—cocaine hydrochloride and norepinephrine, effect on fetal mice, 703
Instantaneous midpoint-input principle—drug absorption, linear pharmacokinetics, 57
Insulin diffusivity—permeability through hydrophilic polyacrylate membranes, 208
secretion—stimulation by sulfonylurea, inhibition by presence of second drug, 157
Interaction energies—alkylamides, alkylmonocarboxylic acids, and alkylketones with phospholipid

monolayers, 65
Interactions—adsorption of cimetidine onto various pharmaceutical adsorbents, 352
In vitro–in vivo correlation—prednisone tablets, prediction of relative *in vivo* performance in humans, peristaltic dissolution apparatus, 220
Iodine—semiautomated colorimetric analysis in individual thyroid tablets, 948
***o*-Iodobenzoic acid**—deiodination, metal-catalyzed S_N1 mechanism, 671
Ionization constants—various azulòic acids, 337
Ionophores, Ca^{2+}—surface properties of films on electrolyte solutions, effect of membrane lipids, 406
Iopamidol—radiopaque, deiodination mechanism, 671
Isatins—condensation products with acetone and related ketones, evaluation for anticonvulsant activity, 1235
Isoniazid—binding of toxic metabolites by aconiazide, 1284
—high-performance liquid chromatography, isoniazid tablet formulation analysis, simultaneous determination with 1-isonicotinyl-2-lactosylhydrazine, 222
1-Isonicotinyl -2- lactosylhydrazine—high-performance liquid chromatography, isoniazid tablet analysis, simultaneous determination with isoniazid, 222
Isophenindamine—analysis, high-performance liquid chromatography, argentated mobile phase, phenindamine tartrate bulk powder, 342
Itanoxone—synthesis, synthesis and detection of impurities, 49

J

JOURNALS
Asian Journal of Pharmaceutical Sciences, 1110
Biomaterials, 874
Journal of Ethnopharmacology, 132
Journal of Immunoassay, 1244
Journal of Immunopharmacology, 132
Medicinal and Aromatic Plants Abstracts, 1110

K

Kaolin—adsorption of *Pseudomonas aeruginosa* toxin, effect of pH and various agents, 1238
Ketones, pyridyl—ligand interaction with cytochrome P-450, effects of lipid solubility and pKa values on ligand activity, 850
Ketophosphonium salts—synthesis, relationship between neuromuscular blocking activity and interatomic distances, 888
Ketoprofen—high-performance liquid chromatographic analysis, human plasma and urine, 763
—urinary excretion of unchanged drug, 1254
Khellin—high-performance liquid chromatographic analysis in human serum and urine, 1434
Kinetics—amoxicillin and ampicillin, simultaneous partitioning and hydrolysis, 655
—analysis of carnitine analogs on carnitine acetyltransferase activity, spectrophotometric and radiometric measurements, 202
—aromatic S_N1 deiodination of radiopaques, 671
degradation—nonisothermal method, programmed temperature steps, comparison with isothermal kinetic method, 287
drug release—effects of particle size, drug loading, and matrix coating on polymer–drug mixtures, 265
—heterogeneous model of drug release from polymeric matrix, 1311
—hydrolysis of methenamine in citrate–phosphate buffers, 1261
—solid-state activation energy, decarboxylation, decomposition, 5-(tetradecyloxy)-2-furoic acid, 123

L

Lactic acid cyclic analogs—topical mosquito repellents, *in vivo* testing, humans, 196
Lactones, sesquiterpene—antihyperlipidemic activity, structure–activity relationships, serum levels of cholesterol and triglycerides, mice, 694
LD_{50} testing—gravid and nongravid mice, morphine sulfate, cobalt chloride, phenytoin sodium, teratological study, 214
Lecithin—adsorption by cholesterol, effect of total bile acid concentration, lecithin concentration and type of bile acid, 413
egg—dispersions in distilled water and physiological electrolyte fluids, oxygen solubilization, 62
Levodopa—bioavailability, dosage form design, dogs and humans, 261
—decarboxylation, effect of pyridoxal 5-phosphate, 1145
—pharmacokinetics, effect of dose, dogs and parkinsonian patients, 1374
Levomethorphan—NMR determination with dextromethorphan, 459
Lidocaine, 2-aminopyrrole analogs—^{99m}Tc-labeled iminodiacetic acid derivatives, evaluation as hepatobiliary imaging agents, rats, 731
—determination of transfer and clearance rates of parent drug and analogs across everted rat intestinal mucosa, mucosal concentrations and pH, *in vitro* absorption, 643
—effect of smoking on binding to human serum proteins, 749
—enhancement of rectal absorption by salicylate, 744
—high-pressure liquid chromatographic analysis, human plasma, 1341
—pharmacokinetics following rectal, oral, and intraarterial administration, rats, 804
—pharmacokinetics, pregnant and nonpregnant sheep, 32
—simultaneous GLC analysis with mepivacaine, bupivacaine, etidocaine, and tetracaine in biological fluids, 603
Ligands—interaction of substituted pyridines and pyridyl ketones with cytochrome P-450, effects of lipid solubility and pKa values on ligand activity, 850
Liposomes—base-catalyzed hydrolysis of *p*-nitrophenyl acetate in liposomal suspensions, 745
Liriodenine—antibacterial and antifungal activity, 1180
Lomustine, ^{14}C-labeled—biodistribution, rat tumor model, 87
Lysine—simultaneous high-performance liquid chromatographic determination with cephalexin in their salt using derivatization, 1378
Lysosomal membrane—effect of sesquiterpene lactones on membrane stability, hydrolytic enzyme release, mode of action in inflammation process, 537

M

Magnesium salicylate—plasma salicylate levels following administration of solid dosage form, comparison with aspirin and choline magnesium trisalicylate, 1355
***cis*-Malonato-diammino platinum (II)**—synthesis and evaluation for antineoplastic activity *in vivo* and *in vitro*, mice, 1160
***N*-Mannich bases**—derivatives of amides, amines, imides, and ureides, potential as prodrugs, hydrolysis kinetics, 44
—synthesized from conjugated styryl ketones and acetophenones, evaluation for antineoplastic activity, 575
Maprotiline—GLC–mass spectrometric analysis, human and animal plasma, 684
Marine algae—antineoplastic evaluation against P-388 lymphocytic leukemia and Ehrlich ascites tumor, 735
Mass fragmentography—application to pharmacokinetic study of single oral phenytoin dose using stable isotope labeling, humans, 1300
Mass spectrometry—analysis, deuterated analogs of apomorphine, 1040
—comparison of spectra of betamethasone and dexamethasone, 991
selected-ion monitoring—chlorambucil, degradation products and metabolite, human plasma and urine, 80
Mass transfer—phenol self-association, effect on membrane transport, 133
Mediator release—antigen dependency, calcium dependency, antiallergic drugs, 243
Medicinal plants—*Curatella americana*, chemical constituents, isolation and identification, 360
—isolation of flavonoids from *Enicostemma hyssopifolium*, identification, 53
Mefenamic acid—analysis, high-performance liquid chromatography, plasma, rats, humans, 95
Membrane permeability—hydrophilic polyacrylate membranes, effect on insulin diffusivity, extent of cross-linkage, hydration effect, 208
systems—surface properties, interaction of electrolytes and lipids with Ca^{2+} ionophores, 406
Mepivacaine—brain-to-blood and saliva-to-blood ratios, rats, 217
—simultaneous GLC analysis with bupivacaine, etidocaine, lidocaine, and tetracaine in biological fluids, 603
Meprobamate—GLC determination in serum, wall-coated tubular column coupled with nitrogen-selective detector, 835
—identification of impurities in tablets, 1444
Mercaptans—evaluation of efficacy and toxicity as mercurial scavengers using rat liver mitochondrial assay, 964
Mercurial scavengers—thiol-containing compounds, evaluation of efficacy and toxicity using rat liver mitochondrial assay, 964
Mescaline—GLC–mass spectral determination, rabbit plasma, intravenous injection, 118
Metabolism—carprofen in rats, dogs, and humans, 1245
—prediction of steady-state metabolite concentration, cinromide and carbamazepine, monkeys, 610
renal—sulfisoxazole, acetylation by the isolated perfused rat kidney, 1359
—streptozocin distribution and transport, mice, mathematical model, 691
—tocainide in humans, conjugation, 47
Metabolites—of heroin, pharmacokinetics, dogs, 1116
—of 3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5-nitro -1*H*- imidazol-2-yl)-1,2-benzisoxazole, identification, dog urine, 1288
potential—1-aryl -3- formyl -3- methyltriazenes, synthesis as oxidation products of 1-aryl-3,3-dimethyltriazenes, 1098
—suxibuzone, simultaneous high-performance liquid chromatographic determination with parent drug in plasma and urine, 1258
Metal catalysis—neighboring carboxylate deiodination, 671
Metaraminol bitartrate—high-performance liquid chromatographic analysis in the presence of methylparaben and propylparaben, 1459
Metered-dose aerosols—bronchodilators, solution and powder preparations, effect of low and high humidity, 334
Methadone—binding to human serum albumin, varying albumin concentration, 71
Methenamine—hydrolysis kinetics in citrate–phosphate buffers, 1261
3-Methoxymorphinan—synthesis by *N*-demethylation of dextromethorphan, 1447
***O*-(4-Methoxylphenylcarbamoyl)-3-diethylaminopropiophenone oxime hydrochloride**—analgesic, behavioral, and dependence properties, compared to morphine sulfate, 225
Methyldopa—high-pressure liquid chromatographic analysis using electrochemical detection, separation from plasma by alumina adsorption, 897
3,4 - Methylenedioxyphenylisopropylamine—synthesis of centrally active *N*-substituted analogs, 192
Methylmercuric chloride toxicity—protection by mercapto steroids, 556
Methylparaben—high-performance liquid chromatographic analysis with metaraminol bitartrate and propylparaben, 1459
Methylprednisolone—and hemisuccinate ester, high-pressure liquid chromatographic and spectrophotometric monitoring of USP assay with blue tetrazolium, 960
Microcapsules—preparation of enteric-coated microcapsules for tableting by a spray-drying technique, drug release from tableted microcapsules,

1388
Microencapsulation—sulfamethoxazole, gelatin–acacia coacervation, 513
Microhelenins—isolation from *Helenium microcephalum*, determination of structure and stereochemistry, 1044
Microsomes, rat liver—inhibition of cholesterol biosynthesis, monoesters of substituted glutaric acids, 506
Microspheres—biodegradable polyacryldextran particles, immobilization of proteins, 838
—cerium 141 labeled, clearance from blood and distribution in specific organs following intravenous and intraarterial administration, dogs, 755
Minerals—size distribution characteristics in renal stones, 829
Mitodepressive activity—evaluation of aminoalkanesulfonic acids and *N*-nitroso derivatives, 930
Model-independent analysis—linear pharmacokinetic systems, polyexponential impulse response, analysis of input, 305
Models, animal—mepivacaine, brain-to-blood and saliva-to-blood ratios, rats, 217
—bioavailability estimation, equations, 77
—evaluation of neuroleptic potency, prolactin response in rats, 74
hydrodynamic—mass transport models of intestinal wall permeability, 1369
—intestinal absorption of water-insoluble drugs, improved membrane permeability through synthesis of soluble derivative as prodrug, 1363
mathematical—calculation of hydrogen-ion concentration in multicomponent acid–base mixtures, comparison with experimental results, 891
pharmacokinetic—derivation of equations for linear compartmental systems, model-independent method of input analysis, 298
pharmacokinetic—of doxycycline reabsorption, 204
pharmacokinetic—steady-state plasma drug concentration, queueing theory, 558
physical—based on simultaneous transport and bioconversion, effect of homogeneous distribution on prodrug evaluation, 770
physical—based on simultaneous transport and metabolism, effect of nonhomogeneous distribution on prodrug evaluation, 772
physical—homogeneous and nonhomogeneous enzyme distributions, various mouse skin strata, vidarabine valerate prodrug, topical dosage forms, mathematical analysis, 775
simulation—cost evaluation of tableting processes, 621
Model systems, pulmonary surfactant—egg lecithin dispersions in distilled water and physiological electrolyte fluids, oxygen solubilization, 62
Molecular connectivity—description of molecules containing substituted benzene rings by $^4\chi_{PC}$ index, 1034
—hydrazide monoamine oxidase inhibitors, structure–activity relationships, 124
indexes—aldoximes, influences of molecular structure on sweet or bitter taste, 416
indexes—substituted aryl hydroxamic acids, inhibition of ribonucleotide reductase, structure–activity relationships, 856
Molecular weight—effect on drug diffusion and activity, parabolic model, 648
Molephantin—isolation from *Elephantopus mollis* and structural determination, 1050
Molephantinin—isolation from *Elephantopus mollis* and structural determination, 1050
Monoamine oxidase inhibitors—hydrazides, structure–activity relationships, molecular connectivity analysis, 124
Montmorillonite—mechanism of interaction with chlorpheniramine maleate, 1142
—saturation with organic cations for potential treatment of poisoning by weak bases, 1393
Morphine—analysis, high-performance liquid chromatography, ion-pair formation, effect of carbon chain length of pairing ions, 152
—binding to human serum albumin, varying albumin concentration, 71
congeners—ferro-ferricyanide oxidation, fluorescence characteristics, 253
sulfate—comparative effects with *O*-(4-methoxylphenylcarbamoyl)-3-diethylaminopropiophenone oxime hydrochloride in rodents, pain threshold, physical dependency, tolerance, analgesic, withdrawal syndrome, 225
sulfate—LD_{50} testing, gravid and nongravid mice, 214
—sustained release from polydimethylsiloxane pellets, mice, 980
Morphine–tristearin—solid dispersion, reduced presystemic inactivation, rats, 466
Mosquitoes—topical repellents, lactic acid cyclic analogs, *in vivo* testing, humans, 196
Mucins—isolation from rabbit conjunctiva, fractionation by gel filtration and anion-exchange chromatography, determination of molecular weight, role in tear film stability, 430
Mucolytic agents—bromhexine, electron-capture GLC analysis, human plasma, 99
Multiple regression analysis—correlation of bioavailability of erythromycin stearate tablets with *in vitro* tests, 1307
Myocardial depressants—propranolol, effects of hypertonic mannitol, β-adrenergic blocking activity, dogs, 447

N

Nafcillin sodium—high-pressure liquid chromatographic analysis, 1264
Naproxen—urinary excretion of unchanged drug, 1254
Narcotic agonist–antagonist—serum butorphanol pharmacokinetics by radioimmunoassay, 160
Negentropy—mathematical analysis of correlation between biological activity and molecular structure, molecular information content available to receptor molecule, 807
Neomycin—microbiological determination with spiramycin, 458
Neuroleptic agents—model for evaluation of potency, prolactin response in rats, 74
potential—*p*-bromospiperone, synthesis and biological evaluation, 984
Neuromuscular blocking activity—ketophosphonium salts, relationship between activity and interatomic distances, 888
Neuromuscular blocking agents, potential—*E,E*- and *Z,Z*-isomeric *O*-ethers of 4-androstene-3,17-dione dioximes, synthesis, stereochemical analysis, and pharmacological testing, 995
Niacinamide—complexation with drug molecules, aqueous solution, frontier molecular orbital calculations, 104
Nicotine—comparison of pharmacokinetic parameters following single-cigarette smoke inhalation and intravenous administration, cotinine as major nicotine metabolite, rats, 1087
Nimetazepam—kinetics and mechanisms of reversible hydrolysis, pKa determination, 1331
Ninhydrin—condensation products with indoles and thiourea, structural elucidation by NMR spectroscopy, 1431
Nitrazepam—kinetics and mechanisms of reversible hydrolysis, pKa determination, 1331
Nitrofurantoin—fluorescence assay, plasma and urine, 106
—reduced dialysis from methylcellulose solutions, 1173
—suspensions, effect of viscosity on absorption, 403
Nitrogen mustards—chlorambucil, hydrolysis kinetics, 861
—chlorambucil, hydrolysis, potential errors in kinetic studies based on chloride-ion determination, 859
Nitroglycerin—ointment, reversed-phase high-performance liquid chromatographic analysis, 1084
—percutaneous absorption, rhesus monkeys, 365
***p*-Nitrophenyl acetate**—base-catalyzed hydrolysis in liposomal suspensions, 745
***N*-Nitrosoaminoalkanesulfonic acids**—synthesis, evaluation for mitodepressive activity, 930
NMR spectroscopy—analysis, deuterated analogs of apomorphine, 1040
—analysis, synthesized bis(methylthio)vinyl derivatives, 477
—determination of dextro- and levomethorphan mixtures, chiral lanthanide shift reagents, 459
—proton transfer in amitriptyline hydrochloride–chlordiazepoxide hydrochloride mixtures, dipolar aprotic solvent, 180
—structural elucidation of condensation products of ninhydrin with indoles and thiourea, 1431
^{13}C-NMR spectroscopy—ajmaline, chemical shifts assigned, 824
—brucine and strychnine, chemical shifts assigned, 865
—tetracyclines, chemical shifts assigned, 229
Nofedone—analysis, electron-capture GLC, human serum, 273
Nonelectrolytes—estimation of solubility in water, 912
Noraporphines—trifluoroacetyl derivatives, GLC and mass spectrometry, 936
Norethindrone—coupling to poly(α-aminoacids), controlled release from coupled compounds, 871
Nortropanyl benzoate—*para*-substituted derivatives, synthesis, NMR, IR, and mass spectral characterization, 1357
Nystatin—thermal degradation, colorimetry, relationship between loss of microbiological potency and color change, 697

O

Ocular agents—pilocarpine, high-performance liquid chromatographic determination in aqueous humor, 257
Ocular mucins—isolation from rabbit conjunctiva, fractionation by gel filtration and anion-exchange chromatography, determination of molecular weight, role in tear film stability, 430
Odoratin—recommended assignment of name only to isolate from *Cedrela odorata*, 1107
Ointments—nitroglycerin, reversed-phase high-performance liquid chromatographic analysis, 1084
Ophthalmic drugs—pilocarpine, high-performance liquid chromatographic analysis, 1096
drugs—pilocarpine, ocular volume of distribution, 615
preparations—*N*-demethylated carbachol, effect on iris and ciliary muscles, treatment of open-angle glaucoma, 332
preparations—dexamethasone suspensions, bioavailability, effect of particle size, rabbits, 391
preparations—polarographic determination of edetate disodium in eyewash and ophthalmic decongestant solutions, 826
Organic solvents—extent of hydration in aqueous solution, viscosity data, 369
Organotin compounds—*N*-substituted *N*-(triphenylstannyl)cyanamides and triethylammonium (organocyanoamino)triphenylstannates evaluated for antibacterial activity, triethylammonium (acetylcyanoamino)triphenylstannate and triethylammonium dichlorostannate evaluated for antibacterial activity, 340
Ornithine carboxylase activity—inhibition of polyamine synthesis, effects of inhibitors on tumor cell growth, *in vitro* testing, 733
decarboxylase—inhibition by anticancer agents, chemotherapy of neuroblastoma, 592
Oxaprozin—high-performance liquid chromatographic analysis with macro- and microextraction methods, comparison with GLC, human and rat plasma, 794
Oxidation—cytochrome P-450, inhibition of *in vitro* metabolism of aniline and aminopyrine, effect of substituted pyridines on inhibition, 465
Oxidative phosphorylation—effect of marine natural products on mitochondrial respiration, 462
—uncoupling effect of sesquiterpene lactones, mode of action determined in inflammation process, 537
Oxoaporphine alkaloids—preparation and evaluation for antimicrobial activity, 1180
Oxygen—solubilization in egg lecithin dispersions in distilled water and physiological electrolyte fluids, 62

P

Pancreas—distribution of sulfonylureas, displacement of sulfonylurea by second drug, 157
—drug transport, various drugs, effect of secretin, pancreozymin, pancreatic juice flow, 27
Pancreatic juice—effect of flow rate on pancreatic drug transport, various drugs, 27
Parabens—interaction with polysorbate 80, effect of propylene glycol and glycerol, 169
Parenteral solutions, commercial—barium sulfate crystal formation, identification by polarizing microscopy, scanning electron microscopy, micro X-ray powder diffraction, and micro Raman spectroscopy, 608
Particle size, distribution—milled and micronized pharmaceutical powders, geometric volume mean diameter, electrolytic sensing zone method with and without a pulse-width discriminator, 651
—proquazone, effect on *in vitro* dissolution rate, 605
Partition coefficients—acidic, basic, and neutral drugs, effects of various octanol–buffer systems, 662
—*n*-alkanols in intact hairless mouse skin and human skin, effect of temperature and carbon chain length, biphasic partitioning, 781
—unstable compounds, cyclohept-2-enone, calculation by kinetic methods, 527
Partition constants—various azulenes, 337
Partitioning kinetics—amoxicillin and ampicillin, simultaneous hydrolysis, 655
Pathophysiology—asthma, immunologically induced release of primary and secondary mediators, membrane permeability changes, calcium-ion dependency, antiallergic drugs, 236
Pattern recognition methods—classification of steroids in therapeutic categories using fragment molecular connectivity, 1030
Penicillin—TLC–bioautographic analysis as contaminant in erythromycin, 616
Penicillins—interactions with a nonpolar octadecylsilyl stationary phase, 501
Pentobarbital—effect of short-term dietary exposure to polychlorinated biphenyls on pharmacokinetics following intravenous administration, rats, 1274
—effect of short-term exposure of polychlorinated biphenyls on first-pass metabolism, rats, 1279
Percutaneous absorption—benzocaine, release from suspension hydrogels, influence of solvent power and microscopic viscosity of vehicle, *in vitro*, 387
Permeability—effect of edetate disodium on goldfish membrane, 972
—intestinal absorption of water-insoluble drugs, improved membrane permeability through synthesis of soluble derivative as prodrug, 1363
—lidocaine and derivatives across everted rat intestinal mucosa, *in vitro* absorption, 643
—mass transport models of intestinal wall permeability, 1369
Permeation—*n*-alkanols through intact hairless mouse skin and human skin, effect of temperature and carbon chain length, biphasic partitioning, 781
—*p*-aminobenzoates, membrane transport, fluid flow in aqueous diffusion region, 210
—reduced dialysis of nitrofurantoin and hydrocortisone acetate from methylcellulose solutions, 1173
Phantomolin—isolation from *Elephantopus mollis* and structural determination, 1050
Pharmaceutical preparations—simultaneous determination of cough syrup active ingredients by high-pressure liquid chromatography, 212
Pharmacokinetic models, linear—model-independent method of input analysis, derivation of equations for linear compartmental systems, blood drug levels, polyexponential impulse response, 298
—streptozocin metabolism, bioassay and chemical assay, mice, membrane-limited transport, 691
Pharmacokinetics—aspirin administered alone and with acetaminophen or caffeine, absorption, distribution in gastric tissue, blood plasma levels, rats, 900
—atenolol, effect of exercise on renal clearance, 344
—barbital, plasma concentrations of unlabeled and labeled drug following simultaneous oral and intravenous administration, GLC–mass spectrometric analysis, 640
—butorphanol in human serum, 160
—butorphanol, subcutaneous and intramuscular administration, dogs, 801
—butylated hydroxyanisole and butylated hydroxytoluene, rabbits, 1455
—chlorpheniramine, GLC–mass spectrometric analysis, human serum, 707
—cimetidine, humans, 394
—clinical testing in mildly asthmatic human volunteers, dose–response curve of antiallergic drugs, 251
—comparison of nicotine pharmacokinetic parameters following single-cigarette smoke inhalation and intravenous administration, cotinine as major metabolite of nicotine, rats, 1087
—comparison of quinidine and its *O*-desmethyl metabolite, rabbits, 1400
—deconvolution method, linear pharmacokinetics, polyexponential impulse response, drug input into blood, 312
—doxycycline reabsorption, two cyclic linear compartment models proposed, 204
—effect of blood sampling time on calculated parameters after intravenous administration, 867
—effect of changes in plasma protein binding on biological half-life of drugs, 751
—effect of heparin on plasma concentrations of bilirubin, rats, 1228
—estimation of infinity values of intact drug and metabolites in urine using Prony's method, effect of time errors, 1231
—estimation of volume of distribution at steady state, 1222
—fluorouracil levels in human plasma following intravenous and oral doses, 1428
—furosemide with and without probenecid pretreatment, humans, 571
—heroin and metabolites, dogs, 1116
humans—ceforanide, 398
—levodopa, effect of dose, dogs and parkinsonian patients, 1374
—lidocaine following rectal, oral, and intraarterial administration, rats, 804
—lidocaine, pregnant and nonpregnant sheep, 32
linear—compartment- and model-independent drug absorption calculation, 57
—linear systems, polyexponential impulse response, analysis of input, model-independent method, 305
—mean total body clearance, calculation, harmonic mean method, 90
—pentobarbital, effect of short-term dietary exposure to polychlorinated biphenyls following intravenous administration, rats, 1274
—phenylbutazone, single and multiple oral doses, 1413
—phenytoin, application of mass fragmentography after single oral dose using stable isotope labeling, humans, 1300
—plasma protein binding, hepatic extraction of endogenous inhibitors, 480
—potassium chloride in slow-release capsule, 1416
—propoxyphene, effect of portacaval shunt on systemic availability, dogs, 786
—propoxyphene, effect of renal failure on systemic clearance, rats, 363
—sodium dichloroacetate, plasma concentration level–time curve, rats, dogs, humans, 419
—steady-state plasma drug concentration, queueing theory, 558
—*N*-substituted amphetamines, quantitative structure–activity relationships, humans, 497
—theophylline, trough serum concentrations at steady state, temporal variations, 358
—warfarin biotransformation, inductive enzyme effect of phenobarbital, rats, 634
—warfarin, dose dependence, rats, 9
Phenacetin—simultaneous quantitation with acetaminophen, aspirin, caffeine, codeine phosphate, and salicylamide, high-pressure liquid chromatography, 110
Phenindamine tartrate—analysis of isophenindamine in bulk powder, high-performance liquid chromatography, argentated mobile phase, 342
Phenobarbital—effect on enzyme induction, effect on warfarin biotransformation, pharmacokinetics, intersubject variability determination, rats, 634
—simultaneous analysis with *p*-hydroxyphenobarbital by GLC–chemical-ionization mass spectrometry in biological fluids, 1218
Phenol—effect of association on transport across polyethylene film, 133
Phenothiazines—chlorpromazine hydrochloride and two oxidation products, rapid determination by high-performance liquid chromatography and fluorescence detection, dosage forms, 184
—comparison of differential UV and differential fluorescence methods with official assays, 1069
—derivatives, spectra in solution and solid state, effect of R_2 and R_{10} substituents, 378
—model for evaluation of potency, prolactin response in rats, 74
—promethazine, high-performance liquid chromatographic analysis in whole blood and parotid saliva following oral and intramuscular administration, 1457
—2-substituted, dipole moments and conformational structures as solutes, 116
Phenoxybenzamine—effect on catecholamine-induced arrhythmias, steroid-pretreated rats, 441
Phenylbutazone—GLC determination in serum, wall-coated open tubular column coupled with nitrogen-selective detector, 835
—interaction with warfarin, pharmacokinetics, *in vitro* and *in vivo*, rats, prothrombin complex activity, 14
—pharmacokinetics after single and multiple oral doses, 1413
—tablets, identification of degradation products, 469
Phenylephrine hydrochloride—GLC analysis, capsule preparations, 854
Phenylfurans—3-diethylamino -2,2- (dimethyl)propyl esters of 5-substituted phenyl-2-furancarboxylic acids, synthesis, potential use as spasmolytic agents, 107
Phenylpropanolamine hydrochloride—GLC analysis, capsule preparations, 854
Phenylurethans—synthesized from 1,2-dialkyl-4-pyrazolidinols, evaluation as anticonvulsant agents, 729
Phenytoin—pharmacokinetics, application of mass fragmentography after single oral dose using stable isotope labeling, humans, 1300
sodium—LD_{50} testing, gravid and nongravid mice, 214
pH measurements—complexation of *trans*-cinnamic acid–α-cyclodextrin, 173
Phospholipid monolayers—adsorption free energy, barbital, phenobarbital, pentobarbital, 102
monolayers—interaction energies with alkylamides, alkylmonocarboxylic acids, and alkylketones, 65
vesicles, negatively charged—tissue distribution in rats, 1338
Photodecomposition—of sulfonamides and tetracyclines at oil–water interface, 5
Phthalazines—synthesis of 3-azapapaverine from veratric acid *via* Reissert compound derivative of 6,7-dimethoxyphthalazine, 120
Physical stability—semisynthetic suppository bases, 955
Pilocarpine—complexation with cobalt(II), nickel(II), copper(II), and zinc(II) halides, 1220
—high-performance liquid chromatographic determination in aqueous humor, quaternization of the methylimidazole tertiary amine group, 257
—mechanisms of distribution to cornea, tear, aqueous humor, and blood following subconjunctival injection, rabbits, 875
—ocular volume of distribution, 615
—reversed-phase high-performance liquid chromatographic analysis, 1096
Pindolol—electron-capture GLC analysis in biological

fluids, 1191
Plasma protein binding—effect on renal clearance of drugs, 482
—hepatic extraction of endogenous inhibitors, 480
Platelet aggregation—effect of antibiotics, 1282
—evaluation of inhibition and stimulation by prostaglandin endoperoxide analogs, 1007
***cis*-Platinum**—reaction with sodium bisulfite, 364
—synthesis of *cis*-malonato-diammino platinum(II) and evaluation for antineoplastic activity *in vivo* and *in vitro*, mice, 1160
Poisoning—weak bases, potential treatment with organic cation-saturated montmorillonite, 1393
Poison ivy—urushiol components in vegetable oil preparations, GLC analysis, 587
Polarography, differential pulse—analysis, colchicine, 1436
differential pulse—analysis, edetate disodium in eyewash and ophthalmic decongestant solutions, 826
differential pulse—indicine-*N*-oxide, quantitation in human plasma, 727
Poloxamer 188—use as vehicle for reduction of thrombosis and inflammation induced by injectable diazepam, rabbits, 970
Polyacrylate membrane—effect on insulin diffusivity, extent of cross-linkage, hydration effect, 208
Polyacryldextran—microspheres, immobilization of proteins, 838
Polyamines—inhibition of synthesis, effects of inhibitors on tumor cell growth, *in vitro* testing, 733
Polyarthritis, adjuvant induced—assay, asymmetric triazines, 282
Polybasic acids—oxalic acid, citric acid, and their sodium salts, effect on aluminum hydroxycarbonate gel structure, complexation of polybasic acids with aluminum, adsorption of polybasic anion, acid neutralization, 668
Polychlorinated biphenyls—effect of short-term dietary exposure on pharmacokinetics of intravenous pentobarbital, rats, 1274
—effect of short-term exposure on first-pass metabolism of pentobarbital, rats, 1279
Polyethylcyanoacrylate nanoparticles—with adsorbed dactinomycin and vinblastine, distribution patterns in rats, compared to polymethylcyanoacrylate nanoparticles, 199
Polyethylene glycol—carrier matrix in aqueous prostaglandin analog solutions, GLC analysis, pre-GLC sample cleanup procedure, 718
—comparison with polyoxyethylene stearate as excipient for solid dispersion systems of griseofulvin and tolbutamide, dissolution and solubility studies, 1321
—comparison with polyoxyethylene stearate as excipient for solid dispersion systems of griseofulvin and tolbutamide, phase equilibria, 1317
—use as solvents in implantable osmotic pumps, 747
Polymers, biodegradable—poly(α-amino acids), coupling to norethindrone, controlled release of norethindrone from coupled compounds, 871
—use in sustained-release film formation, preparation methods of polymer–drug matrix, low temperature effects on polymeric matrix, 265
Polymethylcyanoacrylate nanoparticles—with adsorbed dactinomycin and vinblastine, distribution patterns in rats, compared to polyethylcyanoacrylate nanoparticles, 199
Polyols—effect of propylene glycol and glycerol on interaction of parabens with polysorbate 80, 169
Polyoxyethylene stearate—comparison with polyethylene glycol as excipient for solid dispersion systems of griseofulvin and tolbutamide, dissolution and solubility studies, 1321
—comparison with polyethylene glycol as excipient for solid dispersion systems of griseofulvin and tolbutamide, phase equilibria, 1317
Polysorbate 80—interaction with paraben preservatives, effect of propylene glycol and glycerol, 169
Polyvinylpyrrolidone—model of interaction with ajmaline, 824
Pore-size distribution—overall porosity of poorly soluble substances, effect on hygroscopicity, equilibrium moisture content, 742
Potassium chloride—bioavailability and pharmacokinetics of slow-release capsule, 1416
Povidone—coacervation with sulfathiazole, dissolution of coacervated system, 492
—complex formation with salicylic acid and benzoic acid, effects of temperature, buffer composition, and ionic strength, 1403
Powders—milled and micronized, particle-size distribution, geometric volume mean diameter, electrolytic sensing zone method with and without a pulse-width discriminator, 651
Pralidoxime chloride—influence of various anions on intestinal disappearance in rats, 923
Pramoxine hydrochloride—analysis, high-pressure liquid chromatography, high lipoid aerosol foam dosage form, 475
Prednisolone—serum protein binding in humans, rabbits, dogs, and rats, 977
Prednisone—commercial tablets, time and temperature dependence of disintegration, correlation between dissolution and disintegration rate constants, 290
—tablets, prediction of relative *in vivo* performance in humans, peristaltic dissolution apparatus, 220
Preservatives—benzalkonium chloride, reversed-phase high-pressure liquid chromatographic analysis, 1148
—parabens, interaction with polysorbate 80, effect of propylene glycol and glycerol, 169
Primaquine analogs—synthesis and evaluation for antiprotozoan activity, 933
Probenecid—pharmacokinetics and pharmacodynamics of furosemide with and without probenecid pretreatment, humans, 571
—urinary excretion of unchanged drug, 1254
Procainamide hydrochloride—GLC analysis in rat feed, 1439
—metabolism to *N*-acetylprocainamide, half-life of *N*-acetylprocainamide in rats, 864
—radioimmunoassay in human serum, 721
—simultaneous high-pressure liquid chromatographic determination with *N*-acetylprocainamide in biological fluids, 982
Procaine hydrochloride—colorimetric assay using 1,2-naphthoquinone-4-sulfonic acid sodium salt, 346
Processing formulations—tableting procedures, cost evaluation, simulation model, 621
Prodine analogs—synthesis, testing for analgesic activity, correlation between activity and energy level of highest occupied molecular orbital of aryl moiety, 796
Prodrugs—aspirin, synthesis of 1-*O*-(2′-acetoxy)-benzoyl-α-D-2-deoxyglucopyranose, 231
—chloramphenicol-3-monosuccinate, identification of 1-succinate ester as alternate form in equilibrium mixture with 3-succinate ester, 906
—etilefrine, synthesis and evaluation of 3′-(*O*-acyl) derivatives as prodrugs, 1423
—*N*-Mannich bases of amides, ureides, amines, and imides, hydrolysis kinetics, 44
—prostaglandins, structure–thermodynamic activity and structure–aqueous solubility relationships, 424
topical—based on simultaneous transport and bioconversion of vidarabine, permeability differences in various components of mouse skin, 770
topical—simultaneous transport and bioconversion of vidarabine, distribution of adenosine deaminase and esterase enzymes in mouse skin, pharmacokinetics, 772
topical—simultaneous transport and bioconversion of vidarabine valerate, effect of enzyme distribution and diffusivities on bioavailability, various mouse skin strata, mathematical analysis, 775
Prolactin response—model for evaluation of neuroleptic potency, rats, 74
secretion—stimulation by *p*-bromospiperone, 984
serum—hyperthermic elevation, effect on epididymal cyclic AMP levels, rats, 350
Promethazine—whole blood and parotid saliva concentrations following oral and intramuscular administration, 1457
Prony's method—estimation of amounts of intact drug and metabolites in urine, effect of time errors on infinity values, 1231
Propoxyphene—identification of thermal decomposition products formed during GLC analysis, 1177
—influence of type of controlled-release formulation on drug release, pH dependency, 1327
—pharmacokinetics, effect of portacaval shunt on systemic availability, dogs, 786
—pharmacokinetics, effect of renal failure on systemic clearance, rats, 363
Propranolol—β-adrenergic blocking activity, effect on myocardiai contractility, oxygen requirement, and heart rate, combined action of propranolol and hypertonic mannitol, hemodynamic changes in dogs, 447
—fluorometric measurement of human plasma levels, 1463
—iodinated and radioiodinated analogs, synthesis and testing for β-adrenergic blocking and antiarrhythmic activity, tissue distribution of radioiodinated analogs, potential as myocardial imaging agents, 1010
—nasal absorption from different dosage forms, rats and dogs, 1411
—nasal absorption in humans, 1240
—nitrogen mustard analog, synthesis, potential lung-specific antitumor activity, 190
—ocular absorption in rabbits, 738
Propylene glycol—effect on interaction of parabens with polysorbate 80, 169
Propylparaben—high-performance liquid chromatographic analysis with metaraminol bitartrate and propylparaben, 1459
Proquazone—effect of particle size on area under the curve, 605
Prostaglandin analogs—GLC analysis, pre-GLC sample cleanup procedure, polyethylene glycol carrier matrix, 718
—carboprost, high-pressure liquid chromatographic analysis, comparison of procedures with and without derivatization, 1396
endoperoxide analogs—synthesis and evaluation for inhibition and stimulation of platelet aggregation, 1007
E_2—preparation, characterization, and stability of gel delivery system, 1271
—prodrugs, structure–thermodynamic activity and structure–aqueous solubility relationships, 424
Protein binding—cephalosporin antibiotics, alteration by fatty acids and their derivatives, serum, 354
—clorobiocin analogs, correlation with hydrophobicity, 799
—effect of changes in plasma protein binding on biological half-life of drugs, 751
—effect of sodium oleate on binding of salicylic acid to human serum albumin, 1345
—gold to bovine serum albumin, effect of plasma protein and gold concentration on gold binding, effect of salicylic acid on gold bound to albumin, flameless atomic absorption determination, 585
—lidocaine, effect of smoking, human serum, 749
serum—effect on drug metabolism, 746
—spironolactone, 7α-carboxymethyl analog, *in vitro* human serum, 30
Proteins—adsorption onto glass surfaces, activity decrease, 279
—immobilization in polyacryldextran microspheres, 838
Protoberberines, quaternary—thalifaurine and dehydrodiscretine, isolation from *Thalictrum fauriei*, structural determination, 1061
Pseudoephedrine—bioavailability in sustained-release dosage form with chlorpheniramine, 1077
Pseudomorphine—structural variations, fluorescence, 253
Psychotomimetic agents—*N*-substituted analogs of known centrally active agents, 192
Psychotropic drugs—phenothiazine derivatives, spectra in solution and solid state, effect of R_2 and R_{10} substituents, 378
Pulmonary surfactant model systems—egg lecithin dispersions in distilled water and physiological

electrolyte fluids, oxygen solubilization, 62
Pyridines, substituted—ligand interaction with cytochrome P-450, effects of lipid solubility and pKa values on ligand activity, 850
Pyridones—4-pyridones and bioisosteres of 3-acetoxy-2-pyridone, synthesis and evaluation for antitumor activity, 1074
Pyridoxal 5-phosphate—interaction with carbidopa and effect on decarboxylation of levodopa, 1145
Pyrilamine maleate—GLC analysis, capsule preparations, 854
Pyrimido[4,5-*d*]pyrimidines—synthesis and evaluation for antidepressant activity, binding at presynaptic α-receptor sites, structure–activity relationships, 1343
Pyrrolo[2,3-*d*]pyrimidine-2,4-diones and intermediates—anticonvulsant activity, structure–activity relationships, 473

Q

Quantitative structure–activity relationships—*N*-substituted amphetamines, pharmacokinetics, humans, 497
Quaternary ammonium drugs—hexamethonium chloride and pralidoxime chloride, influence of various anions on intestinal disappearance in rats, 923
Queueing theory—application to pharmacokinetics, steady-state plasma drug concentration, 558
Quinazolones—substituted derivatives, synthesis and evaluation for antibacterial, antifungal, and anti-acetylcholinesterase activities, 1313
Quinestrol—high-pressure liquid chromatographic analysis, tablets, 1461
Quinidine—and its *O*-desmethyl metabolite, comparison of pharmacokinetics in rabbits, 1400

R

Radiochemistry—analysis of bretylium in biological fluids, compared to GLC determination, humans, 681
Radioimmunoassay—butorphanol in human serum, 160
—flurazepam, plasma levels in humans, 601
—hydromorphone in human plasma, 1171
—procainamide in human serum, 721
—terfenadine, human plasma, 1419
Radionuclide imaging—radioiodinated analogs of propranolol and *N,N*-dimethylpropranolol, tissue distribution, potential as myocardial imaging agents, 1010
imaging—19-radioiodinated cholesterol, evaluation as ovarian imaging agent, 1014
—use in determination of cardiac output, comparison to dye dilution method, dogs, 509
Radiopaques—diatrizoic acid and iopamidol, deiodination kinetics, 671
Radiopharmaceuticals—^{99m}Tc-labeled iminodiacetic acid derivatives of 2-aminopyrroles, evaluation as hepatobiliary imaging agents, rats, 731
—^{99m}Tc-labeled triethylenetetraamine–polystyrene resin, determination of gastric emptying rate and pattern, humans, 568
—technetium 99m complexes of *N*-(2-mercapto-1-oxopropyl)glycine and ethylenediamine-*N,N'*-bis(α-2-hydroxy-5-bromophenyl)acetic acid, localization in hepatobiliary system, 581
Radioprotective compounds—*N*-heterocyclic aminoethyl disulfides and thiosulfates, DNA binding ability, 84
Ranitidine—high-pressure liquid chromatographic analysis in plasma and urine, 1155
H_2-Receptor antagonists—ranitidine, high-pressure liquid chromatographic analysis in plasma and urine, 1155
Reissert compounds—synthesis of 3-azapapaverine from veratric acid, 120
Relaxants, skeletal muscle—dantrolene and clodanolene, quaternary ammonium salts, synthesis, activity, 327
Release rates—heterogeneous model of drug release from polymeric matrix, 1311
—propoxyphene, influence of type of controlled-release formulation, pH dependency, 1327
Renal clearance—atenolol, effect of exercise, 344
—effect of plasma protein binding, 482
Renal stones—size distribution characteristics of mineral phase, 829
Repellents, mosquito—topical use in humans, lactic acid cyclic analogs, 196
Respiration, mitochondrial—effect of marine natural products, 462
Rotating-basket apparatus—dissolution testing, modification to eliminate tablet air entrapment, 129
Rotating disk—analysis, cutaneous metabolism of vidarabine, guinea pig, *in vitro* study, 126, 127

S

Salicylamide—GLC analysis, capsule preparations, 854
—simultaneous quantitation with acetaminophen, aspirin, caffeine, codeine phosphate, and phenacetin, high-pressure liquid chromatography, 110
Salicylate—comparison of plasma levels following administration of aspirin, magnesium salicylate, and choline magnesium trisalicylate, 1355
—enhancement of rectal absorption of theophylline and lidocaine, 744
Salicylic acid—analysis in aspirin powder and dosage forms, high-pressure liquid chromatography, 113
—binding to human serum albumin, effect of sodium oleate, 1345
—binding to povidone, effects of temperature, buffer composition, and ionic strength, 1403
—effect on gold bound to serum albumin, flameless atomic absorption determination, 585
—high-pressure liquid chromatographic analysis with salicylsalicylic acid and aspirin in human plasma and urine, 1268
—high-pressure liquid chromatographic analysis with salicyluric acid and gentisic acid in biological matrixes, 1224
—high-pressure liquid chromatographic determination, 1188
—high-pressure liquid chromatography, fluorescence detection and measurement, 548
—semiautomated colorimetric determination in tablet formulations, 544
Salicylsalicylic acid—high-pressure liquid chromatographic analysis with aspirin and salicylic acid in human plasma and urine, 1268
—high-pressure liquid chrometographic determination, 550
Saturation adsorption region—surface tension decrease with increasing bulk concentration of surfactant, 852
Scintigraphic imaging agents—complexes of technetium 99m with *N*-(2-mercapto-1-oxopropyl)glycine and ethylenediamine-*N,N'*-bis(α-2-hydroxy-5-bromophenyl)acetic acid, localization in hepatobiliary system, 581
Scintigraphy, external—monitoring of *in vivo* tablet disintegration time, 1107
Secobarbital sodium—absorption in goldfish, effect of edetate disodium, 972
Sedatives—diazepam, reduction of thrombosis and inflammation using poloxamer 188 as vehicle, rabbits, 970
—flurazepam, IR spectroscopy, 270
6-Selenoguanosine—stabilization with antioxidants, formulation of parenteral dosage form, 1168
Self-association—phenol, effect on transport across polyethylene film, 133
Serotonin—effect on schistosomes, anticholinergic agents, scanning fluorescence method, 516
Serum protein binding—prednisolone in humans, rabbits, dogs, and rats, 977
Sesquiterpene lactones—anti-inflammatory agents, antiarthritic agents, mode of action determined in rat and human neutrophils and rat and mouse liver cells, 537
—microhelenins, microlenin acetate, and plenolin, isolation from *Helenium microcephalum*, determination of structure and stereochemistry, 1044
Sickle cell anemia—deformability of erythrocytes, effect of etidronate disodium, 599
Simplex method—optimization of capsule formulation, 1135
Size distribution—mineral phase of renal stones, 829
Skin—metabolism of vidarabine, rotating-disk method, guinea pig, *in vitro* study, 126, 127
Smoking—effect on binding of lidocaine to human serum proteins, 749
Sodium bicarbonate—effect on conversion of fibrinogen to fibrin, synergistic action with sodium citrate, 978
Sodium bisulfite—reaction with *cis*-platinum, 364
Sodium citrate—effect on fibrin clot formation, synergistic action with sodium bicarbonate, 978
Sodium dichloroacetate—pharmacokinetics, plasma concentration levels, rats, dogs, humans, 419
Sodium γ-hydroxybutyrate—relationship between *in vitro* transport and *in vivo* absorption, 356
Sodium montmorillonite—effect on acid–base equilibria of tetracycline, 811
Sodium oleate—effect on binding of salicylic acid to human serum albumin, 1345
Solubility—caffeine in water–dioxane mixtures, prediction of solubility, extended Hildebrand approach, 659
—ergotamine tartrate, various dissolution media, 832
measurements—complexation of *trans*-cinnamic acid with α-cyclodextrin, 173
—modification, niacinamide complexation with drug molecules, aqueous solution, frontier molecular orbital calculations, 104
—nonelectrolytes in water, estimation techniques, 912
—polar organic solutes in nonaqueous systems, role of specific interactions, 676
—prostaglandin prodrugs, solubility in isooctane and water, 424
Solubilization—of oxygen in egg lecithin dispersed in distilled water and physiological electrolyte fluids, 62
—steroid hormones in polysorbate 40 and in tetradecyltrimethylammonium bromide, thermodynamics, 20
Solute–solvent interactions—polar organic solutes in nonaqueous systems, role of specific interactions, 676
Solvents, nonaqueous—solubility of polar organic solutes, role of specific interactions, 676
—polyethylene glycols, use in implantable osmotic pumps, 747
Solvent systems—benzene–acetonitrile, determination of half-neutralization potentials of selected bases, 1151
—solubility of theophylline in polar binary solvents, 487
—various octanol–buffer systems, effects on partitioning of acidic, basic, and neutral drugs, 662
Sotalol—high-performance liquid chromatographic analysis with fluorometric detection, human plasma and urine, 1216
Spasmolytic agents—3-diethylamino-2,2-(dimethyl)propyl esters of 5-substituted phenyl-2-furancarboxylic acids, synthesis and pharmacological properties, 107
Spectrofluorometry—analysis, propranolol, human plasma, 1463
Spectrophotofluorometry—analysis, ethinyl estradiol in the presence of norethindrone and common tablet excipients, 857
—analysis, nitrofurantoin, plasma and urine, 106
Spectrophotometry—analyses, hydrastine and canadine in pharmaceutical preparations and synthetic mixtures of hydrastis alkaloids, effect of pH on alkaloid–dye complex formation, 597
—analysis of carnitine analogs on carnitine acetyltransferase activity, kinetics, 202
—determination of composition and formation constants of copper(II)–thiobarbiturate complexes, 1164
—turbidimetric determination of blood levels of amikacin, gentamicin, kanamycin, and tobramycin, effect on bacterial growth, 1442
Spectroscopy, fluorescence—thiazole-containing compounds, 275
IR—flurazepam analysis, effect of various extraction solvents, 270

—UV and visible spectra of phenothiazine derivatives, solution and solid state, 378
UV—changeable matrixes of pharmaceutical preparations, comparison of three background correction methods, interference by excipients or degradation products, 629
Spiperone—*p*-bromo analog, synthesis and biological evaluation as a potential neuroleptic, 984
Spiramycin—microbiological determination with neomycin, 458
Spironolactone—distribution coefficients, *in vitro* human serum protein binding, 7α-carboxymethyl analog, 30
Stability—apomorphine in solutions containing ascorbic acid and sodium bisulfite, 974
constants—complexes of α-cyclodextrin with cinnamic acid, benzalacetone, and methyl cinnamate, 564
—digoxin in acidic solution, high-pressure liquid chromatography, kinetic study, incorporation of antacid, 410
—ergocalciferol (vitamin D_2) and cholecalciferol (vitamin D_3), effects of humidity and temperature, 1099
—furosemide in aqueous solutions, effect of formulation factors, 594
—prediction, nonisothermal kinetic method, programmed temperature steps, comparison with isothermal kinetic method, 287
—product potency, calculation, kinetic ratio parameter, 325
—6-selenoguanosine, stabilization with antioxidants, 1168
—tolmetin sodium, spectrophotometric assay, solid dosage forms, 147
Staphylococcus aureus—microbiological determination of antibiotic mixtures, induced resistance to neomycin and spiramycin, 458
Steady-state concentration—prediction of metabolite and parent drug concentrations, metabolism, cinromide and carbamazepine, monkeys, 610
Stereoisomers—apomorphine, synthesis of (*S*)-(+)-stereoisomer from (*R*)-(−)-stereoisomer, 1056
Steroid hormones—solubilization, thermodynamics, temperature effect, micellar structure, androgens, estrogens, C_{21}-steroids, in polysorbate 40 and in tetradecyltrimethylammonium bromide, 20
Steroids—mercapto compounds, protection against mercury and lead poisoning, 556
—pattern recognition using fragment molecular connectivity, 1030
Streptozocin—drug metabolism and distribution, mathematical model based on bioassay and chemical assay, mice, 691
Structure–activity relationships—acetylcarnitine, conformational analysis, comparison to cholinergic receptor patterns, 1065
—*n*-alkanols, α,ω-*n*-alkanediols, and ω-chloro-α-alkanols, antifungal activity, *in vitro*, effect of chain length, 381
—chlorambucil analogs, synthesis and testing for antitumor activity, 1232
—cyanamides evaluated for antifungal activity, chlorotriphenylstannates evaluated for antifungal and antibacterial activity, 340
—dansylated acetylcholine analogs, effect on motility and neuroactivity in schistosomes, scanning fluorescence method, motility studies, 516
—distamycin A and congocidine derivatives based on 2,5-disubstituted pyrroles, antiviral activity, 1334
—dopaminergic drugs, 1059
—effect of furan analogs of benzilate esters on receptor binding activity, synthesis of antimuscarinic agents, 534
—effect of molecular weight, parabolic model, 648
—effect of sesquiterpene lactones on inflammation process, several modes of action determined *in vitro* and *in vivo*, 537
—evaluation of 2-azabicyclo[2.2.2]octane analogs of 4-anilidopiperidines for analgesic activity, mice, 1104
—hydrazide monoamine oxidase inhibitors, molecular connectivity analysis, 124
—ketophosphonium salts, relationship between neuromuscular blocking activity and interatomic distances, 888
—molecules containing substituted benzene rings, interpretation of structure–activity relationship from molecular connectivity $^4\chi_{PC}$ index, 1034
—pseudomorphine and congeners, 253
—4-pyridones and bioisosteres of 3-acetoxy-2-pyridone, synthesis and evaluation for antitumor activity, 1074
—pyrimido[4,5-*d*]pyrimidines, synthesis and evaluation for antidepressant activity, binding at presynaptic α-receptor sites, 1343
—pyrrolo[2,3-*d*]pyrimidine-2,4-diones and intermediates, anticonvulsant activity, 473
—quantitation of molecular information content by negentropy calculations, correlation between biological activity and molecular structure, 807
—sesquiterpene lactones, antihyperlipidemic activity, effect on serum levels of cholesterol and triglycerides, mice, 694
—substituted aryl hydroxamic acids, inhibition of ribonucleotide reductase, molecular connectivity indexes, 856
Strychnine—^{13}C-NMR spectral analysis, chemical shifts assigned, 865
Styryl ketones, conjugated—synthesis of ketals, hemithioketals, and dithioketals, evaluation for antineoplastic activity, 575
Substituent constants—various azulenes, 337
1-(Substituted benzyl)-3,4,5,6-tetrahydro-2(1*H*)-pyrimidones—synthesis and testing for stimulant and depressant activities, mice, 1194
Sulfamethazine—high-pressure liquid chromatographic determination, beef tissues, 701
Sulfamethoxazole—microcapsules, prepared by gelatin–acacia coacervation, 513
—simultaneous analysis with trimethoprim and methylparaben, high-performance liquid chromatography, oral suspension and solid dosage forms, 144
Sulfathiazole—coacervation with povidone, dissolution of coacervated system, 492
Sulfisoxazole—renal metabolism to N^4-acetyl metabolite using the isolated perfused rat kidney, 1359
Sulfonamides—photodecomposition at oil–water interface, 5
Sulfonylureas—distribution in pancreas, displacement by second drug, 157
Sunscreens—titanium, analysis, atomic absorption spectrometry, 101
Suppositories—aminophylline, decomposition in suppository formulations, 942
—physical stability of semisynthetic suppository bases, 955
Surface activity—alkylamides, alkylmonocarboxylic acids, and alkylketones, interaction energies with phospholipid monolayers, 65
—barbital, phenobarbital, pentobarbital, interaction with phospholipid monolayers, 102
Surface potential—films of Ca^{2+} ionophores on electrolyte solutions, effect of membrane lipids, 406
Surface pressure—films of Ca^{2+} ionophores on electrolyte solutions, effect of membrane lipids, 406
Surface tension—decrease with increasing bulk concentration of surfactant in saturation adsorption region, 852
Surfactants—surface tension decrease with increasing bulk concentration of surfactant in saturation adsorption region, 852
Suspensions—flocculation effect of xanthan gum, 1209
—nitrofurantoin, effect of viscosity on absorption, 403
Sustained-release systems—delivery of morphine from polydimethylsiloxane pellets, mice, 980
Suxibuzone—simultaneous high-performance liquid chromatographic determination with metabolites in plasma and urine, 1258
Sweeteners, noncaloric—analysis of aldoximes for potential use as sweeteners, molecular connectivity indexes, discriminant analysis, 416
Systemic availability—propoxyphene, effect of portacaval shunt, dogs, 786

T

Tablet breakage—capsule-shaped tablets, determination of flexure breaking strength, new instrumentation, 384
disintegration—correlation between porosity and dissolution rate, 607
Tableting processes—cost evaluation, simulation model, 621
Tablets—commercial film-coated preparations, measurement of adhesion of film coating to tablet surface, effect of solvents and humidity on bonding of film to tablet surface, 439
—disintegration *in vivo*, monitoring by external scintigraphy, 1107
—preparation of enteric-coated microcapsules for tableting, drug release from tableted microcapsules, 1388
Technetium 99m—complexes with *N*-(2-mercapto-1-oxopropyl)glycine and ethylenediamine-*N,N'*-bis(α-2-hydroxy-5-bromophenyl)acetic acid, localization in hepatobiliary system, 581
Teratogenic drugs—cocaine hydrochloride, effect on fetal mice, 703
Teratological study—gravid and nongravid mice, morphine sulfate, cobalt chloride, phenytoin sodium, LD_{50} testing, 214
Terfenadine—radioimmunoassay, human plasma, 1419
Tertiary amines—derivatization, quaternization, high-performance liquid chromatographic determination, 257
Testosterone esters—high-performance liquid chromatographic analysis in oily solution, 1214
Tetracaine—simultaneous GLC analysis with mepivacaine, bupivacaine, etidocaine, and lidocaine in biological fluids, 603
Tetracycline—acid–base equilibria in sodium montmorillonite suspensions, 811
—distribution in red blood cells, 455
hydrochloride—adsorption onto clay, interaction with pharmaceutical grade clay, adsorptive properties of clay, 816
—photodecomposition at oil–water interface, 5
—simultaneous high-performance liquid chromatographic analysis of tetracycline epimers in tetracycline preparations, 928
Tetracyclines—^{13}C-NMR spectra, chemical shifts assigned, 229
various—TLC–bioautographic analysis of four cephalosporins as contaminants, 616
Tetrazolium salts—colorimetric analysis of diethylstilbestrol and diethylbestrol dipropionate, 24
Thalictrum fauriei—isolation of thalifaurine and dehydrodiscretine and their structural determination, 1061
Thalifaurine—new quaternary protoberberine isolated from *Thalictrum fauriei*, structural determination, 1061
Theophylline—enhancement of rectal absorption by salicylate, 744
—hydrogen bonding in complex with *p*-cresol, 613
—solubility in polar binary solvents, 487
—trough serum concentrations at steady state, temporal variations, 358
Thermal decomposition—ibuproxam, analysis of degradation products, 521
Thermal energy analyzer—analysis of trinitroglycerin and metabolites in whole blood, 444
Thermodynamics—complexation analysis, determined by spectral, solubility, and pH measurements, *trans*-cinnamic acid–α-cyclodextrin complex, 173
—differential heat of solution, determination in real solutions from variation in solubility with temperature, 1241
—steroid hormone solubilization in polysorbate 40 and in tetradecyltrimethylammonium bromide, 20
Thiazole—thiazole-containing compounds, fluorometry, 275
Thiobarbiturates—complex formulation with copper(II), 1164

Thioridazine—GLC determination in serum, wall-coated open tubular column coupled with nitrogen-selective detector, 835
Thyroid—semiautomated colorimetric analysis in individual tablets, 948
Ticarcillin disodium—high-pressure liquid chromatographic analysis, 1264
12-*O*-Tigloyl-4-deoxyphorbol-13-isobutyrate—isolation from *Synadenium grantii* and identification, 1446
Timolol—capillary column GLC–mass spectrometric analysis, stable isotope-labeled drug, human plasma and urine, 1111
Titanium—analysis, atomic absorption spectrometry, sunscreens, 101
Titrimetry—determination of half-neutralization potentials of selected bases in benzene–acetonitrile binary solvent system, 1151
TLC—determination of griseofulvin in plasma and 6-demethylgriseofulvin in urine, 561
Tocainide—human metabolism, conjugation, 47
Tolmetin sodium—stability-indicating assay, solid dosage forms, 147
Tolnaftate—antifungal activity *in vitro* and *in vivo*, comparison with various undecylenates, 739, 741
1-(*p*-Tolyl)-3-acetyl-3-methyltriazene—evaluation of activity against African trypanosomiasis, mice, 1465
***N*-Tosyl amino acids**—diazomethyl ketone and chloromethyl ketone analogs, evaluation for anti-inflammatory activity, 1451
Total body clearance—mean calculation, harmonic mean method, dosage rate, 90
Toxicity—acetaminophen, evaluation of protection offered by *N*-acetyl-DL-penicillamine, mice, 1005
Tranquilizers—identification by high-pressure liquid chromatography, arthritis treatment, 590
Transport inhibitors—latentiated forms of α-amino acid adamantanine, synthesis, 1022
Triamcinolone acetonide—high-pressure liquid chromatographic analysis, effects of various octadecylsilane columns on mobility, 481
Triazines, asymmetric—synthesis, evaluation of anti-inflammatory activity, 282
Tribenoside—GLC determination of α- and β-anomers, human plasma, 167
Triethylammonium (organocyanoamino)chlorotriphenylstannates—evaluated for antifungal and antibacterial activity, 340
Triethylenetetraamine–polystyrene resin, ^{99m}Tc-labeled—determination of gastric emptying rate and pattern, humans, 568
***N*-2,2,2-Trifluoroethyl-2-(3,4-dihydroxyphenyl)-ethylamine**—dopamine analog, adenylate cyclase activity, 149
Trimethoprim—simultaneous analysis with sulfamethoxazole and methylparaben, high-performance liquid chromatography, oral suspension and solid dosage forms, 144
Trinitroglycerin—high-pressure liquid chromatographic analysis of parent drug and metabolites in whole blood, 444
***N*-(Triphenylstannyl)cyanamides, *N*-substituted**—evaluated for antifungal activity, 340
Tropanyl esters—demethylation to yield nortropanyl esters for comparison of kinetic data, 1357
Tuberculostatic antibacterials—ethambutol, GLC analysis in biological fluids, 362

U

Undecanortriterpenoids—odoratin, recommended assignment of name only to isolate from *Cedrela odorata*, 1107
Undecylenates—antifungal activity *in vitro* and *in vivo*, comparison with tolnaftate, 739, 741
Uracil—GLC–mass spectrometric analysis in biological materials, 1296
Ureides—*N*-Mannich base derivatives as prodrugs, hydrolysis kinetics, 44
Urinary stones—size distribution characteristics of mineral phase, 829
Urushiols—GLC analysis, pharmaceutical preparations containing poison ivy and poison oak extracts in vegetable oils, 587
UV spectrometry—complexation of *trans*-cinnamic acid–α-cyclodextrin, 173

V

Vasodilators—khellin, high-performance liquid chromatographic analysis in human serum and urine, 1434
—nitroglycerin, percutaneous absorption, rhesus monkeys, 365
Vehicles—suspension hydrogels, percutaneous absorption of benzocaine, influence of solvent power and microscopic viscosity of vehicle, *in vitro*, 387
Ventricular fibrillation—role of α- and β-adrenergic activity, desoxycorticosterone acetate-pretreated rats, 441
Vidarabine—cutaneous metabolism, analysis by rotating-disk method, guinea pig, *in vitro* study, 126, 127
valerate prodrug—topical dosage forms, distribution of adenosine deaminase and esterase enzymes in various mouse skin strata, 772
valerate prodrug—topical dosage forms, permeability differences through various mouse skin strata, 770
valerate prodrug—topical dosage forms, physical models employing homogeneous and nonhomogeneous enzyme distributions, various mouse skin strata, mathematical analysis, 775
Vinblastine—on polymethylcyanoacrylate and polyethylcyanoacrylate nanoparticles, distribution patterns in rats, 199
Viscosity—determination of extent of hydration of water-miscible organic liquids in aqueous solution, 369
Vitamin D—ergocalciferol (vitamin D_2) and cholecalciferol (vitamin D_3), effects of temperature and humidity on decomposition, 1099
—high-performance liquid chromatographic determination of potential content of vitamins D_2 and D_3 in gelatin-coated beadlets, oil-based mixtures, and multivitamin tablet and capsule formulations, 846
Volume of distribution—effect of blood sampling time on values calculated after intravenous administration, 867
—estimation at steady state, 1222
—ocular distribution of pilocarpine, 615

W

Warfarin—dose-dependent pharmacokinetics, rats, 9
—interaction with phenylbutazone, pharmacokinetics, *in vitro* and *in vivo*, rats, prothrombin complex activity, 14
—pharmacokinetics, effect of phenobarbital on drug biotransformation and enzyme induction, rats, 634

X

Xanthan gum—flocculation effect in pharmaceutical suspensions, 1209

Y

Z

Zearalenone—allyl derivatives, synthesis, 1017